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В ab A H.pylori adhesin for Le(b) antigen
BSA bovine serum albumine
cagA cytotoxin-associated gene A
CagA cytotoxin-associated CagA protein, coded by cagA
ELISA enzyme-linked immunosorbent assay
H.pylori Helicobacter pylori
HSP60 heat shock protein 60 kDa




Le(a,b,x,y) Lewis antigens a,b,x,y
LPS lipopolysaccharide
MAb monoclonal antibody
NAP neutrophil activating protein
NBT nitro blue tétrazolium
O.D. optical density
PAI pathogenicity island
PBS phosphate buffered saline
RAA relative antibody activity
SabA sialic acid binding adhesin of H.pylori (a receptor for sialyl- 
dimeric-Lewis x glycosphingolipid)
SDS-PAGE sodium-dodecyl-sulphate polyacrylamide gel electrophoresis
Se/se secretory status: secretor/non-secretor
TNFa tumor necrosis factor alpha
T antigen Thomsen-Friedenreich antigen (Galßl,3GalNAc)
TRIS tris(hydroxymethyl) aminomethane
vacA a gene coding for vacuolating cytotoxin
Vac A vacuolating cytotoxin
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INTRODUCTION
Helicobacter pylori is a spiral microaerophilic, Gram-negative bacterium 2-5 
ЦЛ1 long, 0.5-1 |j.m in diameter, and with 1-6 unipolar flagella (Marshall and 
Warren, 1983). H.pylori colonizes under a mucous layer on the surface of the 
epithelium of human gastric mucosa. Bacteria adhere to the gastric epithelial 
cells and trigger intracellular signalling pathways leading to the damage of the 
host cells (Haas et al., 2001; Stein et al., 2002). The recognition that H.pylori is 
almost invariably associated with long-term chronic active gastritis, responsible 
for peptic ulcer, increased risk for gastric cancer and MALT lymphoma is the 
most important advance that has been made in gastroenterology over the past 
decades (Axon, 1999). This issue is currently one of the most active research 
topics in biomedicine. The complete genome of two H.pylori strains is now 
sequenced (Aim et al., 1999). This information will allow for the selection of 
novel target gene candidates that are closely related to the virulence of H.pylori 
and the pathogenesis of H.pylori-associated diseases.
Although H.pylori is believed to infect more than half the world’s 
population, marked differences in prevalence exist between different countries 
and geographical areas. Approximately 40 and 80 percent of individuals in 
developed and developing countries, respectively, are infected. In Estonia, more 
than 80% of the adults are infected, and the incidence of H.pylori-associated 
diseases, including gastric cancer, is also extremely prevalent (Maaroos et al., 
1990; 1995; Vorobjova et al., 1994, 1998; Thomson et al., 1996).
If not treated an infection by H. pylory persists for decades. However, a 
majority of infected remain asymptomatic and never develop overt disease or 
symptoms. In 10-20% of carriers, gastroduodenal disease develops including 
gastric or duodenal ulcer, type В chronic and atrophic gastritis, which is a 
precondition to gastric cancer (Siurala et al., 1988; Kuipers et al., 1995b; Correa 
and Miller, 1998; Sipponen, 2002). However, the precise mechanisms of 
mucosal injury, ulceration and gastric carcinogenesis are not fully understood. 
This is due to no reliable indicators which predict the clinical outcome of the 
infection at the individual level. Therefore, it is a big challenge to determine 
why the disease strikes only a small percentage of H.pylori carriers and what 
determines the differences in the clinical outcome of the infection. At least three 
main possibilities have been considered: (i) H.pylori diversity and the existence 
of more virulent strains or the strains which are preferably involved in the 
pathogenesis of a particular disease; (ii) unique or aberrant host response to 
infection contributes to a specific outcome; (iii) other co-factors, such as 
enviromental exposures, that can modulate the H.pylori-host interrelationships. 
It seems, however, that the right combination of several factors in a genetically 
susceptible host determines a specific clinical outcome. Many evidences 
support these considerations. (Blaser et al., 1995,1996; Finlay and Fialkow,
11
1997; Dubois et al., 1999; Casadevall & Pirofski, 2000; Blaser, 2000). 
However, it should be a priori expected, that an interplay between two such 
genetically diverse, polymorphic systems, such as H.pylori and the host could 
not lead to a single effect.
On the basis of the evidence to date, the H.pylori infection is a typical ‘slow 
infection’ where the host is the major factor in determining the natural course 
and clinical outcome of the infection (Nguen et al., 1999; Blaser, 2000, 2002). 
To evaluate the role of host polymorphism in the host-H.pylori immunologic 
interplay we monitored an immunologic response of the individual to H.pylori 
in relation to a highly polymorphic system of ABO(H) and Lewis blood group 
antigens which were used as predictors.
H.pylori diversity at genetic and phenotypic level
Analysis of the H.pylori genome, predicts a small genome (-1.6-1,7Mb) with 
relatively few regulatory genes needed for adaptation to the environment 
(Tomb et al., 1997). The first genomic comparison of two unrelated H.pylori 
isolates showed that about 40% of the genes were of unknown function and 
only 6 to 7% of the genes were specific to each strain, with almost half of them 
being clustered in a single hyper-variable region (Aim et al., 1999). Salama et 
al. (2000) found that out of 1643 genes analyzed in 15 strains of H.pylori, 1281 
were common to all strains suggesting that about 20% of the genes may be 
strain specific. Different human populations also show appreciable differences 
in genotypes of H.pylori (Kersulyte et al., 2000).
Many important virulence genes of pathogenic bacteria are often grouped in 
genetic elements termed pathogenecity islands (PAIs) (Hacker et al., 1997). 
More than half of the H.pylori strains contain a pathogenecity island (cagPAI), 
termed the cag region, whose presence has a marked influence on the virulence 
of the organism (Censini et al., 1996). The cag region was probably acquired by 
DNA uptake from a different species (Censini et al., 1996). The cagPAI 
encodes for the CagA (cytotoxin associated protein), which may be translocated 
into host cell cytoplasm through a type IV secretion machinery, phosphorylated 
by the host cellular kinases, and converted into tyrosine-phosphorylated CagA. 
(Odenbreit et al., 2000; Haas et al., 2001; Censini et al., 2001). The molecular 
mass of CagA varies from 120 to 145 kDa among the strains due to variability 
in the cagA 3’ region. This may alter tyrosine phosphorylation sites and the 
duplication of a varied number of a 102-bp repeat sequences (Covacci and 
Rappuoli, 1998; Dong et al., 2002). It has now been suggested that the cag 
sequence is the major player in the host-pathogen relationships (Censini et al.,
2001).
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The unusually high degree of diversity of H.pylori strains suggests that 
natural transformation may occur in situ. Recombination between H.pylori 
strains is extremely common (Sauerbaum et al., 1998) and novel subtypes 
appear during colonization (Owen et al., 1994; Kersulyte et al., 1999). 
Colonization with two or more strains is typical. (Taylor et al., 1995; Figura et 
al., 1998). Genetic analysis showed mosaicism for many genes, in particular 
vacuolating cytotoxin (vacA) and cagA genes (Cover et al., 1994; Atherton et 
al.,1995; Logan and Berg, 1996; Dong et al., 2002). Similar polymorphism has 
been shown for some other genes of H.pylori such as ureA, iceA (induced by 
contact with epithelium) (Peek et al., 1998, 2000) and phospholipase A (pldA) 
gene (Xerry and Owen, 2001), however, their association with pathogenicity 
has not been determined. There is also substantial evidence that some genes 
may be expressed only within the gastric environment or activated upon contact 
with the host cells (iceA) or in response to a ‘unique’ cellular signature (ureA, 
nap) (Finlay and Falkow, 1997; Blom et al., 2002).
The pathogenecity of microbes is closely related to their phenotypic 
diversity which allows their adaptation to host microenvironments and to evade 
the host immune response (Deitsch et al., 1997). Several phenotypic 
characteristics are known to vary among H.pylori strains. These include the 
structure of lipopolysaccharides (LPS), the production of the cagA-encoded 
protein (CagA, 120-140 kDa), expression of vacuolating cytotoxin (VacA), 
Cover et al., 1994; Censini et al., 1996), BabA adhesin (Moran, 1995; Gerhard 
et al., 1999; Printz et al., 2001), the ability to activate neutrophils (Evans et al., 
1995; Satin et al, 2000), and an expression of Lewis antigens (Appelmelk et al., 
1996, 1998; Wirth et al., 1999; Dundon et al., 2001; Webb and Blaser, 2002).
The significance of the LPS diversity is not yet well understood, but 
potentially relates to the organism’s virulence and its interaction with 
neutrophils. LPS of H.pylori has low biological activity, a property which may 
aid in the persistance of the infection, possibly due to an antigenic mimicry 
mechanism: because the О-specific chain of H.pylori LPS mimics structurally 
Lewis blood group antigens in structure (Appelmelk et al., 1996; Moran, 1996). 
Besides, immune cross-reactivity between the bacteria and the gastric mucosa 
may play role in an induction of autoimmunity via antigenic mimicry 
mechanism (Negrini et al., 1991, 1997).
The characterization of proteins of H.pylori via proteomics technology 
including two-dimensional gel electrophoresis, showed even greater 
polymorphism. Three H.pylori strains were analyzed and more than 1500 
protein spots were compared. (Jungblut et al., 2000; Nilsson et al.,2000; Aim et 
al., 2000). There is evidence that a single gene may create multiple proteins as a 
result of post-translational modification. In addition, some disease-type specific 
patterns were detected suggesting the ability of the approach to select candidate 
indicators for clinical manifestations (Haas et al., 2002).
The majority of H.pylori strains was shown to express human blood group 
related antigens: Le type I (Le a,b) and Lewis type П (Le x,y), ABH antigens
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(Sherburne & Taylor, 1995; Appelmelk et al., 1996; Simmons-Smith et al., 
1996; Heneghan et al., 2001). An antigenic variation depending on 
environmental conditions has been shown to be characteristic of these antigens 
(Appelmelk et al., 1998). An expression of Lewis antigens was shown to be 
dependent on the Lewis phenotype of the host (Wirth et al., 1997) though this 
issue remains contradictory (Taylor et al., 1998). At the same time, phenotypic 
diversity in Lewis expression of H.pylori isolated from the same host has been 
demonstrated, suggesting the continuous selection of optimally host-adapted 
populations suitable for persistence (Wirth et al., 1999; Blaser, 2000). It appears 
that there is host specificity in determining strain selection (Dubois et al., 1999).
It has been hypothesized that an enormous diversity of H.pylori is an 
indication of the long duration history of human-H.pylori interaction (Blaser 
1996, 2000). It may reflect selection for a variety of human phenotypic 
characteristics that are related to the polymorphism of human population and its 
environment, including diet. (Blaser, 1996; Webb & Blaser, 2002). Another 
speculative explanation might be that this diversity itself may in part account 
for the lifelong chronicity of infection.
Virulence factors of H.pylori and their clinical relevance
To date, a number of virulence factors that are known to be involved in the 
pathogenesis of the infection and associated with severe clinical outcome have 
been identified and characterized from the H.pylori. These are: the cag 
pathogenicity island (cag PAI), the vacuolating cytotoxin (VacA), cytotoxin- 
associated protein CagA, urease, the H.pylori neutrophil-activating protein 
(HP-NAP) (Satin et al., 2000), blood group Lewis(b)-binding adhesin (BabA) 
(Boren et al., 1993; Prinz et al., 2001), sialylated Le(x) binding adhesin (SabA) 
(Mahdavi et al., 2002), and some others.
The cagA and vacA genes and their products are two of the most studied 
virulence factors of H.pylori. The cagA is the nonconserved gene of H.pylori 
which is present in 60-90% of H.pylori strains and it is a marker for the 
presence of the cag pathogenicity island. The cag region is related to the 
phenotypic differences between type I proinflammatory (cagA+vacA+) and 
type П (cagA-vacA-) H.pylori strains (Xiang et al., 1995; Censini et al., 1996). 
The CagA protein is involved in downregulation of PHA-induced proliferation 
of T cells and their growth (Paziak-Domanska et al., 2000). The cagPAI is also 
associated with an increased production of proinflammatory interleukin-8 in 
gastric epithelial cells and increased EL-10 and IL-12 mRNA expression 
(Crabtree et al., 1994a,b; Hida et al., 1999).
There are appreciable geographic differences in the distribution of CagA 
positive strains as well as in the degree of the association with gastric diseases
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(van Doom et al., 2000). More than 90% of H.pylori strains isolated from Asian 
countries are CagA positive, irrespective of the clinical expression outcome 
(Maeda et al., 1997,1998). Despite some differences in the prevalence, rather 
similar results were observed in many geographical areas with respect to the 
relation between H.pylori genotypes and histopathology. Many reports have 
shown that distinct H.pylori genotypes are associated with histopathological 
findings in the stomach, confirming their relevance for the development of 
H.pylori-associ&ted pathology. Infection with CagA positive strains is 
associated with an increased risk for development of peptic ulcer disease, 
atrophic gastritis, gastric cancer and intestinal metaplasia (Kuipers et al., 1995 J 
NCI; Kuipers 1995a; Blaser et al., 1995; Parsonnet et al., 1997; Orsini et al., 
1998; Maaroos et al., 1999; Haruma et al., 2000; Asaka et al., 2001). Strains 
with mutations in cag genes showed a reduced capacity to initiate colonization 
in the mouse model of infection compared to wild-type strain (Marchetti and 
Rappuoli, 2002). However, in another experimental study performed in piglets 
and mice it was shown that neither the cagPAI, nor the ability to induce IL-8 in 
vitro is essential for colonization or neutrophilic inflammation and there was no 
direct relationships between the presence of cag PAI, IL-8 induction and 
neutrophilic gastritis (Eaton et al., 2001). Some authors were unable to 
demonstrate that cagA, vacA or other genotypes or the mosaicism of these 
genes might predict clinical outcomes of the infection (Go et al., 1998;; 
Anderson et al., 2002). The latest study of Twisk et al. (2001) found that 716 
consecutive patients showed no relation of CagA status to H.pylori topography 
and colonisation density. These authors also found no correlation between anti- 
CagA antibody titers and above mentioned parameters. No higher risk elevation 
for developing of peptic ulcer disease or cancer was found in China, Korea and 
Japan (Park et al., 1998; Graham and Yamaoka, 2000; Goh et al., 1998). In 
different human populations from five continents several different types of 
changes were found in cagPAI (Kersulyte et al., 2000). Maeda et al., (1998) did 
not find any difference in CagA seroprevalence among H.pylori positive 
patients with different gastric diseases as well as no relation to the mucosa 
histology. Most H.pylori isolates were positive for VacA and CagA irrespective 
of pathology (Maeda et al., 1998). A recent international study (Webb et al.,
1999) showed that the variation in the CagA seroprevalence did not explain 
geographic variation in gastric cancer rates any better than H.pylori 
seroprevalence alone. In addition, it has been shown that not all CagA proteins 
are structured equally and in their potential for initiating host cell responses via 
signal transduction pathway (Evans and Evans, 2001).
Thus, this issue remains controversial in part because of many patients are 
infected with multiple strains of H.pylori. A high degree of heterogenecity in 
many biopsies from an individual patient was detected by ribotyping, restriction 
enzyme and other analysis (Hazell et al., 1996). From 20 to 76% of patients 
were infected with two or more strains (Figura et al., 1998). However, one
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strain is usually dominant in a given host. Most patients (68%) with nonulcer 
dyspepsia were infected by both CagA- and CagA+ H.pylori strains.
In 1988, Leunk and colleagues described the ability of H.pylori to induce 
vacuolization in epithelial cells. The vacA gene seems to be invariably present 
in all H.pylori strains. However, only some of them produce an active toxin. 
The vacA alleles of two variable regions (s and m) differ by a degree of 
cytotoxin production and its ability to interact with the target cells (Atherton et 
al., 1995; Pagliaccia et al., 1998). A maximum of cytotoxic activity was found 
with slm l allele, while no cytotoxic activity was found when the s2m2 allele 
was present (Atherton et al., 1995). In a mouse model, only the VacA- 
producing strains induced gastric lesions (Ghiara et al., 1995). Nearly all 
VacA+ strains are cagA positive. However, the cagA gene does not actually 
encode the vacuolating toxin, it is often со-expressed with VacA (Xiang et al.,
1995). Two known variants of cagA gene cagAl and cagA2 were shown to be 
associated with vacA subtypes, vacAml and vacAslc, respectively. The vacAsl, 
cagA+ genotype was significantly associated with a higher H.pylori density, 
higher symptom scores in patients with functional dyspepsia (Loffeld et al., 
2001), higher degrees of lymphocytic and neutrophilic infiltrates, atrophy, the 
type of intestinal metaplasia, and the presence of epithelial damage (Nogueira et 
al., 2001). CagA-positive, VacA producing strains cause significantlly stronger 
inhibition of gastric mucin expression or secretion (Muc5AC and Mucl) in 
mucin-producing cultured gastric epithelial cells (КАТО ПГ) after contact with 
H.pylori (Beil et al., 2000).
The neutrophil-activating protein of H.pylori (HP-NAP) is a high molecular 
mass immunogenic protein. It is chemotactic for leukocytes and induces the 
production of oxygen radicals in human neutrophils via a cascade of 
intracellular events which may contribute to the damage of the stomach mucosa 
(Evans et al., 1995; Satin et al 2000, Dundon et al. 2001). This stimulating effect 
is strongly potentiated by TNFa and IFNy (Satin et al., 2000J. A H.pylori 
mutant lacking HP-NAP was significantly less active than the wild-type strain 
(Montemurro et al., 2001). In addition, a low molecular weight neutrophil 
activating factor (<3kDa) has been demonstrated in H.pylori cell-free extracts 
(Leaky et al., 2001).
H.pylori synthesizes urease at a higher level than any other known organism 
(Scott et al., 1998). Urease hydrolyses urea to form ammonia and carbon 
dioxide which can absorb acid to form ammonium. There are seven genes in 
urease gene cluster of H.pylori (Weeks et al., 2000). The urel sequence 
encoding the Ure I membrane protein is specific for H.pylori and required for 
acidic activation of cytoplasmic urease. Urease seems important for living in 
acidic environment of the stomach because urel-negative mutants of H.pylori 
are not able to colonize the stomach (Tsuda et al., 1994). The H.pylori urease is 
a potent stimulus of mononuclear phagocyte activation and inflammatory 
cytokine production (Hams et al., 1996). In vitro studies have also shown it to 
be toxic to human epithelial cells (Smoot et al., 1990). Urease has a dose-
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dependent, acid-mediated adherence to polysachharides and gastric mucin, thus 
promoting colonization (Icatlo et al., 2000).
Adherence of H.pylori to gastric epithelial cells might be an important 
mechanism for virulence. This may be mediated by the blood group antigen 
binding adhesin BabA targeting human Lewis (b) surface glycoconjugate 
epitopes (Boren et al., 1993; Gerhard et al., 1999; Prinz et al., 2001). Adherence 
via BabA appears to be of importance for efficient delivery of VacA and CagA 
to the host epithelial cells and facilitates bacterial colonization (Printz et al., 
2001; Rad et al., 2002). Another, sialic acid-binding adhesin (SabA) to sialyl- 
Le(x) has been recently identified by the Boren group (Mahdavi et al., 2002). 
The expression of sialyl-dimeric-Lewis(x) glycosphingolipid receptors in 
gastric epithelium was shown to increase during chronic inflammation thus 
promoting the chronicity of H.pylori infection.
Several other ligand-receptor interactions between H.pylori and gastric 
epithelial cells, including N-sialic acid-binding haemagglutinin (Lelwala- 
Guruge et al., 1992) and laminin-binding protein (Trust et al., 1991; Moran et 
al., 1993; Wadström et al.,1996), suggest that the adhesion of H.pylori might be 
a multi-factorial and multi-step process. In vitro H.pylori strains bind 
extracellular matrix components such as laminin, fibronectin, collagens and 
heparan sulphate (Wadström et al., 1996, Wadström and Ljungh., 1999).
Thus, H.pylori may use various strategies in different hosts to colonize the 
stomach using different targets such as proteins and gastric glycoconjugates. It 
is clear, however, that the carbohydrates of both H.pylori (LPS and other 
glycoconjugates) and the host play an important role in the adhesion process. It 
should be expected that variable expression of specific adhesins on bacterial 
strains as well as host polymorphism in expression of related receptors may 
appreciably influence this interaction.
The heat shock protein 60 (HSP60) of H.pylori cross-react with HSP60 of 
other bacteria and human HSPs. Strong immune response was demonstrated to 
these proteins in H.pylori infected subjects. (Engstrand et al., 1991, 1993). 
Yamaguchi et al., (2000) reported that H.pylori HSP also share a unique epitope 
which was protective against H.pylori infection in mice immunized with this 
peptide. Interestingly, the H.pylori infected animals had a significantly lower 
antibody level to this epitope than uninfected ones.
Heat shock protein В (HspB) of H.pylori is highly conserved. HspB gene has 
been cloned and sequenced (Sauerbaum et al., 1994). The HspA is unique in 
that it contains a nickel-binding site and may play a role in the integration of 
nickel into functional urease molecule. The expression of HSP60 on H.pylori 
surface was shown to correlate with the adhesion to primary human gastric 
epithelial and cultured gastric carcinoma cells (Yamaguchi et al., 1996, 1997). 
An inflammation induced by H.pylori leads to an enhanced expression of HSP 
in human gastric epithelial cells thus allowing H.pylori to persist.
The unique feature of the H.pylori LPS is its low proinflammatory activity 
(Moran, 1996). Low immunological response to H.pylori LPS may be a factor
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leading to a chronic ‘slow’ infection. An inhibitory effect of H.pylori LPS on 
the process of mucus glycosylation and sulphatation (Slomiany et al., 1992) 
suggests that the appearance of carbohydrate precursors may be expected in 
gastric glycoconjugates during H.pylori-host interplay. In rats, H.pylori LPS can 
cause acute gastritis and an induction of gastric epithelial cell apoptosis 
(Piotrowski et al., 1997).
Other factors such as bacterial motility, the chemokine CheYl and CheA 
system regulating chemotactic response, MUC5AC gastric mucin expression 
has been shown to be also important in H.pylori colonization (Foynes et al., 
2000; Van den Brink et al.,2001).
Altogether, H.pylori possesses several virulence factors that are related to 
the pathogenesis of the infection. However the virulence factor model alone can 
not explain clinical polymorphism of H.pylori associates pathology (Graham 
and Yamaoka, 2000). No strong disease type-specific associations were 
demonstrated possibly because in most situations infectious diseases are not the 
consequence of a single virulence determinant. It appears that virulence factors 
of H.pylori are just markers for enhanced inflammation and are not directly 
involved in the pathogenesis of a specific gastric disease. There is now a 
growing evidence to suggest that virulence of H.pylori is largely host-dependent 
(Dubois et al., 1999; Graham and Yamaoka, 2000;). Variability in host immune 
responses may contribute to mucosal damage in H.pylori associated gastritis 
(Shimoyama and Crabtree, 1998). It appears that the inflammatory activity in 
H.pylori infection is also predominantly organism related (Michetti, 2000; Ernst 
and Gold, 2000). An expression of iceA gene alleles (Peek et al., 1998; van 
Doom et al., 1998; Nishiya et al., 2000) is a good example. Since host factors 
seem to be important in determining which strain of H.pylori predominates, in 
animal models at least (Dubois et al., 1999), this may also be important in 
human beings for susceptibility to initial or persistent infection and for disease 
(Logan and Berg, 1996).
Host response to H.pylori and its clinical relevance
It is known that the resistance to infections can vary widely between individuals 
and may strongly influence the outcome of infection (Abel & Dessein, 1997). 
Interestingly, even in the populations with extremely high prevalence of 
H.pylori infection there are always individuals which are non-infected though it 
is likely that everyone has been exposed to the organism. This suggests that 
some individuals are either resistant (immune) to H.pylori or able to 
spontaneously eradicate the bacteria. This supports the cases when a small 
proportion of infected subjects loose their infection (seroconversion). The role 
of host factors in susceptibility to H.pylori infection was appropriately
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demonstrated by the twin study (Malati et al., 1994). Among monozygotic twins 
81% were infected compared to 66% for dizygotic twins (p=0.001). H.pylori 
infection and family history of peptic ulcer were shown the independent risk 
factors for peptic ulcer: OR 3.8 and 8.4, respectively (Brenner et al., 1998). 
However, if both factors were present the risk for peptic ulcer increased to OR- 
29.5 suggesting that several factors are involved.
Natural immunity
A principle mechanism of natural immunity to microbs is phagocytosis by 
neutrophils, monocytes, and tissue macrophages. Microbial LPS’s were shown 
to activate the alternative complement pathway, in the absence of antibody, 
through the stimulation of macrophages and other cells to produce cytokines 
(TNFa, EL-1; IL-6, and chemokines) which stimulate inflammation (Bliss et al., 
1998; Shimoyama and Crabtree, 1998). However, LPS of H.pylori was shown 
to have a much lower biological activity (Moran, 1996). Another effect of 
cytokines is a synthesis of HSP’s and other acute phase proteins. It is to note 
that some of these cytokines (TNFa) may also stimulate T and В lymphocytes 
thus amplificating the specific immunity (Eigler et al., 1997). The NAP of 
H.pylori and urease are also potent stimuli of phagocyte activation and 
inflammatory cytokine production (Harris et al., 1996; Satin et al., 2000).
Naturally occuring antibodies that are able to bind self and nonself antigens, 
including those related to blood group epitopes, also participate in natural 
resistance against the infections (Blackwell, 1989; Bouvet & Digiero, 1998). In 
addition, there is a close relationship between natural immune mechnisms and 
acquired immunity: antibodies promote phagocytosis via opsonization of 
bacteria and activation of the complement thus enhancing an effector arm of the 
response (Haberle et al., 1995; Sommer et al., 1998). The effector immune 
mechanisms are nonspecific in terms of they can be induced by a great variety 
of inductors including infections.
Acquired immune response to H.pylori
In the majority of infected individuals, H.pylori elicits a strong systemic and 
mucosal immune response both humoral and cell-mediated. Given that infection 
persists for decades, it is clear that neither humoral nor cellular immune 
defences eliminate the organism. However, after H.pylori eradication re­
infection in adults is uncommon (Mitchell et al., 1998; Gisbert et al., 1998), 
suggesting that immune mechnisms can prevent re-infection. In addition, 
protective immune response can be generated after vaccination with bacterial 
antigens together with appropriate adjuvants (Marchetti et al., 1995). From the
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point of protective immunity, the membrane-associated proteins of H.pylori are 
more promising (Nilsson et al., 2000).
Systemic and mucosal immune response to H.pylori have been extensively 
studied in different clinical conditions but, despite it being useful for diagnostic 
purposes, the role of immune mechanisms in the pathothenesis and natural 
history of H.pylori-associated diseases remains to be clarified. Several main 
aspects of host immune response to H.pylori will be considered in the next 
sections: the type of the response, the antigens involved, the clinical relevance 
of the changes observed, their possible disease type specificity and relation to 
host factors.
Systemic and mucosal humoral immune response
The IgG antibody response to H.pylori is highly polymorphic in terms of its 
strength and antibody patterns. (Kist, 1991; Faulde et al., 1992, 1993; Crabtree 
et al., 1993; Fauchere, 1996; Nilsson et al., 1997, Enroth et al.,2000; Ng et al.,
2001). Each patient appears to have his own pattern. As could be expected, the 
better diagnostic efficiency showed IgG immune response though only the IgA 
systemic response was found in some cases which were IgG negative. The 
crude and partially purified antigenic preparations were used as well as some 
recombinant fragments of H.pylori proteins such as CagA (Xiang et al., 1993; 
Kuipers et al., 1995a). The individual H.pylori strains showed fairly stable 
protein profiles after repeated subcultures (Morgan et al., 1991). In contrast, 
different strains exhibit wide qualitative and quantitative variations in antigenic 
profiles and in immunoblot reactivity especially in the molecular mass range 
from 50 to 70 kDa (Faulde et al.,1992, 1993; Enroth et al., 2000; Pineros et al.; 
2001; Ng et al., 2001). These medium-size proteins (HSP60, flagellins etc.), 
were reported to be responsible for cross-reactivity with antigens of other 
bacterial species (Dunn et al., 1989; Andersen and Espersen, 1992; Engstrand et 
al., 1993; Nilsson et al., 1997).
With the exception of more defined and conserved H.pylori proteins (urease 
subunits, HSP’s, flagellar antigens, CagA, VacA, and some bands with a lower 
molecular mass (25-30 kDa), the specificity of many protein bands for H.pylori 
is not fully proved. However, in spite of inter-individual variations in the 
immune response, the typical band patterns specific for H.pylori can be 
recognized on blots (Nilson et al., 1997; Aucher et al., 1998).
The CagA is highly immunogenic and the presense of serum anti-CagA 
antibodies strongly correlates with the cagA-positive status of the individual, 
and allows infection with the cagA-positive strains to be detected serologically 
(Cover et al., 1995). An enzyme-linked immunosorbent assay (ELISA) has been 
developed using recombinant fragments of CagA protein as antigen (Xiang et 
al., 1993; Blaser et al., 1995). Some ELISA negative patients with gastric cancer 
recognised the CagA band on blot (Crabtree et al., 1993). Such cases were more
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frequent in areas with higher gastric cancer rates (Torres et al., 1998). Thus the 
prevalence of H.pylori infection is obviously underestimated in these patients. 
This implies that CagA antibody may detect past H.pylori exposure (Ekstrom et 
al., 2001; Enroth et al., 2001) whereas ELISA underestimates it.
Most authors found that IgM response to be neither specific nor sensitive in 
serologic diagnosis of H.pylori infection (von Wulffen et al., 1986; Faulde et 
al.,1993; Jones et al., 1986), especially in children (Blecker et al., 1995). It 
appears that IgM antibody is mostly directed to cross-reactive antigens shared 
by other Campylobacter species (Faulde et al., 1992; Andersen and Espersen, 
1992).
Local IgA response is observed in all infected as determined in gastric 
mucosa extracts, gastric juice and in saliva. Bergquist et al., (2000) have shown 
a strong correlation between the anti-H.pylori IgA and IgG levels in the biopsy 
extracts and the frequencies of IgA-, IgG-secreting cells as detected with 
ELISPOT technique. At the same time, the systemic antibody response and 
saliva antibody levels did not correlate with the number of Ig-producing cells in 
the stomach. A similar pattern of IgA and IgG responses to H.pylori extracts or 
H.pylori urease was detected in serum, gastric juice and gastric mucosa tissue 
(Luzza et al., 1994; Futagami et al., 1998). Saliva, serum and gastric mucosa 
H.pylori antibody levels did not differ between superficial and atrophic, active 
and inactive H.pylori positive gastritis (Luzza et al., 1998).
None of the IgG antibody patterns as defined by immunoblotting were 
correlated to gastric atrophy (Aucher et al., 1998) though the simultaneous 
presence of 125,87 and 35 kDa bands predicted the risk of peptic ulcer disease 
with 83% sensitivity and 69% specificity. The IgG2 isotypic response was 
shown to be different in the patients with peptic ulcer or those with only 
gastritis (Bontkes et al., 1992). A recent study of Kimmel et al. (2000) revealed 
no association of specific H.pylori antigenic patterns with antibodies in patients 
with particular gastroduodenal pathology by two-dimensional gel 
electrophoresis. The ratio of H-pylori-specific IgA to total IgA in serum and 
gastric juice was correlated with the histologic grade of gastritis and no 
correlation was found for antibody titers to urease alpha and beta subunits 
(Hayashi et al., 1998). However, in a recent study (Pineros et al., 2001) where 
native strains were used, different clinical groups showed a tendency to react 
preferentially with antigens derived from the same disease. These authors also 
found that H.pylori antibody profile differed in prior and in active infections. 
Different H.pylori strains used as antigens in immunoblotting revealed 
appreciable variations in their ability to detect CagA in immunoblotting with the 
same set of sera, and reacted better when the H.pylori was derived from the 
patients with a similar pathology (cancer) (Vaucher et al., 2000). The 
asympthomatic individuals showed a lower CagA seroprevalence than patients 
with peptic ulcer and gastric cancer. These findings allow to assume that 
insufficient correlation between individual immune response to H.pylori and the 
disease type or natural course of the infection may be explained by inadequate
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antigen used, i.e. standard strain of H.pylori instead of antigenic preparation 
from H.pylori isolate of a given individual.
Another important aspect is the strength of the immune response. The level 
of anti -H.pylori IgG antibodies as detected with ELISA varies enormously 
between infected individuals. Some subjects show ‘gray zone’ values whereas 
others reveal many times higher level of antibodies. However, these variations 
did not correlate strongly with the clinical symptoms or other manifestations of 
the infection. Several studies have demonstrated a correlation between the 
levels of total anti -H.pylori IgG and the colonization of the gastric mucosa by 
the bacteria (Pronovost et al., 1994; Kreuning et al., 1994; Hsu et al., 1997). The 
concentration of soluble H.pylori antigen and circulating specific H.pylori 
antigen immunocomplexes in serum was also shown to correlate with the 
number of H.pylori in gastric mucosa layer (Zhu et al., 2002). The density of 
H.pylori in both on the surface mucous cells and in the surface mucous gel layer 
correlated well with the severity of gastritis (Shimizu et al., 1996). H.pylori 
density of the antrum as well as grade of activity, inflammation and atrophy was 
significantly higher in duodenal ulcer patients than in chronic gastritis, gastric 
ulcer, and gastric cancer. (Kim and Back, 1999). In patients with gastric 
carcinoma, the density of H.pylori infection was decreased in proportion to 
advances in the cancer stage and the mucosal atrophy (Tokunaga et al., 2000), 
indicating that the prevalence of H.pylori may be affected by the stage of the 
disease. However, the levels of anii-H.pylori antibodies in patients with gastric 
cancer and age-matched controls showed no significant differences (Kuipers et 
al., 1993). But IgG antibodies for cagA gene product of H.pylori were more 
common in patients with both diffuse and intestinal type cancer than in 
uninfected controls: OR=10.1 and 5.1, respectively (Parsonnet et al., 1997).
The occurence of dyspeptic symptoms was also not related to the density of 
colonization (Braden et al., 1997). On the other hand, the duodenal ulcer risk 
was found to correlate with antral H.pylori density (Talamini et al., 1997). No 
difference in density between CagA(+) and CagA(-) H.pylori strains neither no 
difference in topographic localization of these strains was noted (Twisk et al.,
2001). But in another study, a higher IgG antibody titer was found in patients 
harboring cagA-positive H.pylori strains (Loffeld et al., 2000b).
Interestingly, the prophylactic immunization against H.pylori is equally 
effective in mice deficient in IgA and В lymphocytes whereas a positive effect 
of therapeutic immunization of В-cell deficient infected mice was antibody 
independent (Sutton et al., 2000; Ernst and Pappo, 2001). It is notable in this 
respect that Thl type immune response is induced early during acute H.pylori 
infection in Rhesus macaques (Mattapallil et al., 2000).
Thus, many controversies still exist regarding the role of immune response 
to H.pylori in host-microbe interplay and it remains unclear, whether systemic 
or local humoral immune response might adequately reflect natural course of 
the infection or its clinical outcome.
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Cell mediated immune response
A number of studies have shown that natural H.pylori infection leads to a Thl - 
type response (Mohammadi M et al. 1996; Bamford et al., 1998; Ren et al.,
2000) which is contributed to delayed-type hypersensitivity and may lead to the 
mucosal damage via stimulation of the innate immune system, e.g. non-antigen 
specific NK cells and mucosal macrophages, leading to production of 
proinflammatory cytokines such as IL-lß, IL-6, IL-8, TNFa and IFN y 
(Crabtree et al., 1993, 1994a; Haberle et al., 1995; D’elios et al., 1997; 
Glupczynski & Devaster, 1997; Sommer et al. 1998; Kuipers, 1999; Nakachi et 
al., 2000;). In contrast, a lower level of anti-inflammatory (Th2) cytokines was 
demonstrated (Fan et al., 1995). However, the changes in the T-cell response of 
blood leukocytes did not always reflect those in the mucosa and may be 
increased irrespective of H.pylori status (Birkholz et al., 1993, Fan et al., 1995; 
Karttunen et al., 1997). It has been shown that gastric mucosa T cells are 
polarized to produce Thl cytokines in the absence of H.pylori (Itoh et al., 
1999). Bodger et al. (1992) reported that, in addition to an increased production 
of TNFa, there was also higher secretion of anti-inflammatory and 
immunosuppressive IL-10 in H.pylori infected mucosa that may be protective 
for H.pylori. Ren et al., 2001 observed a shift from a Thl-type to a Th2-type 
response (increased IL-4 production and decreased IFN gamma production) in 
patients with gastric cancer and dysplasia.
There are close interactions between the immune system and gastric 
epithelial cells in H.pylori gastritis. This includes the the upregulation of 
interleukin-8 and de novo expression of MHC class-П antigen in gastric 
epithelium. (Engstrand et al., 1989, Crabtree et al., 1993, 1994b). In gastric 
epithelial cell cultures H.pylori infection results in increased EL-8 levels which 
correlate with neutrophil infiltration (Crabtree et al., 1993). The ability of 
CagA(+) strains of H.pylori to induce IL-8 transcription correlated with the 
ability of the strain to activate nuclear factor NF-кВ indicating a mechanism for 
a higher inflammatory response seen in individuals infected with CagA(+) 
H.pylori strains (Sharma et al., 1998). Release of lysosomal enzymes and 
oxygen free radicals by neutrophils during phagocytosis of bacteria may further 
contribute to mucosal damage and carcinogenesis (Dunn et al., 1993). 
Moreover, IFNy and TNFa produced by gastric Thl cells can induce epithelial 
cell death or increase apoptosis induced by H.pylori (Wagner et al., 1997; Fan 
et al., 1998). LPS of H.pylori induces apoptosis of gastric epithelial cells in rats 
(Piotrowski et al., 1997) and in human epithelial cells in vivo (Jones et al., 
1996). The strains expressing the cagPAI induce greater level of inflammation 
(Yamaoka et al., 1997) suggesting that the variation in the host response may 
explain a more severe disease in individuals infected with CagA+ strains. 
However, a recent study of Rad et al. (2002) showed that mRNA amounts of the 
Th 1 markers did not differ between patient groups infected with different strain 
types.
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All these data brought to a speculation that the elimination of H.pylori is 
dependent on a Th2 response which helps to promote antibody responses. It 
seems, however, that this is oversimplification because mice deficient for IFN-y 
(where Th2 response is dominated) have showed no protective response after 
immunization (Sawai et al., 1999). Another study showed that H.felis infection 
was even slightly increased in EL-4 (Th2 cytokine) knockout mice (Chen et al.,
1999).
However, recent investigations in mice deficient in IgA or В cells showed 
that they were capable to elicit effective immunity and provide protection 
(Blanchard et al. 1999; Ermak et al., 1998). This points to the fact that other 
effector mechanisms (except В cells or antibody) are also important in 
providing immunity and protection to luminal pathogen (Ernst et al., 2001). 
Interestingly, after immunization, the antigen-specific response is 
predominantly polarized toward a Th2-type response, with production of 
cytokines that can inhibit the activation of Thl cells and of macrophages, and 
the production of proinflammatory cytokines (Del Guidice et al, 2001).
A general conclusion which can be made from all these studies is that the 
ability of an individual to respond to H.pylori with specific immune 
mechanisms can appreciably affect the severity of disease and the risk of 
progressing disorders such as atrophy and cancer. But it seems that none of 
these mechanisms are strongly disease-specific. However, the peculiarities in 
the host response to H.pylori appear to be important determinant. The EL-1 gene 
polymorphism in the interleukin-1 gene cluster is a very attractive example. The 
gastric cancer relatives with hypochlorhydria had a significantly higher 
frequency of the proinflammatory IL-1RN*2 allele and T-T haplotype of EL-lß- 
31 and IL-lß-511, as compared to those without hypochlorhydria (El-Omar et 
al., 2000; El-Omar, 2001) suggesting that host pro-inflammatory EL-1 
genotypes are important in determining the functional response to H.pylori 
infection, the pattern of gastritis and the ultimate clinical outcome of gastric 
cancer.
H.pylori infection and autoimmunity
Immunity, like many other homeostatic mechanisms, is beneficial for the host 
but also has a potential to be detrimental to him. Injury of adjacent normal 
tissue is a pathologic side effect of these defence mechnisms.
Evidence is accumulating that an ongoing immune stimulation by H.pylori 
antigens may lead to the autoimmune reactions of various specificity. 
Antibodies to several target antigens may be involved: autoantibodies to the 
surface of foveolar epithelial cells, mucosal neck cells, anti-canalicular 
antibodies to the canaliculi of parietal cells, intrinsic factor, to the Lewis 
antigens and HSP’s (Negrini et al., 1991; Maccia et al., 1993; Uibo et al., 1995; 
Appelmelk et al., 1996; Faller et al., 2000; Vorobjova et al., 2000). These
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reactions were shown to correlate with the rate of apoptosis in the gastric 
mucosa (Kirchner et al., 1997). This mechanism may represent a pathogenic 
link between H.pylori-related gastritis and atrophy. In an immunohistochemical 
study, many monoclonal antibodies against H.pylori were reacted with gastric 
epithelial cells (Ko et al., 1997). The cross-reacting antigens included urease, 
flagella, LPS and heat shock protein of H.pylori. H+K+ATPase is a major 
target antigen in autoimmune gastritis (D’Elios et al., 2001). The beta subunit of 
H.pylori urease was shown to have a high homology with gastric H+K+ATPase, 
the gastric parietal cell antigen (Uibo et al., 1995). These authors also found a 
negative association between H.pylori and autoimmune corpus gastritis. In 
another cohort study, a significant increase in parietal cell antibody positivity 
was observed among H.pylori-infected individuals (Vorobjova et al., 2000). The 
presense of common or cross-reacting epitopes for gastric mucosa cells and 
H.pylori is considered as an important pathway for induction of autoimmunity 
through the molecular mimicry mechanism (Negrini et al., 1991,1997). 
Molecular mimicry of autoantigens by microbes can stimulate autoreactive cells 
by their cross-reactivity in individuals where there are defects in 
immunoregulation. A strong expression of class П transplantation antigens and 
an increased number of у/ô T-cells was demonstrated in gastric epithelial cells 
of H.pylori-infected individuals suggesting an increased possibility for initiation 
of local immune response and autoimmunity (Engstrand et al., 1989, 1991). 
However, in spite of a significant correlation found between anti-gastric 
autoantibodies and gastric mucosa atrophy (Valle et al., 1996; Claeys et al., 
1998;Vorobjova et al., 2000) it remains unclear whether these are the cause or 
the sequel of gastric atrophy.
An inflammation induced by H.pylori leads to an enhanced expression of 
HSP in human gastric epithelial cells (Engstrand et al., 1991). The presence of 
anti-HSP antibodies was significantly correlated with the grade of chronic 
inflammation, associated with the progression of corpus gastritis (Valle et al.,
1996) but was not related to the development of atrophy during 18 years of 
follow-up (Vorobjova et al., 2001). In an autologic system Hsp60 was shown 
not to be likely a target for autoimmunity in H.pylori infected individuals 
whereas Le(x,y) epitopes did (Taylor et al., 1999).
Possible involvement of blood group related antigens in autoimmunity is 
reviewed in the next section.
H.pylori and gastric glycoconjugates
The gastric mucus and mucosal cell surface glycoconjugates constitute normal 
microenvironment for H.pylori. Mucins are highly glycosylated in О-linkage to 
serine and threonine residues (O-glycans), high molecular weight glycoproteins 
produced by many epithelial cells and tumors (Lesuffleur et al., 1994; Gendler 
et al., 1989). Most of them are secretory or gel-forming mucins except MUC1
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which is a membrane-bound mucin (Van Klinken et al., 1995). Normal gastric 
mucosa expresses MUC1 and MUC5AC mucins in foveolar epithelium and 
MUC6 in the glands (Pinto-De-Sousa et al., 2002).
Expression pattern can be modified under pathological conditions (Silva et 
al., 2002). Besides, mucins show great heterogeneity at the carbohydrate level 
(Lesuffleur et al., 1994) that correlates with Lewis antigen expression in the 
human stomach (De Bolos et al., 1995). Tumor-associated mucins are different, 
in that they are aberrantly (incompletely) glycosylated, leading to the exposure 
of the protein core and to the expression of more short and less-branched 
carbohydrate side chains that constitute several carbohydrate tumor-associated 
epitopes such as blood-group-related antigens Tn (GalNAca-O-Ser/Thr), sialyl- 
Tn and Thomsen-Friedenreich (T) antigen (Galßl-3GalNAca/ß-0-Ser/Thr) 
(Hakomori, 1989; von Mensdorff-Pouilly et al., 2000a). Natural antibodies to 
these, as well as to peptide epitopes exposed due to altered glycosylation of the 
mucin molecule, are present in every individual. The level of anti-carbohydrate 
antibodies is rather stable for a given individual but varies appreciably between 
individuals for yet unknown reasons. Natural immune response to these 
epitopes is considered to be one of the natural defence mechanisms against 
cancer (Springer, 1984; von Mensdorff-Pouilly et al., 2000b).
Blood group ABH and Lewis (Le) antigens are expressed in gastric 
glycoconjugates in both cell membrane-bound and secretion. The expression of 
blood group-related carbohydrate epitopes on gastric mucins and on epithelial 
cell glycoconjugates has been shown to be dependent on secretor/nonsecretor 
(Se/se) status (Sakamoto et al., 1989; Oriol et al., 1992). The secretor status is 
determined by the presence or absence of a fucose residue on the terminal 
galactose residues on the mucosal О-linked oligosaccharides and mucins in 
secretions, which in turn is determined by the inheritance of the appropriate a-1- 
2 fucosy 1-transferase Se (secretor) gene (Oriol et al., 1992; Henry and Oriol, 
1995). At the phenotypical level the secretors belong to Le (a-b+) and those 
who are non-secretors to Le (a+b-) histo-blood-group phenotype. Individuals 
with Le (a-b-) phenotype may be secretors or non-secretors depending on the Se 
gene which are present in about 90% of them (Henry and Oriol., 1995). An 
expression of some other carbohydrate antigens is also related to Se/se status. In 
particular, the difference concerns the expression of cancer related T epitope on 
type 3 mucin-type chains in non-secretors exclusively (Bara et al., 1993). In 
contrast, in secretors this epitope is further glycosylated (Okada et al., 1994). 
Normal surface gastric epithelia express T in alpha-anomeric configuration 
(Sotozono et al., 1994). An expression of T epitope was reported to be increased 
in the cytoplasm of surface and glandular mucous cells in H.pylori infected 
patients with chronic gastritis (Barresi et al., 2001).
Gastric mucosa cells also express Le type 2 epitopes Le(x) and Le(y) but 
histochemically the topography is different. No Le(x) expression was found in 
the foveolar epithelial cells of either secretors or nonsecretors whereas some 
amount of Le(y) can be detected in this area in secretors. However, both
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determinants were demonstrated in gastric glands irrespective of Se/se status 
(Sakamoto et al., 1989). Amano et al. (1997) reported on the presence of natural 
antibody to Le type 2 antigens in the blood of every individual irrespective of 
H.pylori status. It is not known whether the immune response to Le(x) and 
Le(y) is related to the host Lewis phenotype. Anti-Lewis(x) IgG was detected 
more frequently in dyspeptic subjects compared to healthy individuals, whereas 
the prevalence of IgM Le(x) antibodies was higher among healthy people and 
might have protective role (Rudnicka et al., 2001). H.pylori-infected individuals 
with a low level of anti-Le(x) antibodies were shown to be at a higher risk for 
gastric mucosa atrophy development (Kuipers et al., 1997). No relation of anti- 
Le(x,y) antibodies to anticanalicular autoantibodies was demonstrated in 
absorbtion experiments indicating that other mechanism than molecular 
mimicry leads to the formation of parietal cell antibodies (Faller et al., 1998).
Many blood group antigen related carbohydrate epitopes have been shown to 
be expressed in bacteria (Blackwell, 1989). On the other hand, some of 
carbohydrate antigens of gastrointestinal mucosa may be a target for microbial 
adhesins (Rios and Bianco, 2000). The Le (b) blood-group antigen is known to 
mediate the H.pylori attachment to human gastric mucosa (Boren et al., 1993) 
via blood group antigen binding adhesin (BabA) of H.pylori (Gerhard et al., 
1999; Printz et al., 2001) suggesting that the Le(a+b-)/non-secretors might be 
more resistant to H.pylori infection than secretors. However, many researchers 
found no association between the prevalence of H.pylori infection and the 
proportion of non-secretors or the distribution of Lewis blood group phenotypes 
in dyspeptic individuals and patients with peptic ulcers (Höök-Nikanne et al., 
1990; Mentis et al., 1991; Chesner et al., 1992). Interestingly, blocking of 
H.pylori Le(b) with anti-Le(b) monoclonal antibodies did not alter the binding 
of the bacteria to Le(b) thus suggesting that expression of Le(b) in H.pylori 
does not interfere with the bacterial adhesion property to immobilized Le(b) 
(Zheng et al., 2003). BabA is supposed to facilitate colonization of H.pylori and 
increases IL-8 response resulting in enhanced mucosal inflammation (Rad et al.,
2002). The vacAsI+/cagA+ strains harboring babA2I were associated with a 
higher degree of inflammation and colonisation than vacAsI+/cagA+ strains 
lacking babA2. In addition to Le (b) antigen, the H-l disaccharide (Fucal-2Gal) 
was shown to be the minimal receptor for H.pylori adhesion (Boren et al., 
1994).
The majority of H.pylori strains was shown to express human blood group 
antigens ABH, Lewis type 1 and type 2 antigens (Sherburne and Taylor, 1995; 
Appelmelk et al., 1996; Wirth et al., 1997). H.pylori can adapt its pattern of 
Lewis antigen expression in LPS to mimic that of its host, indicating that the 
pathogen is able to regulate this virulence factor (Wirth et al., 1997). However, 
other researchers (Taylor et al., 1998; Henegan et al., 2000) did not find a 
concordance between bacterial and host expression of Le determinants though 
the last authors showed that Le(x) expression was associated with a higher 
density of colonization and inflammation. It may be related to the phenotypic
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diversity of Le antigen expression in H.pylori isolates derived from the same 
host (Wirth et al., 1999). The Lewis antigen expression in H.pylori is also 
related to CagA status (Wirth et al., 1996). No apparent association between 
Lewis phenotype of H.pylori isolate and disease pathology was evident in 
another recent study (Ryan et al., 2000). On the other hand, Zheng et al., (2000) 
demonstrated that, in Asian population, peptic ulcer was associated with the 
increased expression of Le antigens, but not with CagA status, or iceA or vagA 
genotypes in H.pylori isolates.
It has been shown that ILlß and IL-6 stimulated mucus secretion, while IFN- 
Y potentiates H.pylori-decreased mucus secretion by gastric epithelial cells 
(Takahashi et al., 1998). H.pylori was shown to inhibit total mucin synthesis in 
vitro and decrease the expression of MUC5AC and MUC1 mucins (Byrd et al.,
2000). There is an evidence that VacA is involved in down-regulation of mucin 
expression or secretion (Beil et al., 2000). An aberrant expression of Le(x) in 
surface mucous cells has been demonstrated in H.pylori infected subjects (Byrd 
et al., 1997). The prevalence of Le(y) expression was found in patients with 
duodenal ulcer (Thoreson et al., 2000). The glycosylation of gastric mucins has 
been shown to be reversibly altered by H.pylori (Ota et al., 1998). These 
findings may be related to the glycosidase and mucinase activity of H.pylori 
(Smith et al., 1994; Dwarakanath et al., 1995). H.pylori possesses a gene that is 
almost identical to a mucinase gene of Vibrio cholerae (Smith et al., 1994). 
Possible mucinase activity as well as a degradation of the gastric mucus by the 
phospholipase A (Xerry and Owen, 2001) may be contributed to the damage of 
gastric mucosal barrier.
An over-representation of blood group A individuals among patients with 
gastric cancer and the prevalence of blood group О subjects and those who are 
non-secretors among patients with peptic ulcers were shown long ago (Aird et 
al., 1954; Correa et al., 1973; Mourant et al.,1978; Mentis et al., 1991), but the 
basis for this association remains unknown. A higher proportion of blood group 
О subjects but no relation to Lewis type or Se/se status was found among 
H.pylori-infected patients with dyspeptic symptoms who underwent endoscopy 
(Mattos et al., 2002). It has been reported that the leukocytes of blood group О 
donors revealed a stronger inflammatory response to H.pylori and released 
significantly higher amount of IL-6, TNFa and nitric oxide than blood group A 
leukocytes (Alkout et al., 2000).
Altogether, it appears that heterogeneity of H.pylori and gastric 
glycoconjgates is contributed to the pathogenesis of H.pylori infection and 
related to immunologic response of the host to blood group related carbohydrate 
epitopes. It is not clear to what extent these mechanisms are contributed to 
natural course of the infection or its clinical outcome.
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BACKGROUND AND AIMS
An enormous genetic and phenotypic polymorphism of both H.pylori and host 
suggests the heterogeneity of outcomes between the patients. It is still not clear 
yet to what extent and how bacterial virulence and to what extent the genetic 
disposition of the host contribute to this issue. A growing body of evidence 
suggests that a majority of H.pylori pathogenetic pathways are strongly related 
to immunologic mechanisms especially to the effector arm of host immune 
response. Humoral immune response to H.pylori may be considered as an 
integral indicator of H.pylori-host interplay in the sense that it reflects both the 
H.pylori antigenic (phenotypic) polymorphism and the host’s ability to respond 
to H.pylori infection which is a typical ‘slow infection’ where the host is the 
major determinant. Therefore, on the basis of the evidence to date, further 
studies are required to resolve the role of host’s polymorphism in immune 
response to H.pylori and pathogenesis of H.pylori-associated diseases.
An insufficent correlation between the immunological response to H.pylori 
and clinical outcome of the infection may be addressed to several questions: (i) 
to what extent the differences in the immune response are dependent on host 
polymorphism and to what extent on H.pylori diversity? (ii) Is it possible to 
select the disease-type peculiarities of the immune response and to predict the 
clinical outcome of the infection? And (iii) can this decision be based on 
immunological criteria on the individual level?
In the present investigation special attention was paid to the phenotypic traits 
of the host that may influence H.pylori-host immunological interaction. These 
include histo-blood group related antigens and their derivatives which were 
reported to be expressed on both H.pylori and host gastric mucins and mucosal 
cell glycoconjugates. Mucins represent normal in vivo microenvironment for 
H.pylori and undergo appreciable alterations in gastric disease. In the host, this 
is a highly polymorphic system that is controlled by ABH, Le, H and Se/se 
genes and involved in H.pylori adhesion and colonisation. Besides, these 
antigens may be the target for induction of autoimmunity which is closely 
related to gastric mucosa damage and thus to the clinical outcome of the 
infection. A natural and acquired immune response to these carbohydrate 
epitopes may reflect both their expression in H.pylori and the ability of the host 
to recognize them, and to respond to them And finally, we explored a 
hypothesis that H.pylori might be indirectly involved in gastric carcinogenesis 
via systemic impact on naturally occuring immune mechanisms against cancer.
Aims
In the present study, the broad objective was to investigate the humoral immune 
response to Helicobacter pylori antigens in patients with gastroduodenal
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diseases and in blood transfusion donors with special attention to the host 
phenotypic polymorphism for blood group related antigens which may 
contribute to the pathogenesis and clinical outcome of H.pylori-associated 
diseases.
The specific aims o f the thesis were:
• To evaluate the seroprevalence of H.pylori infection and more virulent CagA 
positive H.pylori strains in the patients with gastroduodenal pathology 
(gastric cancer, peptic ulcer disease and chronic gastritis) and blood 
transfusion donors in relation to ABH, Lewis blood group phenotype or 
Se/se secretory status of the host. To assess whether these phenotypic 
characteristics of the host may cause the differences in the seroprevalence of 
H.pylori infection and contribute to the disease type-specific features of the 
immune response to H.pylori antigens.
• To investigate the effect of H.pylori infection and host Le(a,b) phenotype on 
natural immune response to Lewis type2 antigens.
• To study possible systemic impact of H.pylori infection on natural immune 
response to tumor-associated blood group-related Thomsen-Friedenreich 
antigen (Galß 1,3G alN A c< x/ß-0 -S er/T hr) in different clinical groups.
• To test the hypothesis of whether H.pylori might express the tumor- 
associated Thomsen-Friedenreich antigen.
• To evaluate the survival of patients with gastric cancer depending on 
H.pylori serologic status and on the level of natural antibody to tumor- 
associated Thomsen-Friedenreich antigen.
30
MATEM AL AND METHODS
The detailed description of the material and methods used are described in the 
corresponding papers (I-VDI). However, some additional methodological 
aspects are presented in this section to stress some methodological points in 
more detail that were not fully described due to the limited space of journals.
The results were analysed in two ways: by comparison (i) between the 
Я.ру/on-seronegative and -seropositive subgroups within each group (donors, 
patients) to look for a relation of the changes found to H.pylori infection, and 
(ii) between the groups for both infected and non-infected individuals trying to 
find putative disease type-specific features. Host-dependent factors such as 
ABO(H), Lewis(a,b) phenotype, secretory (Se/se) status, a level of T antigen- 
specific IgG, IgM antibodies, anti-Le type П antibodies, the disease type, tumor 
morphology and the stage of cancer, the survival of patients with cancer were 
considered as predictors and correlated with H.pylori serologic status, the level 
of anti-H.pylori antibodies, the CagA status, the immunoblot pattern, and the 
expression of tumor-related T antigen in H.pylori.
Subjects
The patients with benign gastric diseases (n=204) and those with histologically 
verified gastric carcinoma (n=281) were two main study groups. In addition, a 
group of randomly selected blood transfusion donors (n=306) were studied as 
the control group to determine the ABH and Lewis phenotype distribution 
among H.pylori-positive and negative subgroups of individuals, and to evaluate 
the impact of these blood group antigens polymorphism on the other 
parameters. Individuals of younger age (below 40 yrs) were not included in 
some parts of the study (IV, V) to make the distribution by age comparable to 
that of patients with gastric cancer.
Tumor staging and morphology were based on histopathological (pTNM) 
classification of malignant tumors (Sobin and Wittekind, 1997) and evaluated 
according to the system of Lauren (1965) as intestinal and diffuse type of tumor 
growth. Peptic ulcer disease was diagnosed by gastroduodenal endoscopy. In 
patients with chronic gastritis, antrum and corpus biopsy specimens (aa 1-2 
specimens) were assessed histologically in accordance with the updated Sydney 
system (Dixon et al., 1996). Moderate or severe gastric mucosa atrophy in any 
part of the stomach was considered as atrophic gastritis. The distribution of 
cancer patients by stage and other characteristics of individuals studied are 
presented in papers I-VDI.
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H.pylori strains and culture conditions
H.pylori strain NCTC 11637 (CagA and VacA positive) was cultured on 
Gonococcal agar base/Campylobacter (GAB/CAMP) reference agar (Oxoid 
Ltd, Basingstoke, Hampshire, England) supplemented with 10% horse blood, 
selective supplements (Dent) and IsoVitaleX Enrichment (Oxoid) at 37°C for
2-3 days under microaerophilic conditions (5% 02, 10% C02, 85% N2). The 
clinical isolates of H.pylori from antral gastric mucosa were cultured in a 
similar way. The strains were stored at -70°C in Tryptic Soy Broth containing 
15% (v/v) glycerol.
Extraction o f H.pylori cell surface proteins
A glycine cell surface membrane antigens extraction (0.2M acidic glycine, pH 
2.2, for 15 min.) of H.pylori strain NCTC 11637 and H.pylori clinical isolates 
was performed according to Logan and Trust, 1983. Extracts were stored at -  
70°C and used as an antigen for ELISA and SDS-PAGE within 6 months. The 
antigen was a pool of 5-9 different preparations. The individual clinical isolates 
of H.pylori were treated in a similar way.
H.pylori enzyme-linked immunosorbent assay (ELISA)
Flat bottom micrititer plates (Maxi Sorp, Nunc, Roskilde, Denmark) were 
coated with 0.1 ml of antigen (5^ig/ml in carbonate buffer pH 9.6) per well and 
incubated at 4°C overnight. Alkaline phosphatase conjugated goat anti-human 
IgG (Gibco BRL, USA or Dako A/S, Glostrup, Denmark) and p-nitro-phenyl- 
phosphate (Sigma, St.Louis, MO) as substrate were used. A pool of human IgG 
(Kabi AB, Stockholm, Sweden) was placed in each ELISA plate as a positive 
control for 100 units and H.pylori seronegative reference serum was run for 
negative control. The relative antibody activity (RAA) values were calculated 
according to Blomberg et al., 1983. RAA values <25 were regarded as H.pylori 
seronegativity. In control experiments, the method was compared with H.pylori 
ELISA commercial kit (Pyloriset ELA-G, Orion Diagnostica, Finland) in 36 
blood donors (10 seronegative): the coincidence of results was observed in 34 
of 36 (94.4%) subjects. In some studies, (V,VI) to improve the discrimination 
between H.pylori infected and noninfected individuals, the subjects with a ‘gray 
zone’ RAA values (RAA in the ranges of 26-39) were excluded from the 
analysis.
32
ABO(H) phenotyping of erythrocytes was carried out using anti-A and anti-B 
monoclonal antibody (MonoCarb AB, Sweden). Lewis phenotyping of 
erythrocytes was carried out using anti-Le(a) and -Le(b) monoclonal antibody 
gel system (DiaMed, Switzerland) according to the instruction of the 
manufacturer.
In the patients with benign gastric diseases the secretor/non-secretor (Se/se) 
status was determined by tesing of H-antigen in boiled saliva at dilution 1:10 
using H-specific biotin-labelled lectin UEA-1 from Ulex europaeus (Sigma) as 
described by Rahat et al., 1990. The method was compared with Lewis 
phenotype determined by erythrocyte testing in 28 individuals and the results 
were identical in 96% of cases among the subjects of Le(a+b-) /non-secretor 
and Le(a-b+)/secretor phenotype. All non-secretors showed O.D. values below
0.25 (mean ± 2tS.E. at P=0.05). This O.D. value was used as a cut-off limit to 
discriminate between the secretors and non-secretors. No overlapping for O.D. 
values was observed in both groups except one donor of Le(a-b+) phenotype. 
He was classified as Le(a-b+)/secretor as detected with MAb but defined as 
non-secretor by UEAI lectin assay. Apparently he belonged to the so-called 
‘weak’ secretors (Oriol et al., 1992).
Blood group phenotyping and secretor/non-secretor (Se/se) status evaluation
H.pylori cell-ELISA
Freshly prepared from 2 days culture H.pylori cells were fixed with 0.5% 
glutaraldehyde for 20 min at RT. After being blocked with 0.15 M glycine and 
1% bovine albumine and washing 3 times with phosphate buffered saline (PBS) 
pH 7.4, 108 cells per tube in 0.1ml of PBS were incubated with equal volume of 
T antigen-specific MAb dilutions for 2 hrs at room temperature (RT). Bacteria 
were then washed four times in PBS-0.05% Tween-20 and incubated with either 
alkaline phosphatase-conjugated rabbit anti-human IgM or, for murine MAb, 
with biotinylated goat anti-mouse immunoglobulins (Dako, Denmark) for 1 hr 
at RT followed by streptavidin-alkaline phosphatase conjugate (Dako) for 1 hr. 
After additional 3 washes, the bacteria were incubated with p-nitro-phenyl- 
phosphate solution (Sigma, St.Louis, MO) for 30 min. Absorption was read at 
405 nm. Bacteria incubated with PBS instead of MAb were treated in the same 
way and served as control. The assay was performed in duplicate.
Sodium-Dodecylsulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) and 
Western Blot Analysis
SDS-PAGE was performed in 12% polyacrylamide separating gel according to 
Laemmli, 1970. Nitrocellulose sheets (Schleicher&Schuel, Germany) or PDF
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membrane Immobilem P (Millipore, Bedford, MA) were used for immuno­
blotting. After separation and semidry transfer in Hoefer vertical electrophoresis 
equipment (Amersham, Pharmacia Biotech, Finland) the membranes were 
saturated with blocking buffer recommended by Rucheton et al. (1992) 
(glycine, hydrolysed gelatine, Tween 20, polyvinyl-pirrolidone, ethanol amine), 
that results in very low background even at long staining time. After incubation 
with diluted serum or monoclonal antibodies or antiserum the strips were 
washed and incubated with either alkaline posphatase or peroxidase-labelled 
anti-human or anti-mouse IgG, IgM (Gibco, Dako) and, after repeated washing, 
developed with NBT/BCIP substrate (Sigma) or with 3-amino-9-ethylcarbasol, 
respectively (Sigma). All H.pylori extracts were tested under the same 
electrophoretic and blotting conditions, serum and MAb’s dilutions etc. For 
semiquantitative evaluation, the strips were scanned (Sharp image scanner JX- 
330) and the relative proportion of bands was calculated using Image Master 
TotalLab software (Amersham Pharmacia Biotech, Finland).
Evaluation o f CagA serologic status
The CagA serologic status was assessed by two methods:
1. After electrophoretic separation of cell surface membrane proteins of 
H.pylori and blotting the membranes were cut into strips, washed with PBS 
and incubated with patients serum (1:76) in PBS-Tween 20 (0.05%) 
overnight at 4°C under agitation. After washing the strips were incubated 
with peroxidase labelled rabbit anti-human IgG (Gibco) and developed with
3-amino-9-ethylcarbasol (Sigma). A positive reaction was defined as the 
presence of a specific CagA band of -120 kDa on the blots. The CagA- 
seronegative and CagA-seropositive serum were simultaneously run as 
controls. In addition, the distribution of other major protein bands of 
H.pylori on blots was evaluated in patients with gastric cancer and blood 
donors.
2. CagA-ELISA was performed as described by Xiang et al., 1993 with slight 
modifications (IV). Flat-bottomed polystyrene plates (Maxi Sorp, Nunc) 
were coated with 100 )il/well (1.25 (J-g/ml) of the purified recombinant 
fragment coding for the immunodominant region of the CagA protein, 
expressed as a fusion protein in Escherichia coli and purified as described by 
Xiang et al., 1993. An alkaline-phosphatase-conjugated goat anti-human IgG 
(Gibco BRL, Life Technologies, Gaithersburg, MD, USA) and p-nitrophenyl 
phospate (Sigma) as substrate were used. The cut-off limit equal to an 
absorbance of 0.42 was determined on the basis of the investigation of 26 
H.pylori-ELISA and CagA blot-negative and of 46 CagA blot-positive blood 
donors sera. This cut off value gave the best discrimination between the 
groups and the O.D. values more than 0.42 were regarded as positive 
reaction (strong responders). Two reference sera from CagA-seropositive
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and CagA-negative donors, respectively, were included in each plate as 
internal standards to control the interassay variations. A sensitivity of 96.2% 
and specificity of 96.6% has been reported for this assay as compared with 
Western blot (Xiang et al., 1993).
Determination o f serum anti-Thomsen-Friedenreich (T) antigen specific anti­
bodies by ELISA
Plates (MaxiSorp, Nunc, Roskilde, Denmark) were coated with synthetic T- 
hapten-polyacrylamide (PAA) conjugate (Synthesom, Munich, Germany; 10 
mol% of carbohydrates) 5|ig/ml in carbonate buffer, pH 9.6 or 1% BSA in PBS 
(control wells) at 4°C overnight. After washing three times with PBS-Tween the 
plates were blocked with 0.15ml of 1% BSA in PBS for Ihr at room 
temperature (RT) and washed in PBS-Tween. Serum (lOOjxl) diluted 1:50 in 
PBS-Tween were added and incubated for 2 hrs at RT. The plates were then 
washed and bound IgG was detected with 100|il of alkaline phosphatase 
conjugated goat anti-human IgG or IgM (Gibco, BRL, Life Technologies, 
Gaithersburg, MD, USA) diluted 1:1000 in PBS-Tween. Following the 
incubation of 90 min at RT and washing, the plates were developed with p- 
nitro-phenyl-phosphate (Sigma) and absorbance values at 405 nm were 
registered with Labsystem Multiscan MCC/340 (Finland). The optical density 
(O.D.) values of control wells (PBS-BSA) were subtracted from the values of 
the wells coated with the T conjugate. Each serum was analysed in duplicate. 
The intraassay variations did not exceed 7%. For more details, see paper VII.
Depending on the O.D. values individuals were divided into ‘strong’ and 
‘weak’ responders. The cut-off limits for IgG and IgM antibody levels were 
calculated on the basis of the O.D. values distribution and allowed the best 
discrimination between subjects with low and high O.D. values. The 
distribution curves were optimized using CurveExpert v.l.2. program as 
described elsewhere (Kurtenkov et al., 1999).
Expression o f Thomsen-Friedenreich (T) antigen in H.pylori
Cell surface membrane extracts of H.pylori standard NCTC 11637 strain and 
the clinical isolates of H.pylori (n=13) were analysed by immunoblotting and 
cell-ELISA with five different T antigen-specific murine and human 
monoclonal antibodies (VII). The specificity of immunostaining was checked in 
blocking experiments using peanut agglutinin and rabbit anti serum to T antigen. 
Anti-H type 2 and anti-CD-43 Mab’s were used as isotypic controls.
In H.pylori cell-ELISA, freshly prepared from 2 days culture H.pylori cells 
were fixed with 0.5% glutaraldehyde for 20 min at RT. After being blocked
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with 0.15 M glycine and 1% bovine albumine and washing 3 times with PBS, 
108 cells per tube in 0.1ml of PBS were incubated with equal volume of T 
antigen-specific MAb dilutions for 2 hrs at RT. Bacteria were then washed four 
times in PBS-0.05% Tween-20 and incubated with either alkaline phosphatase- 
conjugated rabbit anti-human IgM or, for murine MAb, with biotinylated goat 
anti-mouse immunoglobulins (Dako, Denmark) for 1 hr at RT followed by 
streptavidin-alkaline phosphatase conjugate (Dako) for 1 hr. After additional 3 
washes, the bacteria were incubated with p-nitro-phenylphosphate (Sigma, 
St.Louis, MO) for 30 min. and the absorbance was read at 405 nm. Bacteria 
incubated with PBS instead of MAb were treated in the same way and served as 
control. The assay was performed in duplicate.
H.pylori eradication therapy
The patients with duodenal ulcer were treated with a standard one week triple 
therapy (amoxycillin l.Og, clarithromycin 0.5g, and omeprasol 20mg twice a 
day). All the treated patients and untreated control subjects were followed for 
6-24 months. Serum samples taken before and at different intervals after 
therapy were stored at -20°C and tested in parallel. The decrease of IgG
H.pylori antibody level (RAA) at 6 month after therapy more than by 50% was 
considered as a sign of successful treatment. This group was used for evaluation 
of H.pylori eradication impact on the level of T antigen specific antibodies.
Statistical methods
Statistical comparisons between the groups were performed by the Student’s t- 
test and Pearson two-tailed correlation. Nonparametric chi-square (%2) test and 
Fisher’s exact test (for small groups) were applied for comparison groups 
discriminated by cut-off limits. Odds ratios (OR) and their 95% confidence 
intervals (95% Cl) were calculated to measure the association between the 
studied parameters. The difference was considered to be significant when 
P<0.05.
The cumulative survival of cancer patients was estimated by the Kaplan- 
Meier method, and the resulting curves were compared by the use of the log- 
rank test (SPSS software, version 10.0.5). Mean and median survival time with 
the standard error and 95% confidence interval was calculated for every group 
of patients divided by H.pylori status and/or anti-T antigen specific antibody 
level. Statistical tests were two-sided and the difference in survival between the 




IgG immune response to acid glycine extracted cell surface proteins of the
H.pylori strain NCTC 11637 was studied in different groups of patients and 
blood donors to characterize the background seroprevalence parameters for 
further analysis of their relation to ABH and Le phenotype of the host. The 
individuals over 40 years of age were over represented to make the groups 
comparable to patients with gastric cancer.
The H.pylori seroprevalence was high and strickingly similar in blood 
transfusion donors and patients with gastroduodenal pathology, being in the 
ranges of 74-86%. In the blood donor group, it was 79.1-83.6% in three 
consecutive studies (paper 1-1П). These data are in concordance with the 
findings observed in southern Estonia with no significant age-related 
differences from 20-90 years (Vorobjova et al., 1994; 1998). Such similarity 
suggests that the results reflect the real rate of H.pylori seropositivity in the 
population.
No appreciable disease type-specific differences in H.pylori seroprevalence 
were found between the groups studied. The only exception was a significantly 
lower seroprevalence in patients at advanced stages of gastric cancer compared 
to the seropositivity rate in blood donors, patients with I+П stage cancer (paper
I,V) and patients with duodenal ulcer (V). No relation to the morphological type 
of tumors (diffuse or intestinal type according to Lauren classification) was 
observed (I). These findings may be explained by the fact that very high 
seroprevalence is characteristic of the Estonian population. Higher H.pylori 
prevalence in patients with more severe gastric pathology (peptic ulcer disease, 
gastric cancer) has been mostly demonstrated in geographical areas or ethnic 
groups with a lower (40-50%) prevalence of H.pylori infection in the 
population. In a situation, where a majority of the population is infected with 
H.pylori, it is reasonable to expect that the putative disease type-specific 
differences may be indistinguishable on such background. The prevalence of 
H.pylori infection in patients with gastric cancer seems to be underestimated 
under these circumstances due to an appreciable decrease in the seroprevalence 
rate in patients with advanced cancer.
The CagA status
CagA is the most studied virulence factor of H.pylori. This protein is highly 
immunogenic, which allows the detection of CagA positive phenotypes by
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immunological methods. In the present study, two assays were used to evaluate 
the CagA status: an immunoblotting (Paper I, V) and CagA-ELISA using a 
recombinant fragment of the CagA (Paper IV). The latter assay showed good 
sensitivity and specificity as compared with Western blot (Xiang et al., 1993).
Immunoblotting
In contrast to H.pylori seroprevalence, the CagA seropositivity rates as defined 
by immunoblotting revealed significant differences between the groups studied 
(Paper I,V). Compared to blood donors, a significantly higher proportion of 
CagA seropositive subjects was found in patients with gastric cancer (p=0.008) 
and those with non-malignant gastric diseases (p=0.001). The highest 
seropositivity rate was observed in patients with stomach ulcer (91.17%, 31 of 
45). Only patients with chronic atrophic gastritis did not differ from the donor’s 
group: 56.1% and 59.0%, respectively. Patients with advanced gastric cancer 
(stage IV) showed significant decreases in CagA seroprevalence compare to 
those at stage I+П (p=0.002) and patients with peptic ulcer disease (pcO.OOl).
Our findings are in agreement with many other studies showing that the 
CagA positive phenotype is associated with a more severe pathology including 
gastric cancer (Blaser et al., 1995; Kuipers et al., 1995b; Parsonnet et al., 1997; 
Vorobjova et al., 1998; Orsini et al., 1998; Maaroos et al., 1999). At the same 
time, the cagA status should not be considered as a parameter that could be used 
to predict the clinical outcome of the infection at the individual level. It was 
also impossible to discriminate the disease type-specific peculiarities by an 
immune response to CagA, because a rather high proportion of CagA positive 
subjects were present in all groups studied, regardless of pathology.
Similarly to the H.pylori seroprevalence, a lower proportion of CagA 
seropositive patients was revealed in patients with gastric cancer and, in 
addition, in those with atrophic gastritis, possibly due to a decrease in H.pylori 
density colonisation usually observed in atrophic stomach (Siurala et al., 1988; 
Sipponen, 2002). A clear cut disease stage-dependency was observed in gastric 
cancer patients with a significant decrease of CagA seroprevalence rate in 
advanced cancer.
It should be also noted here that in about 30-50% of cases, both CagA- 
negative and CagA-positive strains or genotypes can be present in one stomach, 
in one biopsy sample or even in one colony of H.pylori culture (Figura et al.,
1998). Therefore we believe that, unlike DNA-based techniques, the serology 
can give more reliable results in CagA status testing because it allows detection 
of the dominant CagA phenotype in a given individual.
In another study (paper I) we analysed the distribution of 10 major protein 
bands on immunoblots of H.pylori-positive blood donors (n=23) and patients 
with gastric cancer (n=72) trying to find the ‘cancer-specific’ features in the 
pattern of protein bands. A decline in the recognition of putatively cross­
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reacting (33-66 kDa) antigens was noted in the cancer group. The response to 
the vacuolating toxin-related 85-kDa and CagA 120-kDa protein antigens was 
not altered but was observed more often in the younger group of cancer patients 
(under 50 years of age). Some tendency toward a higher proportion of patients 
infected with CagA-positive strains was observed in patients with intestinal type 
gastric carcinoma (72% vs 59% for patients with diffuse type of tumor).
We found that about 50% of H.pylori ELISA-seronegative patients 
recognized the 120 kDa (CagA) band as well. This phenomenon has also been 
described by other investigators (Crabtree et al., 1993; Torres et al., 1998) 
suggesting that immune response to CagA may be related to past H.pylori 
infection (Ekstrom et al., 2001; Enroth et al., 2001), possibly due to a high 
immunogenicity of CagA.
IgG Immune response to a recombinant fragment of CagA (Paper IV)
The CagA-ELISA using a recombinant fragment of CagA as antigen showed a 
good correlation with immunoblotting for CagA-positive and CagA-negative 
sera with the sensitivity and specificity of 93.5% and 88.5%, respectively. 
Using O.D. values greater than 0.42 as a cut off limit for strong responders, we 
found a significantly higher CagA seroprevalence rate in H.pylori-seropositive 
patients with gastric cancer (48.8%) than in the related group of controls 
(35,4%) (p=0.02). Like with immunoblotting, a significant decrease in the 
proportion of CagA-seropositive cancer patients was found from disease stage I 
to stage IV with a significant fall in the response at stage Ш-IV. No relation to 
the histological type of tumor (diffuse/intestinal type) was observed.
Immune response to H.pylori in relation to ABO(H) and 
Lewis(a,b) blood group phenotype of the host
The H.pylori and CagA seroprevalence in patients with gastroduodenal 
pathology and blood transfusion donors was correlated with ABO(H), 
Lewis(a,b) phenotypes and the secretory status (Se/se) of the host (Paper 
n,rV,V). Besides, the strength of IgG immune response to H.pylori cell surface 
proteins as defined by relative antibody activity (RAA) was studied in blood 
donors depending on their Lewis(a,b) phenotype (Paper П). We also tested 
whether the immune response to Lewis type 2 Le(x,y) antigens is related to host 
type 1 Lewis(a,b) histo-blood group phenotype and/or H.pylori serologic status 
of the individual (Paper Ш).
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The H.pylori seroprevalence: (Paper П,У)
In blood transfusion donors, no significant differences in H.pylori 
seroprevalence was observed between the individuals of different ABO(H) 
blood group phenotype: the seropositivity was in the ranges of 82-85%. An 
insignificantly lower seroprevalence for blood group A and AB individuals was 
noted among donors (73-79%), patients with gastric cancer (64-71%) and 
benign gastric disorders (80-81%). However, the Le(a+b-)/non-secretor 
phenotype group of donors contained a significantly higher proportion of the 
tf./ry/on-seronegative subjects (34.8%) compared to Le(a-b+)/secretor 
individuals (14.2%; p<0.038) and those with Le negative Le(a-b-) phenotype 
(8.7%). (Fig.l)
Le(a + b-), n=23 Le(a-b+),  Le(a-b-),  
n = 1 13 n=23
F ig .l. The frequency of H.pylori-seronegative individuals among blood donors with 
different Le(a,b) blood group phenotypes.
Dark bars, RAA<25 as criterion for H.pylori seronegativity; light bars, RAA<35 
(low responders). * -  Significantly higher as compared with both Le(a-b+)/secretors and 
Le(a-b-) group (x2=4.26, df 1, P=0.039; OR=3.8, 95%CI 1.1-9.9). ** -  Significantly 
higher as compared with both Le(a-b+)/secretors and Le(a-b-) group (%2=6.58, and 
X2 =5.52, df 1, P=0.01; OR=3.8, 95 Cl 1.3-11.0 and OR=8.1 95% Cl 1.3-46.1, 
respectively).
Thus it appears that Le (b)-negative individuals are more resistant to H.pylori 
infection. This is in agreement with an idea that Le(b) antigen, which is present 
in gastric glycoconjugates of secretors, is a receptor for H.pylori attachment to 
gastric mucosa via BabA adhesin of H.pylori (Boren et al., 1993, 1994; Gerhard 
et al., 1999). Moreover, the proportion of donors with lower RAA values (low
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responders) was significantly higher in Le(a+) than in Le(a-) individuals 
(P=0.004) with no relation to age. No significant difference was noted between 
Le(a-b+) and Le(a-b-) groups (P=0.26). These findings suggest that, in addition 
to Le(b) expression, the presence of Le(a) or some other antigens associated 
with non-secretor status may be important in the natural resistance to H.pylori. 
One of the candidates may be the T epitope (Galßl-3 GalANAca/ß ) which is 
known to be expressed on type 3 mucin-type chains of non-secretors, exclu­
sively (Bara et al., 1993) and is further fucosylated in secretors (Okada et al.,
1994).
Lower IgG immune response to H.pylori in non-secretors indicates that this 
systemic response seems not to be related to their relative resistance to the 
infection. One may speculate that these individuals have stronger cell-mediated 
immune response in situ. A more pronounced local inflammation in H.pylori 
infected non-secretors has been demonstrated (Henegan et al., 1998).
The CagA status (Paper IV,V)
With immunoblotting, blood group A donors showed a significantly lower 
CagA prevalence compared to those of blood group О and В (P=0.0028). (Paper 
V). Similar differences were observed when individuals possessing blood group 
A antigen (blood group A and AB) were compared with A antigen-negative 
(blood group О and B) donors (P=0.006). This was also true for the patients 
suffering from benign gastric disorders (P=0.04). The difference was less 
pronounced in patients with gastric cancer.
A significant association of blood group A phenotype with a lower CagA 
seroprevalence was further demonstrated in blood donors as defined by CagA- 
ELISA which allows a semi quantitative evaluation of the response (Paper IV). 
In patients with gastric cancer, a stage-dependent decrease in CagA- 
seropositivity rate with a drastic fall in the response to CagA at stage IV was 
observed only in the individuals of blood group О and A.
The donors of Le(a+b-) and Le(a-b-) phenotype revealed a significantly 
higher proportion of CagA-positive subjects compared to those of Le(a-b+) 
individuals (P=0.039 and P=0.019, respectively) (IV). As it was described 
above, the Le(b-) individuals had a lower H.pylori seroprevalence. We suggest 
that higher prevalence of CagA-positive strains in these individuals may be 
explained by their relative resistance to H.pylori infection. It shoud be expected 
that more resistant individuals could be infected only with a more virulent, i.e. 
CagA positive, strain.
Some tendency towards a higher proportion of patients infected with CagA- 
positive strains was observed in patients with intestinal type of gastric 
carcinoma (72% vs 59% for patients with diffuse type of tumor). There was no 
Le(a+)-type individuals among patients with gastric cancer. However, the CagA 
positivity rate in patients of Le(a-b+)/secretor phenotype was very similar to
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donors of related phenotype (63.3% and 62.3%, respectively), and was 
significantly higher than in Le(b-) donors group. As with H.pylori 
seroprevalence, the secretory status had no impact on CagA seroprevalence.
Thus the differences in CagA seroprevalence are more related to the Lewis 
phenotype of the host rather than the disease-type or clinical outcome of the 
infection. It seems that the probability of being infected with a CagA positive 
strain is higher in individuals of Le(b-) phenotype.
The secretory (Se/se) status
The Se/se status, as determined by the secretion of H antigen in saliva, was 
studied in patients with benign gastric diseases and those with gastric 
carcinoma.
No significant differences in H.pylori and CagA seroprevalence rate was 
found between secretors and non-secretors in these groups of patients. Higher 
prevalence of CagA-positive strains (12 of 15, 80%) was found in duodenal 
ulcer patients who had a significanly higher proportion of non-secretors (15 of 
45, 33.3%) compared to patients with chronic gastritis (P=0.008). This is in 
concordance with a higher prevalence of CagA-positive strains obtained in 
blood donors of Le(a+)/non-secretor phenotype and described in the previous 
section. It is to note that there is no strong parallelism between the secretion of 
H antigen and Le(a,b) phenotype detected by agglutination of erythrocytes with 
Le antigens-specific antibodies. In particular, about 90% of individuals of 
Lewis negative phenotype (Le a-b-) are secretors.(Oriol et al., 1992). Besides, 
some Le(b+) individuals may be so-called ‘weak secretors’. It appears that the 
expression of Lewis antigens on gastric cell glycoconjugates is a more 
important factor in H.pylori-host interplay than the secretion of ABH or Lewis 
antigens into gastric lumen.
Immune response to Lewis type 2 antigens (Paper III)
An expression of human Le antigens in H.pylori as well as an induction of 
Lewis antigen-specific antibody in infected individuals has been demonstrated 
by many investigators (Sherburne and Taylor, 1995; Appelmelk et al., 1996; 
Heneghan et al., 2000). This expression seems to be related to the host Lewis 
phenotype (Wirth et al., 1997) and important in H.pylori adhesion to gastric 
mucosa (Boren et al., 1993). It has also been considered that this is one of the 
mechanisms for H.pylori to evade the host’s immune defence via an antigenic 
mimicry mechanism since Le antigens are also expressed in normal gastric 
mucosa cells. We aimed to study whether a level of these antibodies is related to 
Lewis (a,b) phenotype of the host and H.pylori serologic status.
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No appreciable differences in IgG immune response to Le(x) epitope 
between individuals of different Le(a,b) phenotypes were observed when the 
data were analysed irrespective of H.pylori serologic status. Individuals of 
Le(b+) phenotype revealed a lower proportion of strong responders to Le(y) 
compared to Le(b-) phenotype subjects. H.pylori-seronegative and -seropositive 
subjects showed different patterns of response, //.py/on-seropositive individuals 
of Le(b-) phenotype showed a significantly higher proportion of strong 
responders to Le(x) determinant compared to H.pylori-seronegative subjects. A 
similar trend was observed for Le(y) antibody levels. In contrast, 
Le(b+)/secretors revealed a high natural immune response to these antigens 
irrespective of H.pylori serologic status.
The data suggest that immune response to Lewis type 2 determinants is 
related to both the H.pylori serologic status and the Le(a,b) phenotype of the 
host. Higher immune response to Le(x) in H.pylori-infected individuals 
observed in this study may be related to the findings of Byrd et al. (1997) who 
reported on an aberrant expression of Le(x) in the surface gastric epithelium of 
H.pylori-infected individuals. On the other hand, Kuipers et al. (1997) showed 
that infected subjects with low levels of Le(x) antibodies had a higher risk of 
gastric atrophy. However, both groups of authors did not relate their findings to 
the Lewis phenotype of the host. One might speculate that putatively ‘immune’ 
Le(x) antibodies which appear in response to H.pylori in Le(b-) type subjects 
may be more pathogenic in terms of their ability to induce inflammation. It 
remains unclear, however, to what extent a natural or H.pylori-induced immune 
response to Lewis type 2 antigens might be beneficial or detrimental for the host 
and how it is related to the clinical outcome of the infection.
H.pylori infection and humoral immune response 
to the tumor-associated Thomsen-Friedenreich antigen (T Ag) 
(Paper VI,VII)
The Thomsen-Friedenreich (T) antigen (Galßl,3GalNAca/ß-0-Ser/Thr) is 
expressed in a majority of human carcinomas and related to invasion, 
métastasés and prognosis (Springer, 1984). Natural T-specific antibodies are 
present in the blood of every individual. Their level has been shown to be low 
in serum of patients with different malignancies (Springer, 1984, Desai et al.,
1995) including gastric cancer (Kurtenkov et al., 1999), and in gastric 
premalignant conditions (Smorodin et al., 1997). Since the H.pylori infection is 
very closely related to gastroduodenal pathology (Kuipers, 1999; Kuipers et al., 
1995, McGee and Mobley, 1999) we suggested that one of the mechanisms 
might be associated with H.pylori infection. We tested the hypothesis that 
H.pylori infection may alter natural immune response to tumor-associated
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Thomsen-Friedenreich (T) antigen, thus modulating natural immune mecha­
nisms against cancer.
The patients with gastric cancer (n=186), benign gastric diseases (n=126) 
and 186 blood transfusion donors were tested for blood level of T antigen 
specific IgG and IgM antibodies. The data were correlated with H.pylori 
serologic status, disease type, Se/se status, stage of cancer, ABH and Lewis 
(a,b) blood group phenotype of the host.
The changes in T antibody levels were analysed in two ways: by comparison 
(i) between the f/./?_y/öW-seronegative and seropositive subgroups within each 
group (donors, patients) to look for a relation of the changes to the H.pylori 
infection, and (ii) between the groups for both infected and noninfected 
individuals trying to find putative disease type-specific features.
An impact of H.pylori serologic status
The changes in IgM and IgG T-antibody level in relation to the H.pylori 
serologic status of patients and blood donors are shown in Fig.2. A common 
feature for IgG immune response was that the H.pylon-seropositive group 
showed a higher proportion of patients with high levels of T antibody (strong 
responders) compared with the related H.pylori-seronegative subgroups. This 
difference was observed in all groups of patients (gastric cancer, peptic ulcer, 
chronic gastritis) and blood donors reaching the statistical significance in 
patients with gastric cancer and gastritis.
In H.pylori-seropositive blood donors, the level of IgG T-specific antibodies 
(O.D. values) positively correlated with anti-H.pylori IgG anibody level (RAA 
values) (VII). It has been shown that higher density of antral gastric mucosa 
colonization with H.pylori is associated with a higher IgG immune response to 
the organism (Kreuning et al., 1994; Hsu et al., 1997) and stronger local 
inflammatory response to H.pylori (Henegan et al., 1998, 2000). We suggest 
that the above mentioned correlation may reflect the density of H.pylori 
colonization or the degree of T epitope expression in a given H.pylori strain. No 
correlation was observed in patients with cancer possibly due to a significant 
decrease of T specific antibody levels in a majority of patients (Kurtenkov et al.,
1999). Unlike IgG antibody, the IgM response was not closely related to 
H.pylori serology. Compared to blood donors, a dramatic decrease of IgM T 
antibody level in every group of patients was found irrespective of H.pylori 




□  H.pylori negative 
Ш H.pylori positive
IgG
Donors Gastric Peptic Gastritis 
cancer ulcer
Donors Gastric Peptic Gastritis 
cancer ulcer
46-145 52-134 13-58 11-43 39-68 46-131 15-58 10-40
Fig.2. The proportion of IgM and IgG strong responders to T-epitope in blood donors 
and patients by H.pylori serology.
P values are shown for significant differences as calculated by Fisher's exact test.
* Significantly higher compared with H.pylori -  seronegative group of patients with 
peptic ulcer (P=0.005) and gastritis (p=0.04).
n- the number of individuals for H.pylori-seronegative and H.pylori-seropositive groups 
respectively.
Interestingly, some disease type-specific traits in T response may also be seen. 
The H.pylori-seropositive patients with gastric cancer and gastritis showed an 
IgG response similar to that of donors. At the same time, the H.pylori- 
seropositive patients with peptic ulcer disease revealed only slight increases in 
IgG response: a proportion of strong responders was significantly lower than in 
any other H.^/on-seropositive group regardless of their H.pylori status.
The data suggest that H.pylori infection stimulates the IgG immune res­
ponse to T epitope. Our preliminary data about the decrease of immune res­
ponse to T epitope in some patients after H.pylori eradication (VI) further 
support the idea that an increase in T antibody level is related to H.pylori 
infection. The effect seems to be dependent on the initial level of T antibody 
and was observed in subjects who were obviously low responders before being 
infected with H.pylori and enhanced their T-specific immune response due to 
the infection.
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A more pronounced difference in anti-T antigen IgG immune response between 
H.pylori-infected and uninfected blood donors was observed in those of Le(b-) 
phenotype (P=0.04): the infected subjects revealed a higher level of T 
antibodies. In contrast, Le(a-b+)/secretor subjects showed no distinction in IgG 
response to T antigen between H.pylori-infected and uninfected blood donors. 
A similar trend was obtained for Le(b-) type patients with gastric cancer. A 
group of H.pylori- seropositive Le(a-b+) patients also showed a higher 
proportion of IgG strong responders but the proportion of strong responders was 
significantly lower compared to H.pylori-seropositive Le(b-) type patients.
It remains unclear whether a lower level of T-antibody in H.pylori- 
seronegative patients with cancer and chronic gastric diseases is due to the 
disease per se or these individuals were weak responders prior to the disease 
development. We did not find any relation of T antibody level to the stage of 
cancer. In contrast, a higher proportion of IgG strong responders was found in 
H.pylori-infected cancer patients irrespective of the stage of cancer. This 
suggests that the changes observed should not be considered as a secondary 
tumor-induced event. Since the level and profile of natural antibodies is 
reported to be fairly stable for years (Springer et al., 1984; Kaveri et al., 1998) 
we speculated that there is some kind of enrichment of weak T responders 
among individuals which are predisposed to gastric pathology or suffering from 
chronic gastric diseases including cancer. An association of T-antibody level 
with Le(a,b) histo-blood group phenotype suggests a possible genetic back­
ground.
Thus, H.pylori infection is associated with an increased IgG immune 
response to tumor-associated T antigen. This systemic impact is dependent on 
the Lewis phenotype of the host and in part disease-type specific. These 
findings suggest that H.pylori may be indirectly involved in gastric 
carcinogenesis via modulation of natural cancer-related immune mechanisms.
Relation to ABH and Lewis phenotype of the host (Paper VI)
Expression of tumor-associated 
Thomsen-Friedenreich antigen in H.pylori 
(Paper VI, VII)
A striking similarity in the increase of IgG T-response in different groups of 
H.pylori-infected individuals compared to uninfected ones (Fig.2) suggests the 
existence of a common pathway. We have suggested that one of the 
mechanisms might be an expression of carbohydrate Thomsen-Friedenreich (T) 
antigen (Galßl,3GalNAcoc/ß-0-Ser/Thr) in H.pylori, like it has been shown for 
many carbohydrate epitopes on bacteria (Blackwell, 1989). If this is the case, an
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ongoing antigenic stimulation in #./?y/on-infected subjects may lead to an 
increased antigen-driven antibody response to T antigen in some individuals.
Cell surface membrane extracts of H.pylori NCTC 11637 strain and 13 
clinical isolates of H.pylori were analysed by immunoblotting with five 
different T antigen-specific human and murine monoclonal antibodies. Two 
major protein bands of ~68kDa and 58 kDa were immunostained on blots of 
H.pylori extract with T specific Mabs but not immunostained with unrelated 
MAb (Fig.3). However, extracts from different H.pylori strains showed 
different patterns in the relative expression of T antigen-related bands. The 68 
kDa protein associated T antigen expression was higher in patients with more 
severe pathology (gastric cancer, peptic ulcer disease) compared to strains 
derived from patients with chronic gastritis. This protein band was almost 
absent in extracts from the NCTC 11637 H.pylori standard strain. Besides, this 
strain did not show reactivity with MAb 9H8 which was reported to be specific 
for T antigen, however, the peptide core seems to be also involved in the 
epitope (Sikut et al., 1996)
In blocking experiments, the PNA and T-specific rabbit antiserum almost 
completely abolished the binding of human TF1, 5C7 and murine JAA-F11 
MAb. The binding of T specific MAb to the 58 kDa protein was also blocked 
by rabbit antiserum against heat shock proteins of H.pylori. Both T-related 
bands did not bind the anti-H-type-2 mouse IgM MAb.
Fig.3. Western blot analysis o f T antigen-specific monoclonal antibodies on cell sur­
face membrane extract from H.pylori NCTC 11637 strain.
Lane 1, H.pylori seropositive human serum (RAA - 94); Lane 2, human Mab 5C7;
Lane 3, human Mab TF1; Lane 4, murine Mab 3C9; Lane 5, murine Mab 9H8;
Lane 6, murine Mab JAA-F11; Lane 7, murine Mab 180LE (anti-H type 2).
Molecular mass markers (kDa) are at left.
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In cell-ELISA, binding of TF1 and 5C7 human MAb to H.pylori cells was 
noted, as was binding of JAA-F11 and 9H8 MAb (Fig.4). All T-specific MAbs 
reacted in a dose-dependent manner. T-epitope unrelated anti-leukosialin MAb 
(3A1) showed very weak nonspecific binding irrespective of the dilution.
A positive correlation was found between the level of serum IgG antibodies 
to T antigen and anti -H.pylori antibodies (RAA values) in /f.py/on-infected 
blood donors (r=0.57, P>0.001). In contrast, no such correlation was observed 
in H.pylori-seronegative blood donors and patients with gastric cancer, 
irrespective of H.pylori status.
Thus, the cancer-related autoimmunogenic T epitope is expressed in surface 
membrane glycoconjugates of H.pylori and associated with an alteration of the 
natural immune response to T antigen in infected subjects.
Reciprocal MAb dilution
—# -T F 1  
— 5C7 
-TÉ T -9 H 8  
—X—3A1 
—Ж—JAA-F11 
- • - P B S
Figure 4. Binding of T antigen-specific monoclonal antibodies to H.pylori NCTC 
11637 strain cells as assessed by cell-ELISA with 108 bacteria. OD (405 nm), optical 
density at 405 nm.
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H.pylori infection and survival of patients 
with gastric carcinoma: relation to the level 
of T antigen specific antibodies (Paper VIII)
Our findings that H.pylori infection modulates humoral immune response to 
tumor-associated T antigen as well as the evidence that H.pylori itself expresses 
this epitope prompted us to study the possible clinical relevance of these 
phenomena.
It has been shown that an increase in the level of antibodies against T and Tn 
epitopes after active immunotherapy of cancer with mucin-type vaccines 
containing these epitopes was associated with a more favourable prognosis of 
patients with cancer (MacLean et al., 1992; Livingstone et al., 1997). On the 
other hand, low level of T-specific antibodies is associated with an increased 
risk for cancer (Springer, 1984). The expression of T antigen in cancer cells is 
related to the biological behaviour of tumors and the prognosis of cancer 
patients (Springer, 1984; Takanami, 1999; Baldus and Hanish, 2000). Thus, we 
proceeded from the assumption that higher levels of T specific antibodies 
induced by H.pylori infection may be beneficial for the patients with cancer due 
to the anti-tumor potential of these antibodies.
H.pylori serologic status and survival
A significantly better survival rate was observed in H.pylori seropositive 
patients at stage I of the disease compared to Я.р^/on-seronegative ones 
(Fig.5A). The survival time (median±SE) was 60.0±3.8 and 37.0±7.8 months 
for H.pylori positive and H.pylori-negative patients, respectively (P=0.0004, 
log-rank test). A similar trend was noted for the patients at stage П (Fig.5 B): 
56±2.7 and 46±11.3, P=0.064. No difference in survival was noted for patients 
with advanced gastric cancer (unpublished). Thus, #./ry/or/-seropositive 
patients with early gastric cancer had better survival rates compared to H.pylori- 
seronegative patients.
Humoral immune response to T antigen and survival 
of patients with early gastric cancer
A comparison of patient’s survival in relation to anti-T Ag antibody levels, 
calculated irrespective of H.pylori status, showed that stage I patients with 
higher level of T Ag specific IgG antibody had significantly better survival rates 
compared to those with low levels of antibody (weak responders); median 
survival time 62.0±2.1 and 35±1.4 months, respectively; P=0.0001 (Fig.5B).
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A significant over-representation of patients with high level of anti-T antigen 
IgG antibodies (strong IgG responders) was observed among H.pylori- 
seropositive stage I patients compared to H./ry/orj-seronegative ones (P=0.023, 
Fishers exact test). A similar trend was found in patients at stage П, but the 
differences did not reach statistical significance (P=0.13). The same was true for 
IgM T antibody level (P=0.12).
To clarify whether better survival of tf.py/ori'-seropositive patients is related 
to a higher level of anti-T antibody in infected patients, the comparisons were 
made for strong and weak responders in both H.pylori-seropositive and 
//.py/on-seronegative subgroups of patients. In fact, only H.pylori-seropositive 
strong IgG responders were better survivors (P=0.0001), (Fig 5C) whereas 
strong IgG responders in the H.pylori-seronegative group were not (P=0.96). 
This suggests that the presence of H.pylori infection seems to be an important 
independent prognostic factor. Similar trends were observed in a group of 
patients at stage П.
It was a general regularity that the level of IgM T antigen-specific antibodies 
did not correlate with survival. One of the reasons is that a very low level of 
natural IgM T antibody, already at early stages of the disease, is a characteristic 
of patients with various cancers (Springer, 1984; Kurtenkov et al., 1999). One 
may speculate that acquired IgG immune response to T antigen induced by 
H.pylori is a more potent mechanism of eliminating tumor cells in the 
circulation by antibody-dependent effector mechanisms. The fact that no 
association of T antibody level or H.pylori serologic status with survival was 
noted for patients with advanced gastric cancer (unpublished) suggests that this 
mechanism may be effective for the elimination of only small numbers of tumor 
cells or micrometastasis which are present or appear in the circulation after 
surgery, thus preventing metastasis and improving the survival.
In addition to antibody-dependent reactions, other immunological 
mechanisms might be considered to explain an association between H.pylori 
infection and better survival rates of patients with early gastric cancer. H.pylori 
upregulates the proinflammatory cytokines IL-6, IL-8, TNFa, IFNy that have 
anti-tumor or growth inhibiting potential, an inhibitory effect on angiogenesis or 
stimulate differentiation (Kang et al., 1999; Arany et al., 1999; Jenkinson et al.,
2002). Contact of lymphocytes with H.pylori was reported to stimulate the 
production of IFN-y and natural killer cell activity (Tarkkanen et al., 1993). 
Theoretically, the H.pylori glycosidases and/or glycosyltransferases may create 
the tumor-related epitopes on host gastric glycoconjugates or tumor cells like it 
has been shown, for instance, for tumor-associated alphaGal-epitope expression 
induced by Klebsiella pneumonia enzymes on erythrocytes (Hamadeh et al.,
1996), with the following induction of autoimmune response.
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Time after operation (months)
Fig.5. Cumulative survival plots (Kaplan-Meier) of gastric cancer patients in relation to 
H.pylori serologic status and/or anti-T antigen antibody level.
A -  stage I gastric cancer patients (n=44), dark line -  H.pylori-seropositive patients; 
dotted line -  H.pylori-seronegative patients. В -  the same for stage П gastric cancer 
patients (n=43).
С -  stage I gastric cancer patients (n=37), dark line -  patients with high level of anti-T 
antigen IgG antibodies (strong responders); dotted line -  patients with low level of anti-T 
antigen IgG antibodies (weak responders). The cumulative survival is calculated 
irrespective of H.pylori serologic status.
D -  H.pylori-seropositive gastric cancer patients at stage I (n=26); dark line -  strong 
responders, dotted line -  weak responders.
P values as calculated by log-rank test.
In summary, H.pylori-seropositive patients with early gastric cancer have better 
survival rates than H.pylori-seronegative patients, and this impact is related to 




During the past couple of years, it has become increasingly evident that the 
“virulence factors model” alone is insufficient to explain the differences in the 
clinical outcome of H.pylori infection. There is evidence that human genetic 
polymorphism is associated with the susceptibility of the host to a particular 
H.pylori-related disease (El Omar, 2000; Figueiredo et al., 2002). Therefore, 
combining bacterial/host genotyping may be an important approach to define 
disease risk since “specific combination of microbial and host genotypes may 
shape the equilibrium in ways that augment or lessen risk of disease” (Blaser,
2002).
However, some associations found so far are closely related to or operated 
via immunological mechanisms. For instance, the polymorphism of IL-1B gene 
coding for IL-lß , a potent pro-inflammatory cytokine and powerful inhibitor of 
gastric acid secretions (El Omar, 2001; Figueiredo et al., 2002) is actually a 
marker of host immunological response. Another example is an association 
found between TNF-alpha promoter polymorphism and cagA subtype infection 
(Yea et al., 2001). Thus it appears that, in addition to H.pylori genetic 
polymorphism, an investigation of host immunologic response to H.pylori may 
be a promising way for understanding the pathogenesis of H.pylori-associated 
diseases and in defining disease risk at the individual level.
Our data showed that, due to the host and H.pylori diversity at the 
phenotypic level, the host immune response to H.pylori infection is also highly 
polymorphic in both its strength and profile. In spite of the rather small part of 
host phenotypic traits studied, i.e. ABH and Lewis blood group phenotype and 
Se/se status, we found that immune response to both glycine cell surface extract 
of H.pylori and to a recombinant fragment of the CagA showed an association 
with ABH and Lewis phenotype of the host.
A higher proportion of #./?_y/or/-seronegative individuals was found among 
blood donors of Le(a+)/non-secretor phenotype, suggesting that the Lewis 
histo-blood group antigens are implicated in the mechanisms of naturally 
occuring resistance to H.pylori infection. Interestingly, the proportion of 
#./ryfon-seronegative individuals among blood donors was strikingly similar to 
that of Le(a+)/non-secretors in Estonia, i.e. 16.4% and 11.7% (Mark et al., 
1994), respectively. Moreover, there was some disposition for individuals of 
Le(b-) phenotype to be preferentially infected with CagA positive strains of 
H.pylori. An association of CagA-positive strains with a more severe pathology 
demonstrated by many investigators may be related to our findings because a 
significantly higher proportion of non-secretors, which are mostly of Le(b-) 
phenotype subjects, was found among patients with duodenal ulcer. It seems 
that these associations are not related to the BabA or SabA adhesin of H.pylori 
(Boren et al., 1993; Mahdavi et al., 2002) because they were observed in Le(b-) 
type individuals. This suggests that other mechanisms may be involved.
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Another finding was that blood group A individuals showed a lower CagA 
seropositivity rate compared to subjects of other ABO(H) blood group 
phenotypes. These findings further support the idea that the polymorphism of 
gastric glycoconjugates may appreciably influence the H.pylori-host interplay.
We were also able to demonstrate that individuals of Le(a+) phenotype 
showed a lower immune response (RAA values) to cell surface membrane 
antigens of H.pylori compared to those of other Lewis phenotypes. Thus, even 
by using crude antigenic preparations it was possible to demonstrate the 
differences in the strength of immune response between individuals of various 
Le phenotype. ABO(H) or Lewis phenotype-associated differences in immune 
response to H.pylori were more pronounced if well characterized antigens such 
as recombinant fragment of CagA and T disaccharide were used as antigens. 
This point will be discussed below.
Altogether the data show that ABH and Lewis blood group phenotype 
distribution in the population should be considered as an important modulating 
factor which has to be taken into consideration in immunological and 
epidemiological studies of H.pylori-host interrelationships.
One of the aims of the study was to look for disease-type specific traits in 
humoral immune response to H.pylori. At present it is clear that none of the 
currently identified H.pylori putative virulence factors shows strong disease 
specificity. Moreover, they show remarkable geographic variability in 
prevalence irrespective of the disease type. The same seems to be true for 
various events associated with these factors such as immunity.
In the present study, an immune response to H.pylori antigens was also 
shown to be not strongly related to the type of the disease if comparisons were 
made irrespective of host blood group polymorphism. An ability of the host to 
elicit immune response to H.pylori was fairly variable and in part dependent on 
blood group antigens polymorphism. However, some statistically significant 
associations were demonstrated. Like many other investigators, we found a 
significantly higher CagA seroprevalence among patients with gastric cancer 
and peptic ulcer disease (V). A higher proportion of non-secretors was found in 
patients with duodenal ulcer. Compared to donors, the cancer patients showed a 
decline of the response to low molecular weight (<28,33-66kDa) H.pylori 
antigens (I).
It has been shown that only 6-7 % of H.pylori genes may vary between the 
strains (Aim et al., 1999) suggesting that no appreciable difference in the 
spectrum of immune response to peptide-type antigens should be expected 
between the strains. However, if possible post translational modifications such 
as glycoforms are included, the heterogeneity of the strains would be greatly 
increased. Interstrain variations in the expression of T glycotope-related 
proteins in H.pylori and some disease-type differences in immune response to T 
epitope may be related to this issue. Patients with peptic ulcer disease showed 
very low level of T antigen specific IgG antibodies compared to other groups 
studied. In contrast, seropositive patients with gastric cancer and those with
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chronic gastritis revealed significantly higher T antigen specific IgG response 
compared to seronegative subgroups. However, in immune response to 
H.pylori, variations that are related to blood group phenotype of the host are 
dominant over disease-specific changes in the response. The difference became 
more visible for well characterized antigens such as T disaccharide.
Several arguments were taken into account for using the Thomsen- 
Friedenreich (T) antigen as a model to test the hypothesis of whether H.pylori 
infection might influence natural immune mechanisms against cancer: (i) the 
tumor-associated T epitope, like many other carbohydrate antigens, was shown 
to be expressed in tumor cells and some microorganisms (Springer, 1984; 
Blackwell, 1989) (ii) theT epitope is present as a cryptic antigen in gastric 
mucin-type (type 3) glycoconjugates of secretors (Okada et al., 1994); (iii) it is 
expressed in non-secretors (Bara et al., 1993) and thus its expression is related 
to Le phenotype of the host;.(iv) natural humoral immune response to this 
antigen was demonstrated to be low in patients with gastric cancer and 
premalignant conditions of the stomach (Smorodin et al., 1997). And finally, a 
level of naturally occuring T antigen specific antibodies is also related to Le 
(a,b) phenotype (Kurtenkov et al., 1999).
It has been shown recently that H.pylori is very closely associated with 
extracellular MUC5AC mucin and epithelial cells that produce MUC5AC 
suggesting a role of this mucin in the adhesion of H.pylori to the gastric mucosa 
(Van den Brink et al., 2001). H.pylori strains that express the BabA adhesins 
were shown to bind to the Le(b)-positive glycoforms of MUC5AC mucin in 
individuals expressing the Le(b) antigen (Linden et al., 2002). We suggest that 
the lower immune response to H.pylori we found in Le(a+) individuals may be 
related to a lower density of H.pylori due to a weaker H.pylori adhesion to 
gastric epithelial cells compared to subjects of Le(b+) phenotype.
In this study, we demonstrated that H.pylori serologic status is an important 
factor that influences natural immune response to T epitope. A clear-cut 
difference in anti-T antigen IgG antibody level was observed if individuals were 
divided according to H.pylori status: H.py/on-seropositive patients with gastric 
cancer and chronic gastritis showed a significantly higher immune response to T 
antigen compared to seronegative subgroups. A similar trend was found in 
patients with peptic ulcer disease though a very low T antibody level was a 
characteristic of these patients. Moreover, a level of IgG T-specific antibodies 
in serum of blood donors positively correlated with anti-H.pylori IgG antibody 
level which has been shown to be related to the density of H.pylori colonization 
(Pronovost et al., 1994; Kreuning et al., 1994; Hsu et al., 1997). In addition, an 
ability of the host to elicit an acquired IgG immune response to the putatively 
H.pylori-derived T epitope was associated with the Lewis phenotype of the host 
and was more pronounced in individuals of Le(b-) phenotype. Preliminary data 
about the decrease of immune responses to T antigen in some patients after 
H.pylori eradication further support the idea that an increase in T antibody level 
is related to H.pylori infection. A modulation of naturally occuring immune
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response to tumor-associated T glycotope in H.pylori-infected individuals 
suggests that H.pylori infection may alter natural immune mechanisms against 
cancer. However, the degree of this modulation varied appreciably between 
individuals and could not be explained by only the blood group phenotype 
polymorphism.
Further, we tested the hypothesis that H.pylori itself may express cancer- 
related T antigen and presented immunological evidence that T antigen is 
expressed in at least two surface membrane glycoconjugates of H.pylori with 
molecular mass of ~58kDa and 68kDa. The specificity of T antigen specific 
MAbs reaction with H.pylori was shown in that immunostaining was blocked 
with PNA and rabbit antiserum to T antigen. Moreover, different H.pylori 
strains seem to express the T epitope to a different degree with some relation to 
a particular gastric pathology. Variations in T antigen expression between the 
clinical isolates of H.pylori suggest that this antigen may be of value for further 
characterization of H.pylori diversity. An immunological approach allows for 
better characterization of alterations in the glycosylation of H.pylori proteins 
which are still difficult to evaluate by other means.
To evaluate possible clinical relevance of H.pylori infection-associated 
modulation of humoral immune response to T antigen, we analysed the survival 
time of patients with early gastric cancer depending on their H.pylori serologic 
status and the level of T antigen-specific antibodies in the blood before surgery. 
Highly significant (pcO.OOOOl, log-rank test) association of better survival with 
both Я./ry/on-seropositive status of patients and a level of T specific IgG 
antibody was demonstrated (Fig. 5). However, the difference in survival 
between the patients with high and low level of T antigen IgG antibody was 
found only for #./7)>/0/7-seropositive individuals. This indicates that the 
presence of H.pylori infection is an important independent prognostic factor. No 
significant correlation with prognosis was found for IgM T antigen-specific 
antibodies. One may speculate that acquired IgG immune response to T antigen 
induced by H.pylori is a more potent effector mehanism to eliminate tumor cells 
in the circulation by antibody-dependent effector mechnisms, and to interfere 
with metastasis than natural low affinity IgM T-specific antibodies. Besides, 
very low level of IgM isotype T antibodies, already at the early stages of the 
disease, is a characteristic of patients with various cancers (Springer, 1984; 
Kurtenkov et al., 1999).
The main associations between humoral immune response to H.pylori and 
blood group related antigens as well as their possible relation to the 
pathogenesis of H.pylori infection and the clinical relevance are summarized in 
Table 1.
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Blood group A phenotype is 
associated with a significantly 
lower seroprevalence of CagA 
positive H.pylori strains in blood 
donors and patients with benign 
gastric diseases but not in patients 
with gastric cancer (V).
This should be taken into 
consideration in epidemiological 
and immunological studies of 
H.pylori-host interplay in 
populations with different 
distribution of ABH blood group 
phenotypes.
Gastric cancer patients of blood 
group О phenotype have a higher 
proportion of CagA-seropositive 
individuals at early stages of 
disease (IV).
This may be related to a higher 
degree of inflammation in blood 
group 0  individuls (Alkout et 
al.,2000) and to a more rapid 
progression of gastritis to atrophy 
and cancer.
H.pylori seroprevalence is 
significantly lower among 
individuals of Le(b-) phenotype. 
Lower IgG immune response to 
H.pylori was observed in Le(a+b-) 
/non-secretor individuals (II).
Individuals of Le(b-) phenotype are 
more resistant to H.pylori infection, 
possibly due to the absence Le(b) 
antigen which is a receptor for 
BabA adhesin of H.pylori.
Lewis
antigens
Lewis(b-) phenotype is associated 
with a higher prevalence of more 
virulent CagA-positive strain of 
H.pylori (V).
Le(b-) type individuals may be 
infected mostly with more virulent 
strains, because of their higher 
resistance to H.pylori infection.
Increased IgG immune reponse to 
T antigen in H.pylori infected 
blood donors and gastric cancer 
patients was predominantly 
observed in individuals of Le(b-) 
phenotype. In addition, H.pylori 
seropositive Le(b-) individuals 
showed higher proportion of strong 
responders to Le(x) (III, VI).
H.pylori seropositive Le(b-) 
individuals with high level of T 
antigen specific antibody are 
potentially at lower risk for cancer 
development? In contrast, they may 











H.pylori infection is associated 
with an enhanced IgG immune 
response to T antigen in patients 
with gastric cancer and non- 
malignant gastric diseases (VI).
This suggests that H.pylori 
infection may modulate natural 
immunological mechanisms against 
cancer
Immunological evidence is 
presented that tumor-associated T 
antigen is expressed in H.pylori, 
and this expression varies between 
the strains (VII).
T antigen expression in H.pylori 
may be of value for further 
characterization of H.pylori 
diversity. Higher expression of 68 
kDa T antigen-related glycoprotein 
is associated with more severe 
pathology (cancer, duodenal ulcer).
H.pylori seropositive patients with 
early gastric cancer are better 
survivors than H.pylori 
seronegative patients. This 
association was mostly 
pronounced in patients with high 
level o f T antigen specific IgG 
antibodies (VIII).
This implies that both H.pylori 
serologic status and the level of T 
antigen specific antibodies may be 
used as an additional prognostic 
criteria for surgically treated 
patients with early gastric cancer.
A growing body of evidence suggests that H.pylori infection may actually have 
some beneficial effects. The carriage of the more virulent CagA-positive strain 
was shown to be associated with a reduced risk of esophageal and gastric 
cardial adenocarcinoma and of gastroesophageal reflux disease (Chow et al., 
1998; Kuipers,1999; Loffeld et al., 2000a). H.pylori infection may protect 
against diarrheagenic gastrointestinal infections in children (Rothenbacher et 
al., 2000). Our data showed better survival of H.pylori-infected patients with 
gastric cancer suggesting that this infection may be beneficial for patients with 
cancer. Therefore, eradication of H.pylori becomes more controversial, 
especially in individuals of older age.
A key feature of our findings is an association of H.pylori infection with an 
increased immune response to tumor-related T epitope and better survival of 
H.pylori-infected patients with gastric carcinoma, though there is no evidence 
so far for a direct cause-and-effect relationship between the expression of T 
antigen in H.pylori and a higher level of T antibody. We are aware that these 
data are the first evidence of the kind and should be further confirmed by other 
investigators. Anyway, a significant association of T antibody level with
H.pylori infection and the survival of H.pylori-initcted cancer patients strongly 
indicates on the pathogenetic role of H.pylori and these antibodies in protective 
immunity against cancer. It remains to be elucidated, however, whether the 
systemic impact of H.pylori infection on the immune response to tumor-related 
T antigen may work in concert with or contrary to the other in situ operating
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mechanisms which are known to be involved in the pathogenesis of chronic 
gastric diseases including cancer. This could in part explain why only a small 
minority of H.pylori-infected individuals develop gastric cancer. We speculate 
that, if other things being equal, the H.pylori-mfected individuals with high 
levels of T antigen specific antibodies might have some protection against 
gastric cancer development. Anyhow, since infection with H.pylori is relatively 
common, it provides a unique model to study the impact of infections on anti­
tumor immunological mechanisms. H.pylori infection is treatable and so the 
model can be easily manipulated. And finally, this model may be used to further 
demonstrate that, in addition to microbial diversity, several host-dependent 
factors may alter host-microbe immunological interplay and influence the 
clinical outcome of the infection.
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CONCLUSIONS
1. In the Northen Estonia, a high proportion of H.pylori-seropositive indi­
viduals (75.5-86.2%) was demonstrated among patients with gastroduodenal 
pathology and in age-related blood transfusion donors group with no 
association with a particular disease. In patients with gastric cancer, a stage- 
dependent decrease in the seropositivity rate was shown. As defined by 
immunoblotting, a high incidence of more virulent CagA positive strains of 
H.pylori (74.2-91.2%) was characteristic of patients with gastroduodenal 
pathology except those with atrophic gastritis (56.1 %) and advanced gastric 
cancer (62.5%). The highest proportion of CagA-seropositive individuals 
was found among patients with duodenal (81.3%) and gastric (91.2%) peptic 
ulcer disease. A decline in the recognition of putatively cross-reacting (33- 
66 kDa) antigens was noted in cancer patients.
2. An immune response to cell surface membrane antigens of H.pylori NCTC 
11637 strain was strongly influenced by ABH and Lewis(a,b) phenotype of 
the host. This impact had more common rather disease-type specific traits:
• Blood transfusion donors of Le(a+b-)/nonsecretor phenotype revealed a 
significantly higher proportion of H.pylori-seronegative subjects and a 
lower IgG immune response to H.pylori compared with the individuals of 
Le(a-b+)/secretor phenotype.
• As determined by both immunoblotting and enzyme-linked immuno­
sorbent assay with a recombinant fragment of the CagA, blood group A 
blood transfusion donors and patients with non-malignant gastric diseases 
showed a significantly lower CagA seropositivity rate compared to 
subjects of other ABO(H) blood group phenotypes. This association was 
less pronounced in patients with gastric cancer who showed a significant 
stage-dependent suppression of immune response to the CagA with no 
relation to age, gender or tumor histology.
• A significantly higher CagA-seroprevalence was demonstrated among 
blood donors of Le(b-) blood group phenotype compared to those of 
Le(b+) phenotype. This indicates that Le(b-) subjects are predisposed to 
be infected with CagA-positive strains of H.pylori. The secretory (Se/se) 
status of patients with chronic gastric diseases was not associated with 
CagA serologic status though a significantly higher proportion of non- 
secretors was found among patients with duodenal ulcer.
3. IgG immune response to Lewis type 2 determinants [Le(x), Le(y)] is related 
to both the H.pylori serologic status and Le(a,b) phenotype of the host. 
Individuals of the Le(b+)/secretor phenotype revealed a stronger immune 
response to Le(x) and Le(y) epitopes irrespective of H.pylori serologic 
status. In contrast, H.pylori-infected Le(b-) type individuals showed higher
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proportion of strong responders to Le(x) antigen compared with the 
Я./ry/on-uninfected subgroup.
4. H.pylori infection is associated with an increased immune response to 
cancer-associated Thomsen-Friedenreich (T) antigen (Galßl,3-GalNAcoc/ß- 
O-Ser/Thr). This systemic impact appears to be dependent on Lewis(a,b) 
phenotype of the host and in part disease-type specific. Thus, H.pylori 
infection may be indirectly involved in gastric cancerogenesis via modu­
lation of natural immune mechanisms against cancer.
5. An immunological evidence was presented that the cancer-related auto- 
immunogenic T epitope is expressed in H.pylori and this expression is 
associated with an alteration of natural immune response to T antigen in 
infected subjects. Different H.pylori strains seem to express T epitope to a 
different degree with some relation to a particular gastric pathology.
6. The survival of patients with early gastric cancer is significantly better in 
H.pylori-seropositive patients, and this phenomenon is related to up- 




H.pylori infection as a model to study the impact of infections 
on anti-tumor immunological mechanisms
In this study, we have shown that the ABH and Lewis antigenic system 
polymorfism of the host is associated with the H.pylori and CagA sero­
prevalence, and with the ability of the host to respond to H.pylori. The 
expression of cancer-associated T glycotope in H.pylori further suggests that 
blood-group antigens and their derivatives are involved in H.pylori-host 
interplay with the relevance to clinical outcome of the infection. Moreover, the 
Lewis phenotype-dependent enhancement of natural IgG mmune response to T 
antigen in H.pylori-seropositive individuals was found to be beneficial for 
patients at early stages of gastric cancer. We reported recently that natural 
immune response to another cancer-related alpha-galactosyl epitope (Galal,3- 
Gal) is also up-regulated in H.pylori-infected individuals (Kurtenkov et al.,
2001). Thus it appears that T antigen is not a unique example in this respect and 
may reflect a particular case in some common pathway.
In addition to ABH and Le antigens system, other host genotypic/phenotypic 
traits have been shown to be related to H.pylori-host relationships and clinical 
outcome of the infection: IL1 beta polymorphism (El Omar, 2001; Figueiredo et 
al., 2002) TNF-alpha promoter polymorphism (Yea et al., 2001). These results 
provide indirect evidence of the increased pro-inflammatory effect associated 
with some allels and suggest that host genotyping may provide an important 
tool in defining disease risk. It is evident that all above mentioned facts are 
closely related to the immune mechanisms both humoral and cell-mediated.
In addition to the expression of tumor-associated antigens in H.pylori, 
another hypothetical mechanism may be considered for an enhancement of 
tumor-related immune response associated with H.pylori infection. Theoreti­
cally, the H.pylori glycosidases and/or glycosyltransferases may create the 
tumor-related epitopes on gastric glycoconjugates. It has been shown that 
H.pylori strains differ in their fucosidase activity (Dwarakanath et al., 1995). 
Schematically, the hypothetical sequence of events could be as follows: the 
alteration of gastric glycoconjugates glycosylation due to H.pylori glycosidases 
and/or transferases — the expression of autoimmunogenic tumor-related 
carbohydrate and/or peptide epitopes — the induction of autoimmune response 
to these epitopes. Another possibility is the modulation of H.pylori or host 
glycosidases expression and function in inflammatory conditions possibly via 
the formation of isoforms, or glycoforms.
Degradation of gastric mucins and alteration of their glycosylation may lead 
to the expression of autoimmunogenic peptide epitopes such as MUC1. 
Humoral immune response to MUC1 has been shown to increase the survival 
rate of patients with early breast cancer (von Mensdorff-Pouilly et al., 2000b).
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One can not exclude that such a mechanism may operate in //.py/on-infected 
mucosa. Since the beneficial effect of H.pylori infection on the survival of 
surgically treated patients with early gastric cancer is associated with humoral 
immune response to tumor-related T epitope, it should be expected that this 
systemic impact of H.pylori might also operate in patients with other 
malignancies. It is reasonable to look for such associations to further confirm 
the systemic impact of H.pylori infection on natural immune defense against 
cancer.
Several studies are now in progress to evaluate this hypothesis, to provide 
better evidence for the idea that host-microbial interactions may modulate 
tumor-related immune mechanisms, to define better disease risk and to target 
H.pylori eradication to high-risk individuals. In many respects, the H.pylori 
infection may be considered as a good clinical and experimental model for that.
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KOKKUVÕTE
Humoraalne immuun vastus Helicobacter pylori ie: 
peremehest ja mikroobist sõltuvate tegurite uuring
Helicobacter pylori avastamine 20 aastat tagasi (1983.a.) muutis tugevasti 
ettekujutust mao ja kaksteistsõrmiksoole krooniliste haiguste patogeneesist. 
Sellesse infektsiooni on nakatunud üle 50% meie planeedi elanikest, Eestis 
ligikaudu 80% täiskasvanud elanikkonnast. H.pylori infektsiooni seos gastro- 
duodenaalse patoloogiaga ei tekita enam kahtlusi. Põletik ja immunoloogilised 
mehhanismid on keskseks lüliks patogeneesiahelas põhjustades mao limaskesta 
rakkude kahjustusi, mis viivad atroofia, autoimmuunsete protsesside, düsplaasia 
ja maovähi tekkimiseni. Vähe on teada patogeneetilistest mehhanismidest, mis 
määravad infektsiooni kliinilise tulemuse individuaalsel tasemel. Probleem on 
tähtis ka praktilisest küljest vaadatuna kuna selle lahendusest sõltub, keda ja 
millal H.pylori infektsioonist ravida ning kas üldse ravida. Infektsiooni kliinilise 
tagajärje erinevuste selgitamiseks on vähemal kolm võimalust: (1) H.pylori 
muutlikkus ja virulentsemate bakteritüvede olemasolu või eelistatult teatud 
haiguse patogeneesis osalevad bakteritüved; (2) peremeesorganismi unikaalne 
või muutunud reaktsioon nakkusele, mis viib teatud kliinilise tagajärjeni; (3) 
teised tegurid nagu keskkonna mõjurid, mis võivad moduleerida bakteri ja 
peremeesorganismi vahelisi suhteid. Siiski näib, et erinevate omaduste teatud 
kombinatsioon määrab selle nakkuse kliinilise tagajärje.
Nii peremeesorganismi kui ka H.pylori suur geneetiline ja fenotüübiline 
polümorfism lubab a priori oletada erinevusi infektsiooni kliinilises tagajärjes. 
Viimase paari aasta jooksul on saanud selgeks, et "virulentsustegurite mudel" 
üksi ei suuda seletada H.pylori infektsiooni kliiniliste tagajärgede erinevusi 
indiviidide vahel. Sellest räägib ka seose puudumine H.pylori tuntud viru­
lentsustegurite (nende geenide ja alleelide) olemasolu ning konkreetse mao- 
haiguse vahel aga samuti ka segainfektsioonide (erineva genotüübiga H.pylori 
tüvede eksisteerimine maos) suur sagedus. El Omar (2001) ja Figueiredo et al. 
(2002) näitasid, et inimese geneetiline polümorfism (IL-1B geen, TNF-a pro- 
mootori polümorfism) on seotud eelsoodumusega teatud H.pylori põhjustatud 
haigustele. H.pylori infektsiooni pikaajaline püsimine viib maksimaalse vastas­
tikuse adapteerumiseni, mis suurendab veelgi selle vahekorra unikaalsust.
H.pylori vastu suunatud immuunvastus peegeldab nii H.pylori antigeenset 
spektrit kui ka peremeesorganismi võimet vastata sellele tüüpilisele "aeglasele" 
infektsioonile, kus peremeesorganism on peamiseks teguriks (Nguen et al., 
1999; Blaser 2000, 2002). Meie uurimistöös olid erilise tähelepanu all pere­
meesorganismi omadused, mis võivad mõjutada bakter-peremees omavahelist 
vahekorda. Uurisime ABH ja Lewis veregrupi antigeenidega seotud süsivesik- 
antigeene ning nende derivaate, mis on ekspresseeritud nii H.pylori pinnal kui 
ka peremehe mao mutsiinidel ja mukoosa rakkude glükokonjugaatidel. Mut-
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siinid on H.pylori normaalseks in vivo elukeskkonnaks ning kahjustuvad kõige 
rohkem erinevate maohaiguste korral. See on väga polümorfne süsteem, mida 
kontrollivad ABH, Le ja Se/se geenid ning mis on kaasatud H.pylori adhesiooni 
ja kolonisatsiooni läbi BabA ja SabA adhesiinide. Need süsivesikantigeenid 
võivad olla sihtmärgiks autoimmuunsetele protsessidele, mis omakorda on tihe­
dalt seotud mao mukoosa kahjustustega. Loomulikku ja omandatud immuun- 
vastust autoimmunogeensetele süsivesikepitoopidele võib vaadelda kui integ- 
raalset näitajat, mis peegeldab nende epitoopide ekspressiooni H.pylori'X ning 
peremeesorganismi võimet neid ära tunda ja vastata. Selles mõttes on immuun- 
vastus heaks test-süsteemiks peremehe polümorfismi mõju hindamisel pere- 
mees-mikroob vahekorrale.
Eesmärgid
Meie töö eesmärgiks oli uurida humoraalset immuunvastust H.pylori anti­
geenidele gastroduodenaalsete haigustega patsientidel ja veredoonoritel erilise 
tähelepanuga peremehe veregrupiga seotud antigeenide polümorfismile, mis 
võivad olla tegevad H.pyloriga seotud haiguste patogeneesis ja kliiniliste 
tagajärgede tekkimisel.
Töö põhilised ülesanded:
1. Hinnata H.pylori infektsiooni ja selle virulentsemate CagA positiivsete 
tüvede levikut gastroduodenaalsete haigustega patsientide (maovähk, pepti- 
line haavand, krooniline gastriit) ja veredoonorite seas arvestades isiku ABH 
ja Lewis veregrupi fenotüüpi ning Se/se sekretoorset staatust.
2. Uurida H.pylori infektsiooni ja peremehe Le(a,b) fenotüübi mõju Lewis tüüp 
2 antigeenidele suunatud immuunvastusele.
3. Uurida H.pylori infektsiooni võimalikku süsteemset toimet kasvaja- 
seoselisele veregrupiga seotud Thomsen-Friedenreichi antigeenile 
(Galßl,3GalNAc-0-Ser/Thr) suunatud loomulikule immuunvastusele erine­
vates kliinilistes gruppides.
4. Kontrollida hüpoteesi, et H.pylori võib enda pinnal ekspresseerida kasvaja- 
seoselist Thomsen-Friedenreichi antigeeni.
5. Hinnata maovähihaigete elulemust arvestades H.pylori seroloogilist staatust 
ja Thomsen-Friedenreichi antigeenile suunatud loomulike antikehade taset.
Materjal ja  meetodid
Uuriti 204 patsienti mao healoomuliste haigustega, 281 maovähihaiget ning 306 
juhuslikult valitud veredoonorit. Kasvaja staadiumi määramine ja morfoloogi­
line iseloomustus põhinesid histopatoloogilisel pTNM klassifikatsioonil. Pepti- 
lise haavandi diagnoos põhines endoskoopilisel uuringul. Kroonilise gastriidi
83
haigetel hinnati mao korpusest ja antrumist võetud proove histoloogiliselt 
vastavalt Sydney süsteemile. H.pylori standardse tüve NCTC 11637 ning samuti 
H.pylori kliinilised isolaadid kultiveeriti mikroaerofiilsetes tingimustes. 
Antigeenina kasutati H.pylori membraani antigeene (glütsiini ekstrakt), CagA 
rekombinantset fragmenti ning sünteetilisi T ja Lewis a,b,x,y hapteenide 
konjugaate polüakrüülamiidiga (PAA). Anti-H.pylori IgG antikehade tset 
määrati imunoensüümmeetodil (ELISA). Antikehade spektrit uuriti SDS 
elektroforeesi ja immunoblottingu meetodil. ABH ja Lewis fenotüüp määrati 
erütrotsüütidel monokloonsete antikehadega. Sekretoome staatus määrati 
ELISA meetodil H antigeeni sisalduse järgi süljes. Lewis tüüp 2 ning Thomsen- 
Friedenreichi süsivesikantigeenidele suunatud IgG ja IgM antikehade taset 
hinnati ELISA meetodil hapteen-PAA konjugaatidega. T-antigeeni ekspres­
siooni H.pylori pinnal määrati immunoblottingu meetodil terve rea mono- ja 
polükloonsete antikehadega ning samuti cell-ELISA meetodil. Saadud andmeid 
töödeldi parameetriliste ja mitteparameetriliste statistiliste meetoditega. Vähi­
haigete elulemust hinnati Kaplan-Meyeri meetodil (log-rank test).
Tulemusi analüüsiti kahte moodi: (1) võrdlesime tulemusi H.pylori sero- 
negatiivsete ja -positiivsete isikute vahel igas uuringugrupis (doonorid, patsien­
did), et leida erinevusi, mis on seotud H.pylori infektsiooniga (2) võrdlesime 
tulemusi uuringugruppides nakatunud ja nakatumata isikute hulgas, et leida 
haiguse-spetsiifilisi muutusi. Peremehest sõltuvaid tegureid, ABO(H) ja Lewis 
(a,b) fenotüüpi, sekretoorset staatust, T-antigeen spetsiifiliste IgG ja IgM ning 
Lewis tüüp 2 antikehade taset, kasvaja morfoloogiat, haiguse staadiumi ning 
vähihaigete elulemust võrreldi H.pylori seroloogilise staatuse, anti-H.pylori 
antikehade taseme, CagA staatuse, immunoblottingu tulemuste ja T-antigeeni 
ekspressiooniga H.pylori pinnal.
Peamised tulemused
Põhja-Eestis leiti seedetrakti haigustega ja sama vanusegrupi veredoonorite seas 
75.5-86.2% H.pylori seropositiivseid isikuid, mis ei olnud aga seotud mingi 
kindla haigusega. Maovähihaigete hulgas langes H.pylori seropositiivsus sõltu­
valt kasvaja arengu staadiumist. Immunoblottingu tulemused näitasid virulent- 
sema CagA positiivse tüve suuremat esinemissagedust (74.2-91.2%) gastro- 
duodenaalse patoloogiaga v.a. atroofilise gastriidiga (56.1%) patsientidel ning 
kaugelearenenud maovähiga haigetel (62.5%). Kõige rohkem CagA sero­
positiivseid isikuid oli mao- (91.2%) ja kaksteistsõrmiksoole (81.3%) haavan- 
diga patsientide seas. Vähihaigetel vähenes risti-reageerivate (33-66kDa) 
antigeenide tase (määrati immunoblottingu meetodil).
H.pylori NCTC 11637 membraani antigeenidele suunatud immuunvastust 
mõjutasid tugevasti peremehe ABH ja Lewis(a,b) fenotüübid. Mõju oli pigem 
üldine kui haiguse spetsiifiline. Lewis (a+b-/mittesekreetor) fenotüübiga 
doonorite seas oli märgatavalt rohkem H.pylori-seronegatnvseid isikuid ning
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madalam anti -H.pylori IgG immuunvastus kui Le(a-b+)/ sekreetor fenotüübiga 
isikutel. Need andmed kinnitavad kaudselt H.pylori Le(b) adhesiini B ab A 
osalust mao koloniseerimisel H.pylori'ga. Teisest küljest näitas see, et peremehe 
tugev immuunvastus ei ole otseselt seotud H.pylori resistentsusega.
Immunoblottingu ja immunoensüümmeetodil (CagA rekombinantse frag­
mendiga) saadud andmetel oli A veregrupiga doonorite ja mao healoomuliste 
haigustega patsientide seas oluliselt vähem CagA seropositiivseid isikuid 
võrreldes teiste ABO(H) fenotüüpidega doonoritega. Maovähihaigete seas oli 
see seos vähem väljendunud ning anti-CagA immuunvastus vähenes haiguse 
staadiumi arenedes olenemata vanusest, soost või kasvaja histoloogilisest 
iseloomustusest. Nende erinevuste aluseks olevad mehhanismid nõuavad edasisi 
uuringuid.
Le(b-) fenotüübiga veredoonorite seas oli oluliselt kõrgem CagA sero- 
positiivsete isikute protsent võrreldes sama uurimisrühma Le(b+) fenotüübiga 
isikutega. Seega on Le(b-) fenotüübiga isikutel eelsoodumus nakatuda CagA 
positiivse H.pylori tüvega.
Eelmainitud Le(a+b-) fenotüübiga isikute suhteline resistentsus selle 
infektsiooni suhtes ei ole nende andmetega vastuolus kuna on loogiline, et 
H.pylori infektsiooni suhtes resistentsemad isikud võivad nakatuda ainult 
virulentsemate tüvedega. Krooniliste maohaigustega patsientide sekretoome 
(Se/se) staatus ei olnud seotud CagA seroloogilise staatusega kuigi kaksteist- 
sõrmiksoole haavandiga patsientide seas oli oluliselt rohkem mitte-sekreetoreid.
Lewis 2 tüüpi determinantidele [Le(x), Le(y)] suunatud IgG immuunvastus 
oli seotud nii peremeesorganismi H.pylori seroloogilise staatuse kui ka 
Lewis(a,b) fenotüübiga. Le(b+)/sekreetor fenotüübiga isikutel oli tugevam 
Le(x) ja Le(y) epitoopidele suunatud immuunvastus olenemata H.pylori 
seroloogilisest staatusest. H.pylori nakatunud Le(b-) fenotüübiga isikute seas oli 
rohkem tugevaid reageerijaid Le(x) antigeenile võrreldes sama uurimisrühma 
H.pylori nakatumata isikutega. Võib oletada, et nendel isikutel on Le(x) epitoop 
kõige tõenäolisemaks sihtmärgiks H.pylori infektsiooniga seotud autoimmuun- 
setele reaktsioonidele.
H.pylori infektsioon on seotud tugevama immuunvastusega kasvajaseose- 
lisele Thomsen-Friedenreichi (T) antigeenile (Galßl,3-GalNAca/ß-0-Ser/Thr). 
Selline süsteemne toime sõltub permehe Lewis(a,b) fenotüübist ning on 
osaliselt haiguse-spetsiifiline. Anti T antikehade tase oli kõrge kõikides 
Rp};/or/-seropositiivsetes uurimisrühmades. Kõige madalam antikehade tase oli 
peptilise haavandiga haigetel olenemata H.pylori seroloogilisest staatusest. 
Suuremad erinevused H.pylori seropositiivsete ja -negatiivsete doonorite 
võrdlemisel leiti Le(b-) fenotüübiga isikute seas: anti-T spetsiifiliste IgG 
antikehade tase oli kõrgem nakatunutel. H.pylori infektsiooni ravi tulemusena 
antikehade tase langes osadel peptilise haavandi haigetel. Saadud andmed 
näitavad, et H.pylori infektsioon võib moduleerida loomulikke kasvajavastaseid 
immunoloogilisi mehhanisme.
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Tõendasime immunoloogiliselt kasvajaseoselise autoimmunogeense T-epi- 
toobi ekspressiooni H.pylori membraani glükokonjugaatidel ja selle ekspres­
siooni seotust loomuliku anti-T immuunvastuse muutustega nakatunud isikutel. 
T-spetsiifiliste monokloonsete antikehadega andsid värvusreaktsiooni peamiselt 
kaks proteiini 68 kDa ja 58 kDa. Erinevad H.pylori tüved ekspresseerivad T- 
epitoopi erineval määral, mis osaliselt sõltub maohaigusest: 68kDa proteiini 
suurem ekspressioon oli seotud raskema patoloogiaga (kaksteistsõrmiksoole 
haavand, mao vähk).
Maovähi varases staadiumis patsientide elulemus (kuni 6 aasta jälgimise 
andmetel) oli oluliselt parem H.pylori seropositiivsete patsientidel. See fenomen 
oli seotud T-antigeen spetsiifilise IgG immuun vastuse tugevnemisega H.pylori 
nakatunud isikutel. Nii võib öelda, et H.pylori infektsioon on kaudselt seotud 
mao kantserogeneesiga moduleerides loomulikke kas vaja vastaseid immuun- 
mehhanisme ning selline toime võib olla kasulik maovähihaigetele.
Kõik ülaltoodu lubab teha kaks üldist järeldust:
(1) peremeesorganismi veregrupi antigeenide (ABH ja Lewis) polümorfism 
mõjutab tugevalt peremehe immuunvastust H.pylori antigeenidele, 
infektsiooni esinemissagedust ning inimese eelsoodumust nakatuda teatud 
genotüübiga H.pyloriga (näiteks CagA+ tüvedega nakatuvad sagedamini 
Le(b-) fenotüübiga isikud ja harvemini A veregrupiga isikud). Pere­
meesorganismi ABH ja Lewis fenotüüpide moduleerivat efekti tuleks 
arvestada võrdlevatel s.h. ka epidemioloogilistel H.pylori infektsiooniga 
seotud haiguste uuringutel.
(2) Kasvajaseoselise Thomsen-Friedenreichi antigeeni abil näidati, et H.pylori 
infektsioon võib stimuleerida kasvajavastaseid immuunmehhanisme ning 
parandada maovähihaigete elulemuse näitajaid. Sellist süsteemset efekti 
võib oodata ka vähi mitte-mao lokalisatsioonide korral. Arvame, et 
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Helicobacter pylori infection is considered to be a risk factor 
for gastric cancer. A high prevalence of H. pylori infection and 
high gastric-cancer incidence are characteristic of the Estonian 
population. To evaluate the relationship between these 2 
events, we studied the seroprevalence of H. pylori in gastric 
cancer patients (n = 182) and in healthy blood donors (n = 306). 
A relative anti-H. pylori IgG antibody activity, as detected by 
EUSA and immunoblot patterns, was correlated with age, stage 
of the disease and tumor morphology. A significantly higher H. 
pytori seroprevalence was found in patients in the eaHy stages of 
tumor development compared with both advanced cancer 
patients and controls. No significant difference in H. pylori 
seroprevalence between patients with the intestinal and diffuse 
types of tumor growth was observed. A decline in the recogni­
tion of putativeiy cross-reacting (33-66 к Da) antigens was 
noted in the cancer group. The response to vacuolating toxin- 
related 85-kDa and CagA 120-kDa protein antigens was not 
altered and was observed more often in the younger group of 
cancer patients.
© 1996 Wiley-Liss, Inc.
H. pylori gastric infection is supposed to be a risk factor for 
gastric cancer (Correa et aL, 1990; Eurogast Study Group, 
1993; Parsonnet, 1993; IARC, 1994). The most convincing data 
for this supposition reside in the concordant results of prospec­
tive cohort studies in different high- and low-risk populations 
which had been followed over 6-14 years for later development 
of gastric cancer (IARC, 1994). A significantly higher risk of 
gastric cancer development (odds ratio 2.8-6) was found for # . 
pylori-infected individuals compared with H. pylori-negative 
controls, adjusted by age, sex and date of blood sampling.
A high prevalence o f# , pylori infection and a high incidence 
of gastric cancer are both characteristic of the Estonian 
population (Maaroos et al., 1990; Rahu and Aareleid, 1990; 
Vorobjova et aL, 1994). The relationship between these 2 
events is unclear. We studied H. pylori seroprevalence in 
gastric cancer patients and controls by ELISÀ and further 
analyzed anti-#, pylori IgG reactivity patterns by immunoblot­
ting, using a pool of acid glycine H. pylori extracts which 
contained the major surface-exposed immunoreactive # . pylori 
antigens (Lelwala-Guruge et aL, 1992). The data were corre­
lated with age, stage of the disease and tumor morphology.
MATERIAL AND METHODS
Subjects
Serum samples from 182 consecutive patients (105 men, 77 
women; median age 62; range 21-87 years) with histologically 
verified non-cardiac gastric cancer diagnosed in the Estonian 
Cancer Center and from 306 healthy blood donors and healthy 
employees (132 men, 174 women; median age 51; range 18-72 
years) were examined. Donors were not asked about the 
presence of abdominal complaints. The patients and controls 
were divided into 5 10-year age groups (see Table 1). Gastric 
carcinoma was classified histologically into the intestinal 
(n =  102) and diffuse (n = 80) types, according to the system 
of Lauren (1965). Tumor staging was based on the histopatho- 
logical (pTNM) classification system (Hermanek and Sobin, 
1987).
Serum specimens 
Sera were collected from all subjects by centrifugation of 
clotted venous blood after 2 hr incubation at 37°C and stored 
at -20°C.
Antigen preparation
A glycine cell-surface antigen extraction of # . pylori strain 
NCTC 11637 was performed according to Logan and Trust 
(1983). The strain was grown on GAB-CAMP reference agar 
at 37°C for 2 days in plastic jars filled with a gas mixture of 5%
0 2, 10% C 0 2 and 85% N2. The antigen was a pool of 9 
different preparations.
Enzyme-linked immunosorbent assay (ELISA)
Serum samples were examined by ELISA as described 
earlier (Lelwala-Guruge et al., 1990). In brief, the 96-well 
flat-bottomed microtiter plates (Maxi Sorp, Nunc, Roskilde, 
Denmark) were coated with 0.1 ml of antigen (5 jig/ml) per 
well and incubated at 4°C overnight. Alkaline phosphatase 
conjugated anti-human IgG (Dako, Glostrup, Denmark) and 
p-nitro-phenyl-phosphate (Sigma, St. Louis, MO) substrate 
were used. A pool of human IgG (Kabi, Stockholm, Sweden) 
was used in each ELISA plate as a positive control for 100 
units. Relative antibody activity (RAA) values above 25 were 
regarded as positive.
SDS-PAGE and Immunoblotting 
SDS-PAGE was performed in 12% polyacrylamide separat­
ing gel according to Laemmli (1970). A gel was loaded with # . 
pylori glycine extract previously mixed with 0.07 M TRIS HCl 
(pH 6.8) containing glycerol, SDS, bromphenol blue and 
mercaptoethanol, heated for 3 min at 90°C and cooled. Protein 
molecular weight standards (Promega, Madison, WI) were 
diluted in the same sample buffer without mercaptoethanol 
and treated similarly. After separation, the proteins were 
blotted onto a nitrocellulose sheet, 0.45 |xm (Schleicher and 
Schuell, Dassel, Germany) in a semi-dry electroblotter (Milli- 
pore, Sundbyberg, Sweden). The nitrocellulose membrane was 
saturated as described by Rucheton et aL (1992) and, after 
drying, cut into strips. The strips were washed and incubated 
with patients’ sera (1:76), overnight at 4°C under agitation. In 
each plate one strip was incubated with standard IgG (Kabi). 
The strips were washed and incubated for 2 hr at 4°C with 
peroxidase-labelled rabbit anti-human IgG (Dako) and devel­
oped with carbazol (Merck, Darmstadt, Germany).
Statistical analysis 
Statistical comparisons between the groups were performed 
by the Chi-square test. The differences were considered to be 
significant whenp < 0.05.
*To whom correspondence and reprint requests should be sent, at 
the Department of Experimental Oncology, Institute of Experimental 
and Clinical Medicine, Hiiu 42, Tallinn, EE 0016, Estonia. Fax: 
(372)5-248260.
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TABLE I -  PREVALENCE OF H. PYLORI IgG SERUM ANTIBODIES IN 182 GASTRIC CANCER PATIENTS AND 306 CONTROLS BY AGE
AND DISEASE STAGE
Age (years)
Group <40 40-49 50-59 60-69 >69 All
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pylori-seropositive/seronegative individuals. For H. pylori seropositivity criteria, see text.^Tumors were classified according to 
1 criteria for carcinoma of the stomach, established by the International Union Against Cancer (Hermanek and Sobin, 1987).J In 
parentheses: per cent of the H. /^/on-seropositive individuals.-The difference in H. pylori seroprevalence: stage I + II versus stage 1П + 




The overall H. pylori seropositivity rates were 79.4% and 
84.1% for controls and gastric-cancer patients, respectively, 
and did not differ significantly (p  =  0.25). However, the H. 
pylori seroprevalence in the patients in early stages of cancer 
(I + II) was significantly higher (63/68, 92.6%) than in either 
the patients in later stages of the disease (90/114 (78.9%); 
X2 =  4.99, p  =  0.025; odds ratio (OR) =  3.36, 95% Cl (1.1- 
10.6) or controls (243/306 (79.4%), x2 =  5.69, p  = 0.017; 
OR =  3.26, 95% Cl (1.2-9.4) (Table I). No significant age- 
related differences in the H. pylori seropositivity rate were 
found in controls and within the group of cancer patients at 
different stages of the disease. The youngest group of patients 
( <  40 yr) was small (n =  10, 5 of them in stage I-П ) and all of 
them were seropositive. No differences between cancer pa­
tients and controls were found in any age-adjusted groups 
when the data were compared, irrespective of the disease 
stage. Thus, only the stage of the disease showed an associa­
tion with H. pylori seroprevalence in patients with gastric 
cancer aged over 40. The total H. pylori seropositivity rate was 
similar for patients with the diffuse (83.7%) and the intestinal 
(84.3%) types of tumor growth according to Lauren’s classifica­
tion; furthermore, a similar decline in H. pylori seroprevalence 
in advanced cancer was revealed in both groups (Table II).
On immunoblotting, the protein profile consisted predomi­
nantly o f 9 major bands with molecular weights of ~  120, 85, 
66, 62, 59, 47, 43, 33 and 28 kDa (Fig. 1). The significant 
differences between H. pylori-seropositive and -seronegative 
groups were mostly associated with bands of 33,59 and 66 kDa 
for controls and with bands of 85 and 59 kDa for gastric-cancer 
patients (Table III). Three o f 31 (9.7%) controls and 14 of 96 
(14.6%) cancer patients did not recognize any bands at all. All 
of them, with the exception o f 2 cancer patients, were H. pylori 
seronegative in ELISA.
The differences in H. pylori antibody spectra between gastric 
cancer patients and controls became visible if H. pylori-positive 
persons in both groups were compared (Table Ш). In the H. 
/ту/оп-seropositive group, 100% of controls recognized the 
33-kDa and 59-kDa bands, while in the cancer group the 
percentage was 61% and 73% (x2 =  10.8, p  <  0.001 and 
X2 =  6.0, p  <  0.02, respectively). The occurrence of low- 
molecular-weight bands ( < 28kDa) was also significantly higher 
in H. py/on'-seropositive controlindividuals (x2 =  6.6, p  =  0.01). 
The differences concern the 62-66 kDa region as well. The 
number o f persons recognizing these bands was also signifi-
TABLE П -  PREVALENCE OF H. PYLORI IgG SERUM ANTIBODIES IN 
PATIENTS WITH GASTRIC CANCER BY DISEASE STAGE AND 
HISTOLOGICAL TYPE OF TUMOR
Gastric cancer 
patients




(n =  102)
HP+1 H P -1 HP+ H P -
Stage I 15 1 10 2
n = 28 (93.8)3 (83.3)
Stage II 12 1 26 1
n = 40 (92.3) (92.3)
Stage III 6 2 22 5
n = 35 (75.0) (81.5)
Stage IV 34 9 28 8
n = 79 (79.1) (77.8)
All 67 13 86 16
3 II 00 N> (83.7) (84.3)
'According to Lauren classification (1965).-2//. pylori-seroposi- 
tive/seronegative individuals. For H. pylori seropositivity criteria, 
see text.-^In parentheses: percent of H. py/on-seropositive individu­
als.
cantly higher in the control group (p  <  0.05). A decreased 
recognition of 28-66 kDa region bands was more pronounced 
in H. py/on-seropositive patients at stage Ш-IV  compared with 
the seropositive controls, especially for 33-kDa and 66-kDa 
antigens: cancer group, 70.7% and 46.3%; controls, 100% and 
75.9%; p  =  0.01 and p  =  0.06, respectively). No remarkable 
differences between H. py/оп-negative patients and controls 
were found.
The vacuolating cytotoxin-associated 120-kDa protein band 
was recognized by 55% of the H. py/on-seropositive gastric 
cancer patients and by 69% of the controls, but 8 of 24 (33%) 
H. pylori-negative cancer patients and 4 of 8 (50%) H. 
py/ori-negative healthy controls recognized this band as well. A  
higher frequency of the 85-kDa band in blots of sera from 
cancer patients under 50 years of age (13/15,86.7%) was noted 
compared with age-related controls (7/14, 50%, p  =  0.08). 
This band was recognized only by 53.1% (43/81) of the cancer 
patients above this age (x2 =  4.57, p  =  0.032, compared with 
the younger group of patients). A  similar age-related trend was 
noted for 120-kDa protein: 73.3% of patients aged below 50 yr 
and 56.2% of those above this limit show this band on blotting,
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Figure 1 -  H. pylori immunoblots incubated with sera from 
gastric cancer patients (1) and healthy persons (2). M, marker 
proteins; A, H. py/on-seronegative persons; В, H. pylori-seroposi­
tive persons. Molecular masses of Mr standards (left) and the 
major#, pylori antigens (right).
but the opposite result was obtained in age-subgroups of 
controls (57.1% and 70.1%, respectively). No other age- 
related differences were found in the patients and controls. In 
contrast to the 28-66 kDa area, the frequency of 85-kDa and 
120-kDa protein bands was similar for H. py/on'-seropositive 
patients at the early and late stages of gastric cancer (in the 
range of 62-70%).
As in the case of ELISA, we found no difference in blotting 
patterns between the patients according to tumor histology. H. 
pylori-seropositive cancer patients with intestinal-type tumors 
showed a higher percentage of recognition of the 120-kD but 
not the 85-kD protein band as compared with the group of 
patients with diffuse-type cancers (72% vs. 59%), but the 
difference was not significant.
DISCUSSION
The data show that the H. pylori seropositivity rate in 
patients with gastric cancer, as defined by ELISA, is related to 
the stage of the disease and is significantly higher at early 
stages of tumor development, though the overall H. pylori 
seropositivity in the cancer group did not differ significantly 
from that seen in controls. No age-related differences were 
found in controls: the H. pylori seroprevalence almost reached 
its maximum in controls under 40 years of age, remained at a 
level o f 79-84% in those aged up to 70 years and did not differ 
significantly from that seen in the age-related groups of cancer 
patients. The same was true for the differences between 
10-year age subgroups of patients in any stage of cancer except 
the youngest group of patients (under 40 yr) who were all 
seropositive irrespective of the disease stage. Thus, it appears
that the stage distribution is a very important factor influenc­
ing the H. pylori seroprevalence in gastric-cancer patients over 
40 years of age.
A higher rate of histologically detected H. pylori positivity 
was reported for early than for advanced gastric cancer 
(Caruso and Fucci, 1990; Sakaki et al., 1993). Asaka et al. 
(1994) also found that the H. pylori-gastric cancer association 
is restricted to early gastric cancer. It is noteworthy that such 
an association with the highest odds ratio was observed in 
subjects under 50 years of age, though the decrease in odds 
ratio with age was mainly due to an increase in the seropositiv­
ity rate in controls (Kikuchi et al., 1995). Our data are in 
accordance with these findings. It is likely that, in some gastric 
cancer patients, the infection may have disappeared by the 
time the cancer is diagnosed, leading to a classification of 
“false seronegatives,” especially in the group of older patients 
and/or at the later stages of cancer. In spite o f all these 
findings, the distribution of gastric-cancer patients by stage is 
still often overlooked in many case-control studies. It could be 
expected that the situation at the early stages of neoplasia 
reflects the H. pylori-host relationships in a more realistic way 
because many secondary events associated with advanced 
cancer are excluded (an altered microenvironment due to 
aberrant glycosylation, colonization of the stomach by bacteria 
other than H. pylori, microbial overgrowth, tumor-induced 
immunosuppression). Otherwise, an underestimation of H. 
pylori seroprevalence in cancer groups may occur.
It should be mentioned that H. pylori seroprevalence in our 
controls was similar to that obtained in the population-based 
studies performed recently in Estonia (Maaroos et a l, 1990; 
Vorobjova et al, 1994). Keeping in mind that the controls used 
in this study might include some individuals with non-ulcerous 
dyspepsia or even with peptic ulcers, the H. pylori seropreva­
lence in this group is possibly overestimated. However, in spite 
of a very high H. pylori seroprevalence in controls, there was a 
significantly higher seropositivity rate in patients in early stages 
of gastric cancer.
We found no significant difference in H. pylori seropreva­
lence between diffuse- and intestinal-type gastric cancers. The 
prevalence o f# . pylori infection in patients with intestinal-type 
adenocarcinomas has been observed by many investigators but 
not confirmed by others (IARC, 1994). We noted only a slight 
prevalence of recognition of 120-kDa antigen by serum of 
patients with intestinal-type tumor growth.
A  higher proportion of < 28, 33, 59 and 62-66 kDa bands 
was typical in sera of controls compared with those of cancer 
patients. These putatively cross-reacting antigens showed a 
close association with H. pylori seropositivity in ELISA. The 
cell-surface urease, flagellar and heat-shock proteins have 
similar molecular masses and were shown to have properties 
similar to those of some other species (Dunn et al., 1989; 
Maeland et al, 1993). By contrast, the frequency-of the 
vacuolating-toxin-related 85-kDa band was even increased in 
patients with gastric cancer, especially in patients under 50 
years of age. The same was true for 120-kDa protein. Hence, 
the IgG immune response to these cytotoxin-related # . pylori 
antigens remains stable in cancer patients, possibly due to a 
better immunogenicity of these antigens or their enhanced 
production in gastric-cancer patients.
In spite of considerable phenotypic conservation, at least 4 
phenotypic characteristics may be different among H. pylori 
strains: the structure of lipopolysaccharide, expression of 
vacuolating cytotoxin and cagA-encoded protein (120-140 kD) 
and the ability to activate neutrophils (Blaser, 1994). The 
vacuolating cytotoxin-related 85-87 kDa and 120-130 kDa 
protein antigens are present in 50-70% of H. pylori strains 
(Tummuru et al., 1993; IARC, 1994). The expression and 
systemic IgG or mucosal IgA recognition of the 120-kDa 
protein was shown to be associated with active gastritis, peptic
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TABLE Ш -  DISTRIBUTION OF THE MAJOR H. PYLORI ANTIGENS DETECTED BY IMMUNOBLOTTING WITH 
SERA OF Я  m .O W -SER O PO Sm V E (HP+) AND Я  m.OW -SERONEGATIVE (H P -) CANCER PATIENTS 
AND CONTROLS
Gastric cancer Healthy blood donors 
Mol. mass -------------------------------------------------------------  ------------------------- -------------------
(kDa) All H P - HP* All H P - HP+ 
_______________n -  %_______ n -  24 (25) n = 72 (72)_______ n = 31_______ n - 8 ( 2 ž )  n = 23 (74)
120 48 ('50'I3 8 (зз;1 40 ('55;) 20 (64'1 4 (50) 16 (69)
85 56 (’58'1 7 (*29 1 49 (68 I1 17 (54 1 3 37) 14 (’61)
66 41 (’42 1 7 (’29 ) 34 ('47')2 19 (61 1 2 (25) 17 (’73V
62 38 (’39 1 101’41 ) 28 (38 )2 17 (54'I 2 (25) 15 (’65)
59 64 <’66 1 11 (’45 I 53 (73 ,u  27 (87*) 4 (50) 23 ('lOO)12
47 60 <’62 1 11 (’45 I 49 (68*1 23 (74*) 5 (62) 181 78)
43 28 (29 1 4 (’16*I 24 (>33<) 10 (32') 1 (12) 9 (39)
33 57 (>59<1 13 (’54 ) 44 <>61<)2 26 (83 ) 3 (37) 23 (’lOO)1
28 59 (61 1 11 (45 ) 48 (’66') 18 (58*) 3 (37) 15 (65)
<28 32 (33*) 6< 25 I 26 (’36 I2 18 (58 1 2 (25) 16 (!69)
'Significantly different from related H P - group as calculated by Chi-square test.^Significantly 
different from HP+ group of blood donors. J In parentheses, percent of seropositive cases within each 
subgroup.
ulceration and gastric cancer (Crabtree et a l, 1991, 1993). 
Some differences in anti-#, pylori IgGi and IgG2 subclass 
antibody immune response were found between # . pylori- 
infected patients with duodenal ulcer and those without ulcer 
(Bontkes et al., 1992). Immunoblot patterns of different # . 
pylori-positive sera, when tested with the same # .  pylori extract, 
also showed appreciable differences (Dunnef al., 1989). Taken 
together, these findings suggest that the antigenic differences 
between strains and/or host-dependent peculiarities in anti-#. 
pylori immune response may be differently implicated in the 
pathogenesis of various #  pylori infection-associated diseases.
However no direct evidence has been presented so far 
concerning the involvement of #  pylori toxins in tumor- 
inducing specific mechanisms or in damaging of the anti-tumor 
defense system. We have shown (Kurtenkov et al, 1995) that 
# . pylori gastric infections are associated with a suppressed 
anti-Thomsen-Friedenreich antigen natural immune response, 
which is considered to be an important factor in the natural 
anti-tumor defense system (Springer, 1984). The sequence of 
events remains unclear: whether this suppression is induced by 
the H. pylori infection perse, or whether individuals with a low 
natural immune response to this tumor-associated antigen are 
more susceptible to # .  pylori infection.
In conclusion, the distribution of cancer patients by stage is 
an important factor in the evaluation of anti-#, pylori systemic 
immune response of patients with gastric cancer and in 
comparisons between cancer patients and controls. Patients in 
the early stages of cancer should be examined in the first place
to avoid an underestimation of # .  pylori seroprevalence due to 
the possible modulation of the immune response in patients 
with advanced cancer. We suggest that “the early-stage—early- 
age situation” seems to be a more favorable condition for 
studying the # . pylori infection-gastric-cancer relationships. 
The cancer patients were characterized by a decline in recogni­
tion of putatively cross-reacting low-molecular-weight ( < 28, 
33-66 kDa) # .  pylori antigens. The systemic IgG immune 
response to toxin-related 85- and 120-kDa #  pylori proteins 
was not altered, and was observed more often in the younger 
group of cancer patients. These changes may be connected 
with the existence of # .  pylori strains, preferably involved in 
gastric carcinogenesis, such as toxin-producing strains, or be 
related to the peculiarities of the host immune response. A 
further study of the cell-surface antigenic profile of # .  pylori 
isolates derived from gastric-cancer patients and controls, as 
well as a comparison of the immune response to homologous 
and heterologous # .  pylori antigens, are required to answer the 
question whether any cancer-specific signs of # .  pylori gastric 
infection exist.
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The Helicobacter pylori seroprevalence in blood 
donors related to Lewis (a,b) histo-blood group 
phenotype
Kersti Klaamas1, Oleg Kurtenkov1, Malle Ellamaa2 
and Torkel Wadström3
Objective: To study a possib le  associa tion  of th e  Helicobacter pylori se rop reva lence  
w ith  ABO(H) an d  Lewis (a,b) b lood  g roup  p h en o ty p es  in b lood  donors.
Design: A cross-sectiona l study  o f  b lood  do n o rs  using ABO(H) and  Lewis (a,b) b lood  
g ro u p  p h en o ty p e  as pred icto rs.
Methods: ABO(H) an d  Lewis (a,b) b lo o d  g ro u p  p h en o ty p in g  w as p e rfo rm ed  w ith  
m o n o c lo n a l an tib o d y . T h e  H . p y lo r i  im m u n o g lo b u lin  G  (IgG) a n t ib o d y  re la tiv e  
ac tiv ity  w as ev a lu a ted  by  en zy m e-lin k ed  im m u n o so rb en t assay  (ELISA) using ac id  
g lyc ine  ex trac t from  H. p y lo r i .
Subjects: O n e  h u nd red  a n d  fifty-nine random ly  se lec ted  b lood  transfusion  donors.
Results: The indiv iduals w ith  Lewis (a+ b -)/n o n -secre to r p h en o ty p e  sh o w ed  a signifi­
c a n tly  h ig h e r p ro p o rtio n  o f th e  H . p y lo r i -se ro n e g a tiv e  su b je c ts  a n d  a lo w er IgG 
im m u n e  response  to  H. p y lo r i  an tigens as co m p a re d  w ith th e  ind iv iduals o f Lewis 
(a -b + )/sec re to r phen o ty p e .
Conclusion: The Lewis (a,b) h isto -b lood  g roup  an tigens  a re  im plica ted  in th e  m e c h a ­
n ism s o f naturally  occu rring  resistance to  H . p y lo r i  infection.
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Introduction
Several Helicobacter pylori cell-surface proteins or adhesins 
have been considered to be involved in the colonization 
o f gastric mucosa by H. pylori: sialic acid-specific lectin, 
adhesins to fucosylated  b lood  group antigens, 
glycosam inoglycans and to the extracellular matrix 
proteins [1 -3 ]. The appropriate host tissue receptors 
belong to the specific glycoconjugates in the mucin layer 
and on the gastric epithelial cells.
It is well known that individuals o f blood group О and 
those who are non-secretors are over-represented among 
patients with peptic ulcers [4,5]. The secretor status is 
determined by the presence or absence o f  a fucose residue 
on the terminal galactose residues on the mucosal O -  
linked oligosaccharides and mucins in secretions, which in 
turn is determined by the inheritance o f  the appropriate 
a-1-2  fucosyl-transferase Se (secretor) gene [6,7]. At the 
phenotypical level the secretors belong to Lewis (Le)
(a-b+) and those who are non-secretors to Le (a+b—) 
histo-blood-group phenotype. Individuals with Le (a-b-) 
phenotype may be secretors or non-secretors depending 
on the presence or absence o f  a Se gene [6].
The Le (b) histo-blood group antigen has been shown 
to mediate the H. pylori attachment to human gastric 
mucosa [1], suggesting that the Le (a+b-) /non-secretors 
may be more resistant to H. pylori infection than secretors. 
However, no convincing clinical support for this has- been 
presented so far. In Estonia, more than 80% of adults over 
the age o f 30 are H. pylori infected [8,9] and a rather low  
proportion o f Le (a+b-)/non-secretors (~12%) is charac­
teristic o f the Estonian population [10]. We hypothesized 
that in populations with a very high prevalence of H. pylori 
infection, an over-representation o f Le (a+b-)/non-secre- 
tors should be expected among the H. py/on'-uninfected 
individuals mainly at the age when the H. pylori infection 
prevalence in a given population is close to its maximum. 
We report here that the Le (a+b—) /non-secretor histo-
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blood g roup phenotype is associated w ith  a significantly 
low er p roportion  o f  H . pylori-infected b lood  transfusion 
donors as com pared with Le (a-b+)/secretors, supporting 
the idea that the Lewis (a,b) blood group antigens may be 
involved in the natural resistance to H . pylori infection.
Material and methods
B lood samples w ere taken from 159 random ly selected 
blood transfusion donors (67 w om en and 92 men) ranging 
in age from  17 to  60 years, mean age 48 years. D onors 
w e re  n o t  a sk e d  a b o u t  th e  p re s e n c e  o f  a b d o m in a l 
com plaints. A B O (H ) and Lewis blood group phenotype 
distribution is show n in Tables 1 and 2.
Sera w ere collected from  all subjects by centrifugation 
o f  clotted venous blood after incubation for 2 h at +37°C  
and stored at -2 0 °C .
A BO (H ) and Lewis (a,b) phenotyping o f  erythrocytes 
was carried ou t using anti-A and anti-B monoclonal antibody 
(M onoCarb AB, Sweden) and anti-Lewis (a) and anti-Lewis 
(b) monoclonal antibody gel system (DiaM ed, Switzerland) 
according to  the instruction o f  the manufacturers.
A glycine cell surface antigen extraction o f  H . pylori strain 
N C T C  11637 was performed according to Logan and Trust
[11]. T he  strain was grown on G AB-CA M P (Gonococcal 
agar base/ Campylobacter) reference agar at 37°C  for 2 days in 
plastic jars filled w ith  a gas m ixture o f  5% oxygen, 10% 
carbon dioxide and 85% nitrogen. The antigen was a pool of 
nine different preparations.
S erum  sam ples w ere  exam ined  by en z y m e-lin k ed  
im m unosorbent assay (ELISA) as described earlier [12]. In 
brief, th e  9 6 -w ell fla t-bo ttom  m icro titre  plates (M axi 
Sorp, N unc, Roskilde, Denmark) w ere coated w ith  0.1 ml 
o f  a n tig en  (5 } ig /m l) p e r  w ell and  in c u b a te d  a t 4°C  
overnight. A lkaline phosphatase conjugated  anti-hum an 
im m u n o g lo b u l in  G (IgG ) (D ak o  A /S ,  G lo s tru p , 
Denm ark) and p-nitro-phenyl-phosphate (Sigma, St Louis, 
M O ) substrate w ere used. A pool o f  hum an IgG (Kabi 
AB, Stockholm , Sweden) was used in each ELISA plate as 
a positive  c o n tro l for 100 units. A re la tive  an tibody  
activity (RAA) value above 25 was regarded as positive. 
T he  individuals w ith  so-called ‘grey zone’ R A A  values 
(26-35) w eré also taken into account and together with 
the negative subjects w ere designated as ‘low  responders’.
S ta tis tic a l com parisons  b e tw e en  th e  g ro u p s  w ere  
performed by the %2 test. O dds ratios (O Rs) and their 95% 
confidence intervals (95% C l) w ere calculated to measure 
an association between the parameters studied. T he differ­
ences w ere considered to be significant w hen P<0.05.
Results
T h e  d is tribu tion  o f  A B U (H ) and Le (a,b) phenotypes 
am ong  b lood  donors was similar to tha t ob ta ined  in a 
popu la tion -based  study perform ed recen tly  in Estonia 
[10]. A higher percentage o f  individuals w ith blood group 
A was found am ong the non-secretors (11 o f  23, 47.8%) 
com pared w ith both sccretors (33 o f  113, 29.2%) and the 
Le (a-b -) group (5 o f 23, 21.8%), bu t the differences were 
not significant (P > 0 .1 ). The IgG im m une response to H.
Table 1. The H. p y lo r i  serological status of 159 blood 
donors in relation to ABO(H) blood group phenotype.
H. py lo ri  serological status
ABO(H)
blood type n Negative Positive*
О 67 10 (14.9) 57(85.1)
A 52 9(17.3) 43 (82.7)
В 23 4 (17.4) 19 (82.6)
AB 17 3(17.6) 14(82.4)
159 26 (16.4) 133 (83.6)
•R elative an tibody activity (RAA) >25. In parentheses:
percentage of H. pylori-seronegative and -seropositive indi­
viduals in each ABO(H) subgroup.
T able 2. The H. p y lo r i  serological status of 159 blood
donors depending on Le (a,b) blood group phenotype.
H. py lo ri serological status
Le (a,b)
phenotype n Negative Positive
Le ( a+b-) 23 8 (34.8)* 15(65.2)
Le (a-b+) 113 16(14.2) 97 (85.8)
Le (a-b-) 23 2 (8.7) 21 (91.3)
159 26(16.4) 133 (83.6)
•Significantly different from the Le (a-b+) group of donors 
(X2 = 4.26, df 1, P =  0.038, OR = 3.2, 95%  Cl 1.1-9.9).
In parentheses: percentage of H. pylori-seronegative and - 
seropositive individuals in each Le (a,b) subgroup.
pylori was no t dependent on ABO(H ) b lood  group pheno­
type i f  the data w ere analysed irrespective o f  Le (a,b) 
phenotype (Table 1). T he proportion o f  low  responders 
(RA A  < 35) was also similar for individuals w ith  О , A. В 
and AB blood group phenotypes: 15.0%, 23.0%, 21.7% 
and 23.5%, respectively (P >0.05).
T h e  Le (a + b—) /n o n - s e c r e to r  p h e n o ty p e  g ro u p  
con ta ined  a significantly  h igher p ro p o rtio n  o f  the H. 
py/ori-seronegative subjects than the Le (a-b+ )/secre to r 
group (Table 2). If  the individuals w ith  so-called ‘grey 
zo n e ’ RA A  values (RA A  = 26 -35 ) w ere  inc luded, the 
difference was even m ore pronounced (Fig. 1). Five o f  the 
six subjects in this group showed RA A  values less than 30 
(26, 26, 27, 29, 29) and four o f  them  belonged to the Le 
(a+b—) subgroup. T he individuals w ith Le (a—b—) pheno­
type reacted like Le (a—b+)/secretors show ing the lowest 
proportion o f  H . pylori-seronegative results (8.7%). Thus it 
appears that Le (a+b—)/non-secretors are m ore resistant to 
H. pylori infection.
Interestingly, the p roportion  o f  low  responders in a 
group o f  donors possessing Le (a) antigen was significandy 
h ighe r than in Le (a)-negative individuals (43.5%  and 
15.4%, respectively; %2 = 8.14, degrees o f  freedom (df) 1, P  
= 0.004; O R  =  4.2, 95% C l 1.5-12.1), whereas no signifi­
cant difference was noted between Le (b)-positive and Le 
(b)-ncgative donors (x2=1.24, P - 0.26; O R = 0 .6 ) .
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Fig. 1. The frequency of H. pylori-seronegative individuals among 
blood donors with different Le (a,b) blood group phenotypes. Dark 
bars, RAA  <  25 as criterion for H. pylori seronegativity; light bars, 
RAA < 3 5  (low responders). ‘Significantly higher as compared with 
Le (a-b+)/secretors ft2 =  4.26, df 1, P =  0,039; O R  =  3.8, 9 5 %  Cl 
1 .1 -9 .9 ). “ S ign if ican t ly  h igher as com pared  w ith  both Le 
(a-b+)/secretors and Le (a-b-) group (x2 =  6.58, and x 2 =  5.52, df 1, 
P =  0.01 ; O R .=  3.8, 9 5 %  C l 1 .3 -11.0  and O R  = 8.1, 9 5 %  Cl 
1.3-46.1, respectively).
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Fig. 2. Distribution of individuals with different Le (a,b) blood 
group phenotypes by relative H. pylori IgG antibody activity (RAA). 
The following groups of subjects were used for a cross-tabulation 
and X1 calculation: R A A < 2 5 ,  26-50, 51 -75  and > 7 5 .  Subjects 
with RAA  values equal to 76 -100  and >  100 were combined (RAA 
>7 5 )  because of the small number of donors with R A A  values 
more than 100. Le (a+b-) vs. Le (a-b+): x ! = 9.33, df 3, P=0.02; Le 
(a+b-) vs. Le (a-b-): х г =  8 .91, df 3, P =0 .0 3 ;  Le (a-b -) vs. Le 
(a—b+): х г =  1.45, df 3, P =  0.69.
T o  ex c lude  the  in flu en ce  o f  age o n  the  H . pylori  
seropositivity rate we investigated mainly the o lder group 
o f  donors: 132 o f  159 (83%) subjects tested w ere above 40 
years o f  age. T he difference in the proportion o f  H . pylori- 
seronegative individuals o f  different Le (a,b) blood group 
phenotypes was retained also in subgroups o f  individuals at 
41-50 and 51-60  years o f  age: 40.0% and 33.3% for non- 
secretors; ’ 6.7% and 13.3% for secretors, respectively. T he 
percen tage  o f  the H . py/orr'-seronegativc sub jec ts  was 
similar to that observed in the com bined group (Fig. 1), 
thus indicating that this proportion was no t appreciably 
influenced by age.
Am ong the H . pylori-seronegative donors (n =  26), eight 
subjects (30.8%) were o f  Le (a+b-) phenotype (Table 2). 
This is significantly higher than in the H. pylori-seropositive 
group: 15 o f  133 (11.3%); X2 = 5.2, d f  1. />=0.02; O R  =
3.5, 95% C l 1.2—10.5. It should be noted that the propor­
tion o f  Le (a+b—)/non-secretors in the H . pylori-scroposi- 
tive group was almost identical to those obtained in the 
population-based study in Estonia — 11.7% [10]. It was also 
true for H . pylori-seropositive individuals o f  Le (a—b+) and 
Le (a-b -) phenotypes (Table 2): 97 o f  133 (72.9%) and 21 
o f  133 (15.8%) compared with the population-based data 
(70.0% and 16.9%, respectively) [10].
A significandy low er systemic im m une response to H . 
pylori cell surface antigens, as defined by R A A  values, was 
fo und  in  th e  H . py /ori-seropositive ind iv iduals  o f  Le 
(a+ b -) blood group phenotype com pared w ith  those o f  
tw o o ther phenotypes (Fig. 2). T he subjects w ith the Le 
(a -b + )  and Le (a -b - )  pheno type show ed  very  sim ilar 
patterns.
Discussion
T he  data show that the Le (a+b—)/n on -secre to r pheno­
type is associated with a higher proportion o f  H . pylori- 
uninfected individuals am ong blood donors. Furtherm ore, 
the im m une response o f  the H . pylori-seropositive indiv­
id u a ls  in  th is  g ro u p  is also  lo w e r  th a n  th a t  o f  Le 
(a—b+)/secretors. It has been shown that the level o f  H . 
pylori IgG antibodies is related to  the density o f  antrum  
mucosa colonization by H . pylori [13]. Thus, in contrast to 
some examples o f  an association o f  the non-secretor status 
w ith the susceptibility to a num ber o f  infectious diseases
[14], the non-secretors appear to be m ore resistant to  H . 
pylori infection.
T he  role o f  H . pylori adhesins in gastric mucosa colo­
nization is not fully understood. T he ir in teraction  w ith 
th e  ta rg e t tissue  r e c e p to r s , w h ic h  a re  th e  n o rm a l 
constituents o f  the mucus, epithelial cells and connective 
tissue, and are presen t in every ind iv idual, cou ld  n o t 
explain the higher resistance to H . pylori infection in some 
individuals. Therefore, it is likely that this relative resis­
tance is associated w ith  som e m ore polym orphic tissue 
receptors such as h isto -b lood-group  antigens and the ir 
precursors and /o r derivatives. In this context, a possible 
role o f  Le (b) antigen as a receptor for H . pylori attach­
m ent to gastric mucosa |1) is an intriguing idea.
H ow ever, w e found tha t the Le (a-b—) pheno type 
group had a similar proportion o f  H . py/ori-seronegative 
individuals, as well as low responders, as the Le (a—b+) 
phenotype group (Fig. 1). M oreover, no significant differ­
ence in the seronegativity rate was found betw een Le (b+) 
and Le (b-) donors, whereas the Le (a+) individuals had a 
significantly higher proportion o f  H . pylori-seronegative 
persons than the Le (a-) group. These findings suggest that 
the Le (a) o r some o ther antigens associated w ith no n - 
secretor status, but not the presence or absence o f  the Le 
(b) antigen, may be im portant in the natural resistance to
H . pylori.
T h e  expression o f  o th e r carbohydrate  ep itopes on 
gastric mucins and on epithelial cell glycoconjugates has 
been show n to be dependen t on secre to r/non -secre to r 
status [7,15]. In particular, the difference concerns the 
expression o f T  epitope (G alß l-3  GalN A cO t/ßl) on type 
3 m ucin-type chains in non-secretors, exclusively |15 |. In 
contrast, in secretors this epitope is further fucosylated
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[16]. In addition to  Le (b) antigen (F u c l-2 G alß l-3 (F u c l-  
4 )G lcN aA cßl), expressed on type 1 or 2 chain glycocon- 
jugates, the H - l disaccharide (F ucal-2G aI) was show n to 
be th e  m in im al re c e p to r  fo r H . py lo ri adhesion  [17]. 
F urtherm ore, a w ide inter-individual quantitative varia­
tion in the expression o f  the Le antigens on m ucus and 
epithelial cells may influence the adhesin-receptor interac­
tion.
It should  be n o ted  tha t o ther researchers found no 
association betw een the prevalence o f  H . pylori infection 
and the proportion o f  non-secretors or Lewis blood group 
pheno types in dyspeptic  individuals and  patien ts w ith  
peptic ulcers [4,18,19]. H ow ever, the prevalence o f  H . 
pylori in fec tion  in  these patien ts is very high and  one 
m ight expect alteration in  the resistance mechanisms in 
these groups. In fact, our data also showed no appreciable 
alteration in the Le (a,b) phenotype distribution in the H. 
pylori-seroposidve group o f  donors.
W e have intentionally investigated an older group o f 
b lood donors. W e suppose that, in the evaluation o f  the 
n a tu ra l re s is ta n c e  m e ch an ism s  ag a in s t H . p y lo r i ,  a 
m axim um  o f  the H . pylori in fection  prevalence in  the 
population should be chosen as a starting point. U nder 
these circumstances, the individuals that rem ained unin­
fected should be considered as the most resistant popula­
tion. O u r data show ed the significant prevalence o f  Le 
(a+b-) blood group phenotype in this group (Fig. 1). It is 
obvious that this m axim um  is achieved at different ages in 
d iffe ren t popu la tions. In  the  E ston ian  p o p u la tion  the 
prevalence o f  H . pylori infection is very high and reaches 
its plateau at about 30 years o f  age [8,9], w ith a seropreva­
lence rate similar to  that observed in o ther countries for 
patients w ith chronic gastric diseases. O u r  data confirm  
these findings.
H öök-N ikanne et al. [20] studied a group o f  blood 
do n o rs  at 3 6 -4 5  years o f  age and fo u n d  no  re la tion  
betw een H . pylori seropositivity rate and sec re to r/n o n - 
secretor status. These investigators also used the glycine 
extract o f  the H . pylori strain N C T C  11637, bu t o ther 
criteria for the seropositivity based on the end-poin t titre 
w ere em ployed. In addition, a m uch low er H . pylori sero­
prevalence rate (42%, vs. 83.6% in this study) and a higher 
proportion o f  non-secretors (20% vs. 11.7%) was dem on­
strated in the Finnish blood donors, making it difficult to 
com pare w ith o u r findings. O u r data are, how ever, in 
accordance w ith the findings o f  M entis et al. [4] w ho 
revealed the bacteria by either culture or biopsy in 12.5% 
o f  Le (a+)/non-secretors (1 o f  8) com pared with 67% (28 
o f  42) in Le (b+ )/secre to rs  (P < 0 .0 1 )  in  patients w ith 
gastric ulcer.
In conclusion , individuals w ith  Lewis (a+b—)/n o n -  
secretor phenotype showed a significandy higher propor­
tion  o f  H. py/ori-seronegative results and seem ed to  be 
m ore resistant to  H . pylori infection. T he Lewis (a+ b-) 
phenotype was also associated w ith a low er strength o f 
im m une response to  H . pylori antigens as defined by RAA 
values in ELISA. O u r findings support the idea that Le 
(a,b) h isto -b lo o d -g ro u p  antigens are im plicated in the 
mechanism s o f  the naturally occurring resistance to  H. 
pylori infection and in the pathogenesis o f  H. pylori-associ­
ated diseases.
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Abstract
Individuals o f the Le(b+)/secretor phenotype revealed a stronger natural immune response to Le(x) and Le(y) epitopes 
irrespective of Helicobacter pylori serologic status. In contrast, H. pylori-vcSecteà Le(b—) type individuals showed a 
significantly higher proportion o f strong responders to Le(x) antigen compared with the H. /»^/on-uninfected subgroup. The 
data suggest that the immune response to Lewis type 2 determinants is related to both the H. pylori serologic status and the 
Le{a,b) phenotype o f the host. © 1999 Federation of European Microbiological Societies. Published by Elsevier Science B.V. 
All rights reserved.
Keywords: Helicobacter pylori', Lewis antigen; Blood group antigen; Immune response
1. Introduction
The pathogenicity o f  microbes is closely related to 
their phenotypic diversity by which they can adapt to 
host m icroenvironm ents and evade the host immune 
response [6]. The majority o f  H elicobacter pylori 
strains was show n to express hum an blood group 
type 2 m ono- and difucosylated oligosaccharide 
structures, i.e. Le(x) and Le(y) antigens [2,13,14].
* Corresponding author. Tel.: +372 (2) 514 501; 
Fax: +372 (6) 706 814.
This expression is related to the host Le(a,b) histo- 
blood group phenotype and positively associated 
with CagA status [15,16]. The imm une response to  
these epitopes has been dem onstrated in both H. 
pylori-infected and uninfected individuals [1] and 
H. /ry/ori-infected individuals with a low level o f  
anti-Le(x) antibodies were show n to be at a higher 
risk for gastric m ucosa atrophy developm ent [9] sug­
gesting that an immune response to Le type 2 anti­
gens may be related to the clinical outcom e o f  the 
infection. The aim o f  this study was to explore if  the 
immune response to Le(x) and Le(y) antigens is re­
lated to host Lewis(a,b) histo-blood group pheno-
0928-8244/99/$20.00 © 1999 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved. 
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type and/or H. p y lo ri serologic status o f  the individ­
ual.
2. Materials and methods
2.1. Subjects and sam ples
Blood sam ples were obtained from 87 blood trans­
fusion donors (33 m en, 43 wom en, median age 47.2, 
range 19-65 years) selected by Le(a,b) blood group 
phenotype (Table 1). D onors were not asked about 
the presence o f  abdom inal com plaints. The sera were 
separated after b lood clotting and stored at — 20°C  
until studied.
2.2. L ew is(a .b ) phenotyping
Lewis(a,b) phenotyping o f  erythrocytes was car­
ried out using anti-Le(a) and anti-Le(b) m onoclonal 
antibody gel system  (D iaM ed, Switzerland) accord­
ing to the instructions o f  the manufacturer.
2.3. H. py lo ri antigen preparation
A  glycine cell surface antigen extraction o f  H. p y ­
lori strain N C T C  11637 was performed according to 
Logan and Trust [11]. The strain was grown on 
G A B -C A M P reference agar at 37°C for 2 days in 
plastic jars filled with a gas mixture o f  5% 0 2, 10% 
CO 2 and 85% N 2 . A  pool o f  five different prepara­
tions was used as an antigen in H. pylori ELISA.
2.4. H. py lo ri enzym e-linked immunosorbent assay 
(E L IS A )
Serum sam ples were examined by ELISA as de­
scribed earlier [10]. In brief, 96-well flat-bottom mi- 
crotitre plates (M axiSorp, N unc, Roskilde, D en­
mark) were coated with 0.1 ml o f  antigen (5 ng 
m l-1 ) per well and incubated at 4°C  overnight. A l­
kaline phosphatase-conjugated goat anti-human IgG  
(G ibco BRL, Life Technologies, Gaithersburg, M D, 
U SA ) and /bnitrophenylphosphate (Sigma, St. Louis, 
M O, U SA ) were used. A pool o f  human IgG (Kabi 
A B, Stockholm , Sweden) was placed in each ELISA  
plate as a positive control for 100 units, and H.
ду/оп -seronegative reference serum was run as a neg­
ative control. Relative antibody activity values above 
25 were regarded as positive.
2.5. Determination o f  serum L e (x )  and L e (y )  IgG  
antibodies by  E LISA
Plates (M axiSorp, N unc, Roskilde, Denmark) 
were coated with synthetic Le(x) and Le(y) hapten- 
polyacrylamide conjugates (Synthesom , M unich, 
Germany; 20 mol% o f  carbohydrates) 2 ng m l-1 in 
sodium carbonate buffer 50 m M  N ajC O j/N aH C O î 
and 0.02% N a N 3, pH  9.6 at 4°C, or 1% BSA in PBS 
(control wells) overnight. After washing three times 
with PBS (0.13 M  N aC l, 8 m M  N aH 2 P0 4 /K H 2P 0 4 , 
3 mM  KC1, 2 m M  ED TA , pH  7.2)-0.05% Tween 20 
the plates were blocked with 0.15 ml o f  1% B SA  in 
PBS for 1 h  at room  temperature (RT) and washed 
in PBS-Tween. Serum (100 pi) diluted 1:100 in PBS- 
Tween was added for 2 h at RT. The plates were 
then washed and bound IgG  antibodies were de­
tected with 100 pi o f  alkaline phosphatase-conju- 
gated goat anti-human IgG  (G ibco, BRL, Life Tech­
nologies, Gaithersburg, M D , U SA ) diluted 1:1000 in 
PBS-Tween. Follow ing an incubation o f  90 min at 
R T  and washing, the plates were developed with 
p-nitrophenylphosphate (Sigma, St. Louis, MO, 
U SA ), 1 mg m l-1 in 1 M  diethanolamine buffer, 
pH 9.8 for 30 min and the absorbance values at 
405 nm were registered with Labsystem Multiscan 
M CC/340 (Finland). The optical density values of 
control wells were subtracted from the values o f 
the wells coated with the Le conjugates and net 
O D X  100 unit values m ore than 15 were considered 
a strong response. Each serum was analysed in du­
plicate and determ ination o f  Le(x) and Le(y) anti­
bodies in a given serum was performed in the same 
plate. Tw o reference sera from  weak and strong re­
sponders were run in every plate to correct the inter- 
assay variations.
2.6. S ta tistica l analysis
Fisher’s exact test was used to com pare the pro­
portions. The m eans were com pared with Student’s 
f-test. The difference was considered to be significant 
when P < 0 .0 5 .
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3. Results
Typical serum titration curves for IgG antibody to 
Le(x) and Le(y) antigens are shown in Fig. 1. A  low ­
er background and the best discrimination between 
weak and strong responders were obtained at a se­
rum dilution 1:100 and a cut-off limit equal to 15 
O D U .
A  majority o f  the individuals showed an IgG im ­
mune response to the Le(x,y) epitopes. However, no  
appreciable differences between donors o f  different 
Le(a,b) phenotypes were observed when the data 
were analysed irrespective o f  H. pylori serologic sta­
tus (Table 1). The only difference found was a lower 
proportion o f  high responders to the Le(y) epitope 
among donors o f  the L e(a+b—) and L e(a—b —) phe­
notypes com pared with those o f  the L e(a—b+) type 
but the difference was significant only for individuals 
o f the L e ( a -b —) type subgroup ( /> = 0.02). I f the 
L e(a+b—) and Le(a—b —) groups o f  individuals 
were com bined into an L e(b—) group and compared 
with donors o f  the L e(b+) type, the difference 
reached statistical significance for anti-Le(y) IgG  re­
sponse (P  =  0.03).
In contrast, H. py/on-seronegative and -seroposi­
tive donors showed different patterns o f  response 
(Fig. 2). The difference between H. pylori-infected 
and uninfected donors was observed mostly in indi­
viduals o f  the L e(b—) phenotype who showed a sig­
nificantly higher proportion o f  strong responders to 
the Le(x) determinant am ong H. /ry/ori-infected sub­
jects (P  =  0.04). In addition, a significantly lower pro­
portion o f  strong responders to the Le(x) antigen 
was found am ong H. /гу/оп-seronegative donors o f
Reciprocal serum dilution
Reciprocal serum dilution
Fig. 1. Serum titration curves of Le(x) and Le(y) IgG for strong 
anti-Le(y) (A) and anti-Le(x) (B) responders. Wells were coated 
with Le(x) and Le(y) polyacrylamide conjugates 2 (ig ml“ 1, se­
rum dilution 1:100. The OD405 values of control wells (1% BSA 
in PBS) were subtracted. Dotted line: cut-off limit (15 ODU).
the L e(b—) phenotype compared with uninfected in­
dividuals o f  the Le(b+) type. The Le(b+)/secretors 
revealed a stronger response to Le(x) and Le(y) anti­
gens in both the H. pylori-infected and uninfected 
donors. Som e decrease in the level o f  Le(y) antibod-
Table 1
Proportion of strong responders to Le(x) and Le(y) antigens in blood donors of different Le(a,b) blood gTOup phenotype irrespective of 
the H. pylori serologic status
Characteristic Erythrocyte Lewis(a,b) phenotype
a+b— a—b+ a—b— b -*
Number of donors 23 45 19 42
Age (years, mean ± S.D.) 47.1 + 10.1 46.5 ±9.2 47.4 + 7.2 47.4 ±5.7
Males (%) 9 (39.1) 18 (40.0) 6 (31.6) 15 (35.7)
Number (%) of strong responders to Le(x) 15 (65.2) 35 (77.8) 12 (63.2) 27 (64.3)
Number (%) of strong responders to Le(y) 11 (47.8) 28 (62.2) 6 (31.6)b 17 (40.5Г
‘Le(b—) combined group: Le(a+b—)+Le(a—b—) subjects.
bLe(a—b—) compared with Le(a—b+) group: P =  0.02 (Fisher’s exact test).
cLe(b—) compared with Le(b+) group: /* = 0 03 (Fisher’s exact test).
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ies was observed in sera o f  H. pylori-seropositive 
Le(b+)/secretors: 53% vs 80% o f  strong responders 
for infected and uninfected donors, respectively 
(P  =  0.07).
T he Le(y) to  Le(x) antibody ratio (Le y/x ratio) 
was significantly higher in uninfected Le(b+)-type  
individuals (1.27 ± 0 .6 )  com pared with uninfected 
L e(b—)-type donors (0.68 ± 0 .2 6 ; / =  3.47, 
P <  0 .001) indicating that Le(b+) subjects usually 
have a higher level o f  natural Le(y) than Le(x) anti­
bod ies in their b lood  and vice versa for the L e(b—) 
type group. T hese differences were altered and insig­
nificant in H. py lo ri-infected individuals.
Thus a relation o f  the H. py lo ri serologic status to  
the IgG  im m une response against Le type 2 epitopes 
was observed m ostly for individuals o f  the Le(b—) 
phenotype. In contrast, Le(b+)/secretors revealed a 
high natural im m une response to these antigens irre­
spective o f  H. p y lo ri  serologic status.
4. Discussion
T he data show  that the difference in the response 
to Le type 2 antigens between H. py lo ri-infected and 
uninfected donors was observed m ostly in individu­
als o f  the L e(b—) phenotype who revealed a signifi­
cantly higher proportion o f  strong responders to the 
Le(x) determinant am ong H. py lo ri-infected subjects. 
An appreciable though non-significant increase in 
the response to Le(y) antigen was also observed in 
this group.
It has been shown that gastric m ucosa cells express 
Le(x) and Le(y) epitopes but im m unohistochem ically  
the topography is different, N o  Le(x) expression was 
found in the foveolar epithelial cells o f  either secre­
tors or non-secretors whereas som e am ount o f  Le(y) 
can be detected in this area in secretors. However, 
both determinants were dem onstrated in gastric 
glands irrespective o f  Seise  status [12]. The higher 
imm une response to the Le(x) antigen in H. pylori- 
infected subjects that we observed in this study may 
be related to the findings o f  Byrd et al. [5] w ho re­
ported on aberrant expression o f  Le(x) in the surface 
epithelium o f  H. pylori-infected individuals. It would  
be interesting to know  if  this aberrant expression and 
an immune response to this antigen were associated 
with host Le or secretor phenotype and to investigate 
whether certain variants related to the clinical out­
com e o f  the infection.
A m ano et al. [I] reported on the presence o f  nat­
ural antibodies to Le type 1 and type 2 antigens in 
the serum o f  every individual irrespective o f  H. pylori 
serologic status. They used synthetic conjugates o f
□  Kpylori negative ■  HI pylori positive
Le b- Le Ы- Leb- Le b+
anti-Le (x) antibody anti-Le (y) antibody
Fig- 2. IgG immune response to Le(x) and Le(y) synthetic antigens in relation to host Le(b—) and Le(b+) type and H. pylori serologic 
status. The proportion of strong responders (OD values X 100 more than 15) to Le(x) and Le(y) antigens was determined in II. pylori-sc- 
ronegative (я = 24) and H. /77/oW-seropositive (/2 = 63) blood donors. P values as calculated by Fisher’s exact test.
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Le haptens with hum an serum albumin as antigens 
in E L ISA  but did not correlate the results with the 
host Le phenotype. W e also did not find any differ­
ence in im m une response to Le antigens between H. 
pylori-infected and uninfected individuals when the 
data were analysed in a  similar way. This is because 
Le(b+)-type individuals showed a high proportion o f  
strong responders to Le type 2 antigens irrespective 
o f H. p y lo ri  serologic status (Fig. 2). A  predomi­
nance o f  Le(b+)/secretors in a majority o f  popula­
tions m akes it difficult to  reveal an association be­
tween the im m une response to Le(x,y) antigens and 
H. p y lo ri  status i f  the host Le phenotype was not 
taken into account.
The findings o f  Kuipers et al. [9] that H. pylori- 
infected subjects with a low  level o f  Le(x) antibodies 
had a higher risk o f  gastric atrophy m ay also be 
related to our results though these authors did not 
tested the patients for Le phenotype. W e found a 
rather low  and similar proportion o f  low  responders 
to Le(x) am ong H. />y/on-infected donors o f  both  
Le(b—) and L e(b+) phenotype (27% and 20%, re­
spectively). Thus the host Le type did not appreci­
ably influence the imm une response to this antigen in 
H. p y lo ri-m fec itd  individuals. Since the levels o f  
Le(x) and Le(y) antibodies in serum o f  H. pylori- 
uninfected individuals are inversely related, a preva­
lence o f  Le(y) over Le(x) antibodies is characteristic 
o f Le(b+) individuals. In this context, an overrepre­
sentation o f  L e(b+)-type individuals should be ex­
pected am ong subjects w ith a low  level o f  Le(x) anti­
bodies. On the other hand, uninfected individuals o f  
the L e(b+) type had a high level o f  naturally occur­
ring Le(x) and Le(y) antibodies. It is considered that 
natural antibodies, including those related to blood  
group antigens, m ight protect against autoim m unity  
or dow n-regulate the host T-cell response to m icro­
organisms and the cytokine-induced inflammatory  
cascade [3,4,6]. In contrast, putatively ‘im m une’ 
Le(x) antibodies which appear in response to H. p y ­
lori m ainly in L e(b—)-type subjects m ay be m ore 
pathogenic in terms o f  their ability to  induce inflam­
m ation. W e have shown earlier that individuals o f  
the L e(a+b—) phenotype dem onstrated a lower IgG  
immune response to H. p y lo ri  antigens as com pared  
with those o f  the Le(b+)/secretor phenotype [7]. A  
positive correlation between the density o f  co lonisa­
tion by H. py lo ri  and IgG  im m une response [8] in­
dicates that humoral imm une response m ay be not 
beneficial for the host. W e might speculate that the 
individuals who had a low  level o f  natural antibodies 
to Le type 2 antigens before H. py lo ri infection (i.e. 
Le(b—) subjects) but showed a higher im m une re­
sponse to these determinants after being infected  
with H. pylori, m ight be at a higher risk o f  gastric 
atrophy development.
In conclusion, the data suggest that the host 
Le(a,b) phenotype not only m ay be related to the 
expression o f  Lewis type 2 antigens by H. py lo ri [8] 
but also contributes to the host im m une response to  
these determinants in both H. p y lo ri  -infected and  
uninfected individuals. It remains unclear, however, 
to  w hat extent a natural or H. pylori-induced im ­
m une response to these epitopes m ight be beneficial 
or detrimental for the host and how  it is related to  
the clinical outcom e o f  the infection.
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A bstract IgG immune response to CagA was evaluated 
by enzyme-linked imunosorbent assay (ELISA) using a re­
combinant fragment o f CagA as antigen in 171 patients 
with gastric cancer and 298 blood donors to determine 
whether it could be related to the ABO(H) blood group 
phenotype, stage o f  cancer or tumor morphology. The 
CagA-ELISA showed a good specificity (93.5%) and sen­
sitivity (88.5%) as compared with immunoblotting for blot 
CagA-negative and -positive donors. The H elicobacter 
pylori seropositive blood group A donors revealed the 
lowest proportion (37.6% ) o f  strong responders to CagA: 
A < 0  (51.2% )<B (56.9% )<A B  (62.5%). The proportion 
of strong responders to CagA was significantly lower 
among the H. py lo ri-seropositive patients with non-cardial 
cancer (35.4%) than in donors (48.8%). A significant sup­
pression o f immune response to CagA was found in the 
patients with advanced cancer. The proportion o f CagA 
strong responders was higher at the first stage o f gastric 
cancer in only blood group О and A individuals as com­
pared with related controls. The overall CagA seropreva­
lence was not influenced by tumor histology. Thus, the IgG 
immune response to CagA is dependent on the ABO(H) 
blood group phenotype o f  the host and the stage o f cancer. 
The host-dependent differences in the immune response to 
CagA may be more pronounced than those related to the 
putative disease-specific features o f the H. pylori infection.
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Introduction
The cagA  gene o f H elicobacter pylori is the only noncon­
served gene characterized to date which is present in 
about 60-70%  o f H. pylori strains [2, 7, 9]. The infection 
by H. pylori strains which possess the cagA  gene or ex­
press the genomic product, a high molecular weight im­
munodominant protein (CagA), increases the risk o f  de­
veloping athrophic gastritis, peptic ulceration and gastric 
cancer [5, 16, 28]. The cag  region is related to the pheno­
typic differences between type I pro-inflammatory (cagA + 
vacA + ) and type II (cagA-vacA -) H. pylori strains [7, 33]. 
The cagA-positive phenotype is associated with IL-8 ex­
pression in gastric epithelial cells [2, 11]. The CagA is 
highly immunogenic and the presence o f serum anti-CagA 
antibodies strongly correlates with the cagA-positive status 
o f the individual, and allows infection with cagA-positive 
strains to be detected serologically [ 10]. An enzyme-linked 
immunosorbent assay (ELISA) has been developed re­
cently using recombinant fragments o f CagA protein as 
antigen [5, 32].
Gastric epithelial cells, mucus and the H. py lo ri  itself 
contain blood group antigen-related carbohydrate epi­
topes. An expression o f Lewis antigens by H. py lo ri is 
related to the host Lewis phenotype [31] and positively  
associated with the presence o f the cag pathogenecity 
island [13] and cagA status [30]. An over-representation 
o f blood group A individuals among gastric cancer pa­
tients and the prevalence o f  blood group О subjects 
among patients with peptic ulcers were shown a long  
while ago [1, 8] but the basis for this association remains 
unknown. It has been reported recently that the leuko­
cytes o f  blood group О donors revealed a stronger inflam­
matory response to H. py lo ri and released significantly 
higher amount o f IL-6, TNF and nitric oxide than blood 
group A leukocytes [3]. A ll these findings suggest that 
(i) the host blood group phenotype may be associated with 
the infection by a particular H. pylori strain, and (ii) the 
immune response to H. py lo ri may vary depending on 
blood group phenotype o f the host, thus predicting the
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clinical outcom e o f H. py lo ri infection including gastric 
cancer.
We report here that immune responses to CagA, as de­
termined by ELISA using a recombinant fragment o f CagA 
as antigen, are related to the ABO(H) blood group pheno­
type in both H. py lo ri-seropositive blood donors and can­
cer patients, and that it is tumor stage-dependent and sup­
pressed in the patients with advanced gastric cancer.
Material and methods
Subjects and samples
Serum samples were obtained before any treatment from 171 patients 
with gastric cancer admitted consecutively to the Estonian Cancer 
Center with histologically verified gastric carcinoma (106 men, 65 
women, median age 62 years, range 40-75 years). Tumor staging 
(see Fig. 2) was based on histopathological (pTNM) classification 
and morphology was diagnosed according to the system of Lauren 
[19] as intestinal (л = 97) and diffuse (n = 74) type of tumor growth. 
The cancer site was cardial in 19 patients (11%) and all these tumors 
except one were of intestinal type. The controls were 298 randomly 
selected blood transfusion donors (117 men, 181 women, median age 
57 years, range 40-72 years). Donors were not asked about the pres­
ence of abdominal complaints. The sera were separated after blood 
clotting and stored at -2 0  °C until studied.
Antigen preparation
A glycine cell surface antigen extraction of H. pylori strain NCTC 
11637 (CagA and VacA positive) was performed according to Lo­
gan and Trust [22]. The strain was grown on Gonococcal agar base/ 
Campylobacter (GAB-CAMP) reference agar at 37 °C for 2 days in 
plastic jars filled with a gas mixture of 5% 0 2, 10% C 0 2 and 85% 
N2. A pool of nine different preparations was used as antigen in
H. pylori ELISA and immunoblotting.
A recombinant fragment (37.5 kDa) coding for the immunodom­
inant region of the 128-kDa protein (CagA) was expressed as a fu­
sion protein in Escherichia coli, purified as described [32] and used 
in CagA-ELISA.
ELISA H. pylori
Serum samples were examined by ELISA as described earlier [14, 
20]. In brief, 96-well flat bottom microtiter plates (Maxi Sorp, Nunc, 
Roskilde, Denmark) were coated with 0.1 ml antigen (5 (ig/ml) per 
well and incubated at 4°C overnight. Alkaline phosphatase-conju­
gated goat anti-human IgG (Gibco BRL, Life Technologies, Gai­
thersburg, Md.) and p-nitrophenylphosphate (Sigma, St. Louis, Mo.) 
as substrate were used. A pool of human IgG (Kabi AB, Stockholm, 
Sweden) was placed in each ELISA plate as a positive control for 
100 units and H. py/on-seronegative reference serum was run as a 
negative control. Relative antibody activity (RAA) values were cal­
culated according to Blomberg et al. [6] to eliminate interassay vari­
ations. RAA values £25 were regarded as negative. The specificity 
of the test has been reported to be 98% with a sensitivity of 89.7% 
[21].
SDS-PAGE and immunoblotting
SDS-PAGE was performed using a 12% polyacrylamide separating 
gel according to Laemmli [18]. A 1-mm gel (6x10 cm) was loaded 
with H. pylori glycine extract (|ig protein per gel) and protein mo­
lecular weight standards (Merck, Darmstadt, Germany). After sep­
aration and blotting [14], the nitrocellulose membrane was saturat­
ed as described [29] and, after drying, cut into strips. The strips were 
washed and incubated with patients sera (1 :76), overnight at 4°C 
under agitaton. One strip was incubated With standard IgG in each 
plate as a positive control. The strips were washed and incubated for 
2 h at 4°C with peroxidase labelled rabbit anti-human IgG (Gibco) 
and developed with 3-amino-9-ethylcarbazoI (Sigma). A positive re­
action was defined as the presence of a specific CagA band of 
120 kDa on the blots.
CagA-ELISA
CagA-ELISA was performed as described previously [32] with slight 
modifications. Flat-bottom polystyrene plates (Maxi Sorp, Nunc) 
were coated with 100 |il/well of the purified recombinant antigen so­
lution (1.25 |ig/ml). An alkaline-phosphatase-conjugated goat anti­
human IgG and p-mtrophenyl phospate as substrate were used. The 
cut off limit equal to an absorbance of 0.42 was determined on the 
basis of the investigation of 26 H. p y lori-ELISA and CagA blot-neg­
ative and of 46 CagA blot-positive blood donors sera. This cut off 
value gave the best discrimination between the groups, and absor­
bance values greater than 0 .42  were regarded as a positive reaction 
(strong responders). Two reference serum from CagA-seropositive 
and CagA-negative donors, respectively, were included in each plate 
as internal standards to correct the inter-assay variations. A sensitiv­
ity of 96.2% and a specificity of 96.6% have been reported for this 
assay as compared with Western blot [32].
ABO(H) phenotyping
ABO(H) phenotyping of erythrocytes was carried out with anti-A 
and anti-B monoclonal antibodies (MonoCarb AB, Sweden).
Statistical analysis
Statistical comparisons between groups were performed by chi- 
square tests. The difference was considered to be significant when 
the P  value was less than 0.05. Odds ratios (OR) and their 95% con­
fidence intervals (95% Cl) were calculated to measure an associa­
tion between the parameters studied.
Results
A group o f CagA-positive and -negative blood donors 
(л = 72), determined by immunoblotting, were further 
tested by CagA-ELISA. A good correlation between two 
tests was found. Only 3 o f 46 blot-positive individuals 
showed a negative response in CagA-ELISA and 3 o f 26 
CagA blot-negative donors were positive by CagA-ELISA. 
Thus, the sensitivity and specificity o f CagA-ELISA as 
compared with blot was 93.5% and 88.5%, respectively.
The overall H. py/ori-seropositivity rate as evaluated 
by conventional ELISA was very similar in donors (246  
of 298; 82.5%) and in patients with non-cardial gastric 
cancer (130 o f 152; 85.5%). The blood group phenotype 
distribution in donors and cancer patients for both the car­
dial and non-cardial tumors is shown in Table 1. The dis­
tribution of blood donors by AB O(H) blood group pheno­
type did not differ significantly from that found in the pop­
ulation-based study in Estonia [24]. However, a signifi­
cant increase in the prevalence o f blood group A individ­
uals was observed in patients with non-cardial tumors as 
compared with donors (45.4% vs 35.2%; £  -  3.96,
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Table 1 ABO(H) blood group phenotype distribution among blood 
donors and patients with gastric cancer. Blood group distribution in 
the Estonian population: blood group О 33.8%, A 35.3%, В 23.7% 
and AB 7.2% [24]. The values in parentheses represent % of indi­
viduals with blood group О, A, В or AB in each group



































86 30 85 62 51 29 24
* Significantly different from related donor group: £  -  3.96, P ■ 
0.046, odds ratio 1.5 (95% confidence interval 1.0-2.3)
PcO .05). An over-representation o f blood group A sub­
jects was m ostly related to the patients with diffuse-type 
tumors (32 o f 63, 50.8%; £  = 4.7, P  = 0.03, OR = 1.9, 
95% Cl = 1 .1-3 .4). In contrast, a lower proportion o f blood 
group О individuals in patients with non-cardial cancer 
was noted.
The differences in the H. py lo ri seroprevalence among 
the individuals o f different ABO(H) blood group pheno­
type were non-significant: 82.7%, 78.1%, 83.6% and 
85.7% for donors o f  blood group О, A, B, and AB, re­
spectively, and 78.9%, 89.9%, 80.6% and 100% for the 
related group o f  patients. There was also no significant 
difference between patients and controls. Patients pos­
sessing the blood group A antigen (i.e., A + A B ) showed 
a tendency (P  =  0 .08) for a higher H. py lo ri seropreva­
lence (91.0%) compared with blood group O +B  individ­
uals (79.7%).
In contrast, using CagA-ELISA, 46 o f 130 (35.4%) 
H. py/or/'-seropositive non-cardial cancer patients and 120 
of 246 (48.8%) blood donors were CagA strong respond­
ers, which is significantly lower than for patients with gas­
tric cancer: f  =  5.7, P  =  0.02; OR = 1.7,95%  Cl (1.1-2.8). 
Only 1 o f 22 (4.5%) cancer patients and 6 o f 52 (11.5%) 
blood donors, who were negative in conventional H. p y ­
lori-ELIS A , also showed a positive anti-CagA immune re­
sponse. Only the H. py/on-seropositive patients and con­
trols were further analyzed in relation to the other param­
eters studied.
Appreciable differences in the CagA-seropositivity rate 
were found in blood donors o f different ABO(H) blood 
group phenotype. The blood group A  individuals revealed 
the lowest proportion o f strong responders to the CagA 
compared with other phenotypes, especially with subjects 
of В and AB blood group, where the CagA seroprevalence 
was significantly higher (Fig. 1). The proportion o f CagA- 
seropositive donors increased from blood groups A to AB 
in the order: A < 0 < B < A B . However, no remarkable dif­
ferences between individuals o f different blood groups, 
except a slightly higher percentage o f CagA responders 
among blood group О subjects (43.3%), were noted in can-
Fig. 1 The CagA seroprevalence in H elicobacter py lori-seroposi­
tive non-cardial cancer patients and controls by ABO(H) blood group 
phenotype (open bars blood donors, closed bars gastric cancer pa­
tients). The significant differences as calculated by chi-square test: 
blood group A donors vs blood group В donors, дг = 4.0, P  = 0.045, 
OR = 2.2,95% Cl 1.0-4.7; blood group A donors vs blood group AB 
donors, £  = 3.7, P  = 0.052, OR = 2.8,95%  CI 1.0-7.8; blood group 
В donors vs blood group В cancer patients, = 3.96, P  = 0.046, OR 







Fig. 2 The CagA seroprevalence in H. py lori-seropositive patients 
at different stages of gastric cancer. Significant differences as calcu­
lated by chi-square test: patients: stage I vs stage IV, ^  = 9.0, P  = 
0.003, OR 5.3 (1.7-17.2), stage I+ II vs stage III+IV, £  = 7.3, P  =  
0.007, OR 3.0 (1.3-6.8); donors vs patients at stage IV, ^  = 11.6, 
P  = 0.0006, OR 3.2 (1.6—6.6); donors vs patients at stage III+IV, 
/  = 12.1, P = 0.0005, OR 2.7 (1.5-4.9). H orizontal dotted  line shows 
a proportion of CagA-seropoSitive blood donors
cer patients if the data were analyzed regardless o f the dis­
ease stage. Blood group В patients showed significantly 
lower proportion o f CagA responders than blood group В 
donors.
A  significant decrease in the proportion o f CagA-sero- 
positive cancer patients was found from disease stage I to 
stage IV (Fig. 2). An appreciably higher, though insignif­
icant, CagA seroprevalence was observed in patients at the 
first stage o f cancer as compared with controls: OR =  2.1; 
95% Cl (0.6-8.5). The difference between donors and the 
patients at stage IV or stage III+IV, as well as between 
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Fig. 3 The proportion of the CagA-seropositive gastric cancer pa­
tients by the disease stage and ABO(H) blood group phenotype. Bars 
-  the patients with non-cardial gastric cancer at stage I, II, III and 
IV, respectively. Horizontal line is a proportion of CagA-seroposi- 
tive individuals among blood donors of related blood-group pheno­
type. Blood group О cancer patients at stage I+ II vs. patients at stage 
IV £  = 4.4, p  =  0.03, OR = 6.7, 95% CI (1.1-66.4). Blood group A 
cancer patients at stage I vs. patients at stage IV = 4.1, p  = 0.04, 
OR =  5.8, 95% Cl (1.0-34.9)
A stage-dependent decrease in CagA-seropositivity rate 
with a drastic fall in the response to CagA at stage IV was 
observed only in the individuals o f blood group О and A 
(Fig. 3). In addition, a higher CagA seroprevalence was 
found in these groups for the stage I patients as compared 
with donors o f the related blood group. The patients o f В 
and AB phenotypes showed a low proportion of CagA re­
sponders at any stage o f cancer. N o significant difference 
in the CagA seroprevalence was noted between the patients 
with diffuse or intestinal type o f tumor, although it was 
higher in the last group: 30.2% vs 40.3%; OR = 1.6, 95% 
CI (0 .7 -3 .5 ). A s compared with blood donors, a higher pro­
portion o f  CagA-positive subjects at the first stage o f can­
cer was revealed mainly in the patients with intestinal-type 
tumors (8 o f  12, 66.6%). A similar decline in CagA re­
sponse in patients with advanced cancer was noted for both 
groups. It is notable that patients with the diffuse type o f 
cancer showed the highest proportion o f blood group A in­
dividuals (32 o f  63, 50.8%) and at the same time the low ­
est proportion o f  CagA-seropositive subjects in this group 
(7 o f  32, 21.9%) as compared with blood group A patients 
with the intestinal-type tumors (13 o f 29,44.8% ; OR = 2.9; 
95% Cl 0 .8 -10 .3 ). Thus, the blood group distribution 
among the individuals studied may appreciably influence 
the CagA-seropositivity rate.
A ll 19 cardial tumors except 1 were o f intestinal type. 
A lower H. p y lo ri seroprevalence was noted in the patients 
with cancer o f  the cardia (14 o f 19, 73.7%) as compared 
with non-cardial tumors (130 o f 152, 85.5%; OR = 2.1, 
95% C l 0 .6 -7 .1 ), and only 3 o f 14 (21.4%) H. pylori- 
seropositive patients with cardial tumors were CagA sero­
positive. However, a lower H. pylori and CagA seroprev­
alence in this group may be because o f all the patients with 
cardial tumors were at III and IV stage o f cancer.
Ш
Discussion
The data indicate that CagA-ELISA using a recombinant 
fragment of CagA as antigen shows a good correlation with 
immunoblotting for CagA-positive and -negative sera from 
blood donors. It is well known that immunoblotting is a 
more sensitive method but the ELISA permits a quantita­
tive evaluation o f the reaction, whereas blotting permits 
only a semiquantitative one in which an inappropriate es­
timation can not be excluded. Despite some limitations, the 
CagA-ELISA seems to be a reliable assay for the evalua­
tion o f the immune response to CagA and for detection of 
the CagA status, at least in benign gastric disorders.
A rather low  CagA seroprevalence among the H. py- 
/on'-seropositive blood donors (-50%  ) was observed in 
this study and even lower proportion (-35% ) o f cagA-ser- 
opositive gastric cancer patients was demonstrated. Previ­
ously, we reported [14] a lower proportion o f CagA-sero- 
positive individuals, detected by immunoblotting, among 
H. py lo ri-seropositive cancer patients compared with 
blood donors (55% and 69%, respectively), although the 
percentages were higher for both groups compared with 
CagA-ELISA in this study. However, we have shown that 
the stage o f cancer is a crucial factor for the detection of 
CagA antibodies in CagA-ELISA. In addition, the anti- 
CagA response is related to the ABO(H) blood group 
phenotype o f the host. The H. py/ori-seropositive donors 
o f blood group A showed the lowest proportion o f CagA- 
seropositive individuals. This suggest that that blood group 
A individuals more often seem to be the ‘weak CagA 
responders’.
It is possible that the frequency o f CagA-i- H. pylori 
strains, as defined by CagA-ELISA, may be underesti­
mated in the present study because som e individuals with 
a lower response (absorbance <0.42) were considered as 
CagA negative. Our data, however, are very similar to the 
findings o f Kuipers et al. [16], who found 41% o f CagA- 
seropositive subjects among the patients with chronic 
gastritis, using another recombinant fragment o f  CagA as 
antigen in ELISA. Another possibility to explain a low  
response to CagA in some individuals might be that the 
mixed H. pylori infections with CagA-positive and nega­
tive strains are present in some cases with a prevalence of 
the latter. It has been shown that up to 25% o f the mixed 
H. pylori infections may be observed [12]. If so, cagA  gen- 
otyping o f H. pylori culture obtained from a single biopsy 
may be inappropriate due to a possibility o f  missing a 
CagA-positive strain that may be present in another places 
o f the mucosa. A global assay such as serology would be 
more informative in this case. On the other hand, a lower 
response o f some H. py/ori-seropositive cancer patients to 
the CagA may simply reflect a prevalence o f CagA-nega- 
tive strains. In this context it would be interesting to eval­
uate whether the strength o f the immune response to the 
CagA is more related to the quantity o f CagA produced or 
to the genetic variations in the host response. The differ­
ences w e found in the response to CagA between donors 
o f different ABO(H) blood group phenotype support the
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last possibility. It can not be excluded that blood group A  
subjects possess some kind o f resistance against CagA- 
positive H. py lo ri  strains. Blood group-related carbohy­
drate epitopes o f  both the H. pylori and the host have been 
shown to influence the adhesion properties o f H. pylori 
(H -l, H-2, Le b) [4, 13] as w ell as the host immune re­
sponse to the microorganism [5, 17, 27]. Therefore, it is 
likely that the host blood group phenotype might predict 
the infection with the H. pylori strain o f particular pheno- 
type.
Our data suggest that the overall CagA seroprevalence 
evaluated irrespective o f blood group phenotype does not 
reflect the CagA status in cancer patients adequately, es­
pecially in countries with a lower proportion o f CagA-pos- 
itive strains. It is notable that patients with blood group О 
and A showed a higher proportion o f CagA-positive sub­
jects only at the first stage o f  cancer compared with donors 
with related blood group phenotypes. Therefore, the real 
CagA-seroprevalence may be estimated only at the very 
early stages gastric cancer in which the situation may be 
approximated to be similar to that at the onset o f neopla­
sia. Many secondary phenomena observed in the patients 
with advanced cancer, such as an altered microenviroment 
due to aberrant glycosylation, higher pH, microbial over­
growth, and tumor-induced immunosuppression, may ap­
preciably modulate the host-#, pylori relationship. In ad­
dition, it has been shown that the strength o f an associa­
tion between the CagA status and gastric cancer may vary 
appreciably between different populations [23, 26]. No 
such association could be expected in a population in which 
the proportion o f CagA expressing strains reaches 90% or 
more, as in Japan [23]. We believe that the worldwide vari­
ations in ABO(H) blood group phenotype distribution may 
influence the CagA-seropositivity rate obtained by differ­
ent investigators.
We found no significant difference in the immune re­
sponse to CagA between the patients with diffuse and in­
testinal type o f tumor growth. It is known that diffuse-type 
tumors are more often developed on the background o f a 
relatively normal mucosa in younger males with blood 
group A phenotype [8, 25]. We also found an over-repre­
sentation o f  patients with blood group A in diffuse-type 
cancer patients. In spite o f  the observation that blood group 
A donors are more often CagA seronegative, the blood 
group A cagA-seropositive individuals are over-repre- 
sented among the patients with early gastric cancer 
(Fig. 3). It looks like some kind o f  ‘enrichment’ o f blood 
group A CagA-seropositive individuals occurs among 
these patients. We might speculate that blood group A  
CagA-seropositive individuals are persons who are at a 
higher risk for cancer. It remains unclear, however, to what 
extent these associations relate to the host or to a particu­
lar microbial strain.
We can conclude that the immune response to the CagA  
as detected by CagA-ELISA is associated with ABO(H) 
blood group phenotype. Blood group A donors revealed 
the low est proportion o f strong responders to the CagA. 
Gastric cancer patients o f blood group О and A had a higher 
proportion o f  CagA-seropositive individuals at the first
stage o f disease as compared with the blood group-related 
controls. A suppression o f the immune response to CagA  
at the advanced stages o f cancer was observed. Our find­
ings suggest that several factors, such as blood group phe­
notype or other genetic traits o f the individual, may influ­
ence the host immune response to # .  pylori antigens and 
play a role in determining a disposition for an individual 
to be infected with a particular # .  pylori  strain. Before con­
sidering that inter-strain differences may be important in 
determining the clinical outcome o f the # .  pylori infection, 
it w ill be necessary to further evaluate whether this could 
be explained by inter-individual differences in response to 
# . pylori  rather than among # .  pylori strains.
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E p id e m io lo o g ilis e d  u u rin g u d  on n ä id a n u d , e t Eestis on  suur osa tä is k a s v a n u d  e la n ik k o n n a s t  
n a k a tu n u d  H. pylori in fe k ts io o n i, ku id  senini po le  H. pylori in fe k ts io o n i k liin ilin e  tä h e n d u s  ja  
p a to g en ee s  lõ p lik u lt  se lge . Selles uurimuses on selg ita tud  H. pylori es inem issagedust e rin e v a te  
m aohaiguste k o rra l ja  doonorite l, samuti perem eesorganism ist tu lenevate  im m unoloogiliste tegurite  
m õju v iru len tsem ate  H.pylori tü v e d e g a  nakatum isel.
Helicobacter p y lo ri [H. pylori) infektsioon on 
seotud kroonilise gastriidi, peptilise haavandi ning 
maokasvajate (vähk, MALT-lümfoom) tekkimisega 
(1 -3 ). Umbes 80% Eesti täiskasvanud elanik­
konnast on nakatunud sellesse infektsiooni; see on 
ligikaudu kaks korda rohkem kui Skandinaavias ja 
Lääne-Euroopas (4, 5). Siiani pole leitud selliseid 
H. py lori tüvesid, mis oleksid mao haavandtõve 
või vähi otseseks tekitajaks. Küll aga on kindlaks 
tehtud mitmeid seoseid mõnede H. pylori geenide, 
eriti cagA (tsütotoksiiniga seotud geen A) ja vacA 
(vakuoliseerivat tsütotoksiini kodeeriv geen) 
virulentsustegurite ning peptilise haavandi ja 
gastriidi agressiivsuse vahel (1, 6 -8 ). Uurimuste 
tulemused on siiski vasturääkivad, eriti populat­
sioonides, kus suur osa elanikkonnast on nakatunud 
H. py lo ri infektsiooni ning paljud selle nakkuse 
virulentsemate tüvedega (9-11). Paljudel CagA 
(cagA geeni produkt) positiivsetel isikutel ei ole 
mingeid kaebusi ja ka mao limaskestas puuduvad 
ilmsed pa to loogilised muutused. Sageli on 
patsiendid nakatunud mõlema H. pylori tüvega, 
nii CagA+ kui ka C agA - tüvega (12). Selle 
probleemi prioriteetseks ülesandeks on uute 
kriteeriumide otsing H. yc>//o/7infektsiooni kliiniliste 
tagajärgede ennustamiseks ning selle nakkusega 
seotud haiguste patogeneesi väljaselgitamiseks.
Peremeesorganismi ja mikroobi omavahelistes 
suhetes on tähtis roll süsivesikantigeenidel (13). See 
puudutab kõigepealt väga polümorfset ABO(H)- 
süsteemi ja Lewisi antigeene ning nende derivaate, 
mis on laialdaselt esindatud mao mutsiinidel ja 
limaskesta rakkude glükokonjugaatidel, s.t on 
H. p y lo ri vahetuks elukeskkonnaks. Erinevate 
süsivesikantigeenide ekspressioon on seotud 
H. p y lo r i kolonisatsioonitiheduse ja põletiku 
astmega maos ning süsivesik- ja H. py lo ri anti­
geenidele suunatud immuunreaktsioonidega (5, 
14-16). Peremeesorganismi ABO(H) ja Lewisi (Le) 
fenotüübi (raku või organismi jälgitav tunnus) ning 
sekretoorse staatuse võimalikku seost H. py lori 
teatud genotüübiga uuritud ei ole. Sekretoorne 
staatus (Se/se staatus) on võime eritada või mitte 
eritada sekreetidega (sülg, maomahl jt) vere 
ABO(H) grupiantigeene. CagA staatus on selles 
probleemis mugavaks mudeliks, sest see on üks 
kõige spetsiifilisemaid ja läbiuuritumaid H. pylori 
virulentsustegureid, mida on kerge ka seroloogiliselt 
määrata.
Selles töös uurisime ABO(H) ja Lewisi fenotüübi 
ning peremeesorganismi Se/se staatuse mõju 
H. pylori infektsiooni ja H  pylori CagA-positiivsete 
tüvede esinemissagedusele veredoonorite, maovähi 
ja mao healoomuliste haigustega haigete seas.
nH. pylori *
n %




D oonorid 182 144 79,1 85 59,0 52,3
Maovähk 254 188 74,0 138 73,4** 59,7
1 staadium 44 39 86,4 32 72.7 61,6
II staadium 42 34 80,9 27 79,4 56,7
III staadium 59 43 72,9 34 79,0 59,2
IV staadium 109 72 66,0* 45 62,5*** 60,1
H ealoom ulised haigused 204 166 81,4 138 83,1** 55,4
Maohaavand 45 34 75,5 31 91,2** 56,5
Kakste lstsörm lksoole-haavand 87 75 86,2 61 81,3** 54,0
G astriit Ilm a a troofiata 31 25 80,6 23 74,2 53,0
A tro o fllin e  gas triit 41 32 78,0 23 56,1 57,0
Statistiliselt usaldusväärsed erinevused arvutati hii-ruut(x2)-testiga.
* Võrreldes seropositiivsete isikute protsendiga I + II staadiumis vähihaigete ja 
kaksteistsörmiksoole-haavandiga haigete seas;
** statistiliselt usaldusväärne erinevus võrreldes CagA-seropositiivsete doonoritega;
*** statistiliselt usaldusväärne erinevus võrreldes I. II ja III staadiumis maovähihaigete 
(p = 0,002) ja  peptilise haavandiga patsientidega (p <10“).
Uurimismaterjal ja -meetodid
Tehtud katsete maht ja iseloomustus on esitatud 
tabelites 1 -3  ja joonisel 1. Uurimisobjektiks olid 
perifeerne veri, sülg, operatsiooni- ja gastrobiopsia 
materjal (kasvajakoe ja mao limaskesta proovid). 
Maovähi diagnoos kinnitati kõikidel juhtudel 
histoloogiliselt, peptilise haavandi diagnoos 
gastroskoopiliselt. Kroonilise gastriidi haiged jagati 
kahte rühma: atroofilise gastriidiga ja gastriit ilma 
atroofiata. Patohistoloogilist materjali hinnati 
morfoloogiliselt Sydney süsteemi järgi: uuriti mao 
antrumist ja korpusest võetud 1 -2  limaskesta 
proovi. Atroofilise gastriidina hinnati ükskõik 
millisest mao osast võetud proovis leitud mõõdukat 
või tugevat a troofia t. Kõik uuritavad olid 
40aastased või vanemad.
H. py lo ri ja CagA staatus määrati immuno­
blottingu ja immunoensüümmeetodil, mida on 
varem kirjeldatud (5, 16). Anti-//, py lo ri IgG 
antikehade tase väljendati antikehade suhtelise 
aktiivsusena -  RAA (relative antibody activity] ja 
RAA <25 loeti seronegatiivseks tulemuseks. 
Uuritavad, kelle RAA langes vahemikku 26-35, nn 
grey zone, jäeti uuringust välja. Kontrollseerumi- 
tena kasutati H. py lori\a  CagA-negatiivseid ja 
-positiivseid seerumeid. ABO(H) ja Lewisi fenotüüp 
määrati erütrotsüütide järgi, kasutades mono- 
kloonseid antikehi (5).
Sekretoorset staatust [Se/se] määrati immuno­
ensüümmeetodil (17) H-antigeeni sisalduse järgi 
süljes (stimuleerimata sekretsioon) kasutades 
H-antigeen-spetsiifilist biotinüleeritud lektiini Ulex 
EuropeusKS^A I (Sigma, St Luis, MO) ning tulemust 
hinnati värvusreaktsiooni järgi, mis tekkis avidiiniga 
konjugeeritud peroksüdaasi (Sigma) reageerimisel 
substraadi O-fenüleendiamiiniga. Süljega sekre- 
teeritava H-antigeeni tase (OD-väärtus) eelnevalt 
erütrotsüütide järgi testitud sekreetoritel [Le(a-b+)j
oli kõikidel juhtudel (n = 16) 3 -2 0  korda kõrgem 
kui mittesekreetoritel [Le(a+b-)j. Väiksemaid OD- 
väärtusi kui 0,25 (keskmine OD mittesekreetorite 
rühmas (n = 12) ± 2txSE, p = 0,05 juures) hinnati kui 
H-antigeeni sekretsiooni puudumist (mittesekreetorid). 
Igas katses kasutati sisemise standardina 
kontrollseerumeid (üks sekreetori ja üks mittesekreetori 
seerum). Andmeid töödeldi statistiliselt kasutades %2 
ja Fisheri testi (väikeste gruppide jaoks).
Tulemused
H. p y lo r i  ja CagA seroloogiline staatus
(vt tabel 1 )
H. py lo ri seropositiivsete isikute hulk uurimis­
rühmades oluliselt ei erinenud. Ainult maovähi 
IV staadiumis vähenes H. pylori seropositiivsus 
statistiliselt usaldusväärselt võrreldes vähi vara­
semate staadiumide (l-ll), doonorite (p = 0,02)
H. pylori staatus CagA staatus*
n /% О А В AB О А В AB kõik
n /%
D oonorid n = 182 73 60 28 21 60 44 24 16 144
HP+ (n) 62 44 22 16 42 17 16 10 85
HP+ (%) 84,9 73,3 78,5 79.1 70,0 38,6** 70,8 62,5 59,0
M aovähk n = 254 79 88 53 34 61 46 43 38 188
HP+ (n) 61 63 42 22 45 32 34 27 138
HP+ (%) 77,2 71.5 79,2 64,7 73,7 69,5 79,0 71,0 73,4
Hea­ n = 116 35 36 29 16 27 32 27 12 98
loom ulised  HP+ (n) 31 29 25 13 24 21 22 9 76
haigused HP+ (%) 88,5 80,5 86,2 81,2 88,8 65,6*** 81,4 75,0 77,5
HP+: H. pylori seropositiivsed isikud.
* CagA staatust testiti ainult H. pylori positiivsetel isikutel: doonorid -  144, vähihaiged -138, 
healoomuliste haigustega grupp -  98.
** Usaldusväärselt erinev võrreldes O- ja  B-veregmpi doonoritega ning samuti A-antigeeniga 
(A + AB veregrupp) ning ilma A-antigeenita (O + В veregrupp) isikute vahel.
*** Statistiliselt usaldusväärne võrreldes O-veregruplga patsientidega (p = 0,025) ning A- 
antigeeniga (A + AB) ja A-antigeenita (O + B) isikute vahel (Fisheri test).
ning kaksteistsõrmiksoole-haavandi haigetega 
(p <0,01 ).
H. pylori seropositiivsete doonorite seas oli 
CagA seropositiivsuse tase usaldusväärselt mada­
lam võrreldes nii maovähihaigete (p = 0,008) kui 
ka mao healoomuliste haigustega patsientidega 
(p <0,001 ). Kõige rohkem CagA-positiivseid isikuid 
oli maohaavandihaigete hulgas (45st 31 ; 91,2%). 
Maovähihaigete grupis oli see näitaja ligilähedane 
kroonilise mitteatroofilise gastriidiga haigete omale, 
kuid usaldusväärselt väiksem kui peptilise haavandiga 
haigetel. CagA-seropositiivsete isikute arv vähenes 
kasvaja arengu viimases staadiumis (62,5%) ning 
atroofilise gastriidiga haigete hulgas (56,1 %).
ABO(H) fenotüübi seos H. pyloriya  CagA 
staatusega (vt tabel 2)
Kindlat seost H. p y lo ri infektsiooni esinemis­
sageduse ja ABO(H) fenotüübi vahel ei leitud.
A-veregrupiga doonorite ja healoomuliste 
haigustega patsientide seas oli küll vähem 
H. pylori'qa  nakatunud isikuid, kuid erinevused 
ei olnud statistiliselt usaldusväärsed. Statistiliselt 
usaldusväärsed erinevused leiti CagA staatuse 
suhtes. CagA-positiivsete juhtumite arv oli kõige 
väiksem A -veregrupiga doonorite  seas 
(p = 0,0028) võrreldes O- ja B-veregrupi või A+ 
ja A -  fenotüüb iga doon orite  (%2 = 7,4; 
p = 0 ,0 0 6 ), aga samuti healoom uliste  
haigustega haigete seas (p = 0 ,04). M ao­
vähihaigete rühmas olid need erinevused vähem 
märgatavad.
In im ese L e (a ,b ) fe n o tü ü p  ja  C agA  
seroloogiline staatus
Inimese Le fenotüübi ja CagA seropositiivsuse 
võimaliku seose uurimise tulemused on esitatud 
joonisel 1.
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CagA+ CagA- CagA+ CagA- CagA+ C agA-
Maohaavand 19 2 2 1 21 3
(90,5%) (66,7%) (87,5%)
Kakste lstsõrm lksoole-haavand 23 7 12 3 35 10
(76,7%) (80,0%) (77,8%)
G aatrilt Ilma atrooflata 14 5 1 1 15 6
(73.7%) (50,0%) (71,4%)
A troo fllln a  g astrllt 22 6 2 1 24 7
(78,6%) (66,7%) (77,4%)
Kokku 78 20 17 6 95 26
(79,6%) (73,9%) (78,5%)
Sulgudes CagA-positlivsete juhtude protsent.
Le(a+b-) ja Le(a-b-) fenotüübiga doonorite 
seas oli usaldusväärselt kõrgem CagA sero- 
positiivsus võrreldes Le(a-b+) fenotüübiga 
isikutega (p = 0,039 ja p = 0,019 vastavalt 
Le(a+b-) ja ühendatud Le(b-) grupile). Esimesed 
kaks fenotüüpi omavahel selles suhtes oluliselt ei 
erinenud.
Uuritud 35 maovähihaige hulgas ei olnud ühtegi 
Le(a+) fenotüübiga isikut. Le(a-b+) fenotüübiga 
patsientide rühmas oli 63,3% CagA-seropositiivseid 
isikuid, mis on võrreldav sama fenotüübiga 
doonoritega (62,3%), kuid usaldusväärselt vähem 
kui Le(b-) fenotüübiga doonoritel (%2 = 7,31; 
p  = 0,006).
Sekretoom e staatus (Se/se) (vttabel 3)
Mao healoomuliste haigustega patsientide rühmas 
ei mõjutanud sekretoorne staatus oluliselt H. pylori 
infektsiooni esinemissagedust: erinevused sekreeto- 
rite ja mittesekreetorite gruppides ei olnud statisti­
liselt usaldusväärsed ning moodustasid 3-7%  
erinevates uuringurühmades. CagA-positiivsete 
isikute protsent sekreetorite ja mittesekreetorite 
hulgas oluliselt ei erinenud (vastavalt 79,6% ja 
73,9%). Kaksteistsõrmiksoole-haavandiga haigete 
seas oli aga usaldusväärselt suurem mitte­
sekreetorite protsent (45st 15; 33,3%) võrreldes 
kroonilise gastriidiga haigetega (kõik gastriidi 
vormid, ühendgrupp) (%2 = 6,9; p = 0,0089). 
Teistes gruppides oli see näitaja 9,5-12,5% . 
Kaksteistsõrmiksoole-haavandiga haigete seas oli 
CagA-positiivsete isikute protsent suurem mitte­
sekreetorite seas (15st 12; 80%) võrreldes teiste 
haigete mittesekreetorite gruppidega (50-66,6%), 
kuid erinevused ei olnud statistiliselt usaldus­
väärsed.
Arutelu
Me ei leidnud olulisi erinevusi H. pylori infektsiooni 
esinemissageduses mao erinevate haiguste korral. 
Arvata võib, et tingimustes, kus absoluutne enamus 
populatsioonist on H  pylori infektsiooni nakatunud, 
ei saagi oodata suuri erinevusi. Öeldu puudutab 
ka CagA staatust, kuigi maohaavandihaigete seas 
oli märgatavalt suurem CagA+ fenotüübi esinemis­
sagedus. Analoogne situatsioon on iseloomulik ka 
teistele H. py lo ri’ga nakatunud ja CagA-sero- 
positiivsete isikute suure esinemissagedusega 
regioonidele (9-11).
CagA fenotüpeerimine immunoblottingu 
meetodil näitas CagA-positiivsete isikute usaldus­
väärselt väiksemat esinemissagedust A-vere- 
grupiga veredoonorite seas (p = 0,01 ). Sama 
tulemuse saime ka mao healoomuliste haigustega 
patsientide uurimisrühmas, mis räägib A-vere- 
grupiga inimeste suuremast resistentsusest 
H. p y lo r i CagA-positiivsete tüvede suhtes. 
Analoogsed andmed saadi ka varem immuno- 
ensüümmeetodil, kus antigeenina kasutati CagA 
valgu rekombinantsetfragmenti (16). Sellise seose 
puudumist maovähihaigete grupis võib arvatavasti 
põhjendada A-veregrupiga isikute väikese arvuga 
selles uuringurühmas (23,2%; 138st 32) võrreldes 
doonorite (35%; 144st 44; p = 0,1 ) ja mao
healoomuliste haigustega patsientidega (32,6%; 
98st32; p = 0,07).
Leidsime, et Le(a+) fenotüübiga isikute seas on 
rohkem H. pylori CagA+ fenotüübiga nakatunuid. 
Varem näitasime, et mittesekreetorid nakatuvad 
H. pylori infektsiooni harvemini ning H. pylori'\e 
suunatud IgG immuunvastus on nendel nõrgem (5). 
Neid andmeid interpreteerisime nii, et mitte­
sekreetorid on resistentsemad selle infektsiooni 
suhtes, kuna nendel puudub Le(b) antigeen, mis on 
H. /y/fo/7 Le(b)-spetsiifilise BabA adhesiini ligandiks (18). 
Virulentsemate CagA+ H. pylori tüvede ülekaal 
selles rühmas on kaudseks tõendiks meie ideele, 
kuna oleks loogiline oodata, et resistentsem indiviid 
võib nakatuda ainult palju virulentsema 
mikroobitüvega. Seega "määrab" peremees- 
organism ise, millise mikroobitüvega nakatuda. 
ABH ja Lewisi fenotüüpide leviku populat- 
sioonilised ja geograafilised variatsioonid võivad 
osaliselt seletada erinevusi mitmete H. py lori 
infektsiooniga seotud haiguste levikus.
Segainfektsioonide (CagA-negatiivsete ja 
-positiivsete tüvede esinemine ühel ajal maos) suur 
sagedus (12) võib osutuda tõsiselt segavaks 
teguriks CagA staatuse testimisel, kui kasutatakse 
DNA-1 rajanevaid meetodeid. Seoses sellega 
oletame, et seroloogilise meetodi kasutamine 
peegeldab situatsiooni palju adekvaatsemalt, sest 
lubab määrata domineeriva CagA fenotüübi.
Lewisi fenotüübi seos peremehe immuun- 
reaktsiooni tasemega (5, 14) näitab, et mukoosa 
rakkude glükokonjugaatide ja mutsiinide struktuur 
võib oluliselt mõjutada peremehe ning mikroobi 
vahekorda. Sama kehtib ka mitmete teiste 
mikroobide kohta, kellel on retseptorid vere grupi- 
antigeenide (ABH, Lewis) ning nende derivaatide 
vastu (13). Erinevalt Lewisi fenotüübist ei mõjuta 
sekretoorne staatus oluliselt H. py lo ri CagA- 
positiivsete tüvedega nakatumist. Nähtavasti on 
palju tähtsamaks teguriks Le(a,b) antigeenide 
ekspressioon mao limaskesta rakkude glüko­
konjugaatide pinnal ja mitte ABH ning Lewisi 
antigeenide sekretsioon maomahla. Nii H. pylori 
kui ka CagA suur esinemissagedus (81,4 ja 83,1 %)
erinevate healoomuliste haigustega patsientidel 
lubab oletada, et peale Lewisi fenotüübi ja 
sekretoorse staatuse on ka teistel teguritel tähtis 
roll selle infektsiooni kliinilise tagajärje määramisel.
Üha rohkem andmeid koguneb selle kohta, et 
peremeesorganism määrab mitte ainult anti- 
H. p y lo r i immuunreaktsioonide omadused 
(lokaalsete ja süsteemsete immuunreaktsioonide 
tugevus, rakuliste ja humoraalsete immuun­
reaktsioonide ning ka põletiku poolt ja vastu 
tsütokiinide vahekord), vaid olulisel määral ka 
H. pylori enda omadused, sh virulentsustegurite 
ekspressiooni (5, 8, 14, 15, 16, 19, 20). Kõik see 
kokku määrab gastriidi aktiivsuse, H. p y lo r i 
kolonisatsiooni tiheduse mukoosas, põletiku 
aktiivsuse, mao limaskesta atroofia arenemise kiiruse 
ning selle tagajärjed, sh maovähi tekkimise. See käib 
eriti nn aeglaste infektsioonide (nagu H. py lori 
infektsioon) kohta, kus m ikroobi ja 
peremeesorganismi vahekord kestab aastaid ning 
toob kaasa maksimaalse vastastikuse adaptatsiooni.
Kokkuvõte
Eesti kuulub suure H. pylori infektsiooni nakatumise 
ja H. py lori CagA-positiivsete (virulentsemate) 
tüvede suure levikuga reg ioonide hulka. 
Peremeesorganismi ABO(H) ja Lewis(a,b) fenotüüp 
mõjutavad oluliselt CagA seroloogilist staatust:
1 ) A-veregrupiga doonorite ja mao healoomuliste 
haigustega isikute seas on usaldusväärselt väiksem 
CagA-positiivsete tüvede levik; 2) Le(b-) 
fenotüübiga doonorid nakatuvad sagedamini
H. py lori CagA-positiivsete tüvedega kui teiste 
Lewisi fenotüüpidega isikud. Maovähi hilisemates 
staadiumides haigete seas on vähem H. pylori\a  
CagA-positiivseid isikuid. Need seosed on üldise 
iseloomuga ning sõltuvad vähe haigusest. 
Võrdlevatel epidemioloogilistel uuringutel, mille 
eesmärgiks oli selgitada H. pylori infektsiooni rolli 
mao ja kaksteistsõrmiksoole krooniliste haiguste 
patogeneesis, on vajalik arvestada ABO(H) ning 
Lewisi fenotüüpide jaotumist uuritavas populatsioonis.
Uurimust on toetanud Eesti Teadusfond (grant nr 4217).
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S u m m ary
Helicobacter pylori and CagA serologic status in patients with gastroduodenal pathology: relation  
to ABO (H ), Le w is (a ,b ) phenotype and Se/se status of the host
The seroprevalence o f H. p y lo ri and  the CagA positive 
stra in  in b lo o d  d o n o rs  a nd  in p a tie n ts  w ith  
gastroduodenal pa tho logy was tested in relation to 
ABO(H), Lewis(a,b) phenotype and the secretory [Se/se] 
status o f the host. H igh  H. p y lo r i seroprevalence 
(74 -8 6 % ) was found in a ll studied groups including 
blood donors (79.1% ). Compared with blood donors, 
significantly higher C agA seroprevalence was revealed 
in patients with gastric cancer and peptic ulcer disease. 
A  decrease in the prevalence o f H. p y lo ri and CagA 
was noted in patients with advanced cancer. Donors of 
blood group A and those with peptic ulcer disease 
showed a low er C ag A  seropostivity rate (p<0.05) 
co m pa re d  w ith  the re la te d  g rou p s o f the o the r
phenotypes. Donors o f the Le(b-) phenotype w ere  
significantly more often infected w ith C agA  positive 
strains. The proportion of non-secretors was significantly 
higher among patients with duodenal ulcer. However, 
the secretory status was not related to the C agA  status. 
The data suggest that ABH and the Lewis phenotype of 
the host may significantly influence the susceptibility o f 
the host to  be infected w ith a particu la r genotype of 
H. p y lo ri. This should be taken into consideration in 
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ENHANCED HUMORAL IMMUNE RESPONSE TO TUMOR- 
ASSOCIATED T GLYCOTOPE (GALßl ,3-GalNAc) IN HELICOBACTER 
PVTOW-INFECTED PATIENTS WITH GASTRIC CANCER 
AND NON-TUMOR GASTRIC DISEASES
K. Klaamas1, O. Kurtenkov1- *, V. Brjalitt1, L. Miljukhina1, L. Shljapnikova1, L. Engstrand2
11nstitute of Experimental & Clinical Medicine, Tallinn, 11619, Estonia 
2Swedish Institute for Infectious Disease Control, SE-17182, Stockholm, Sweden
УСИЛЕНИЕ ГУМОРАЛЬНОГО ИММУННОГО ОТВЕТА 
НА ОПУХОЛЕАССОЦИИРОВАННЫЙ Т-ГЛИКОТОП 
(GALßl ,3-GalNAc) У ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННЫМИ 
И НЕОПУХОЛЕВЫМИ ЗАБОЛЕВАНИЯМИ ЖЕЛУДКА, 
ИНФИЦИРОВАННЫХ HELICOBACTER PYLORI
К. Клаамас\ О. Куртенков1- *, В. Брялин1, Л. Милюхина1, Л. Шляпникова1, Л. Энгстранд2
1Институт экспериментальной и клинической медицины, Таллинн, Эстония 
} Шведский институт по контролю инфекционных болезней, Стокгольм, Швеция
Natural carbohydrate-binding antibodies are considered to play a role in host defence against infections and neoplasia. 
We aimed to study whether H.pylori infection influences natural immune response to tumor-related T glycotope. A level 
of T-specific antibodies in serum of H.pylori-infected and uninfected blood donors (n = 191), patients with gastric cancer 
(n = 186) and non-tumor gastric disorders (n = 126) was detected by ELISA using T-disaccharide-polyacrylamide 
conjugate as antigen. H.pylori status was evaluated with ELISA and Lewis (a, b) phenotyping of erythrocytes with 
monoclonal antibodies. The Se/se status was determined by testing of H-antigen in saliva. Expression of T epitope in 
H.pylori was evaluated by immunoblotting. An increased IgG response to T antigen was observed in all H.pylori-in­
fected groups compared to uninfected controls. The differences were significant for patients with gastric cancer and 
gastritis (p < 0.05). The H.pylori-uomfected patients with peptic ulcer revealed the lowest level of IgG T-antibody. An 
increased IgG response in infected individuals was mostly related to the subjects of Le(b-) phenotype. A decrease of 
T antibody level was observed after H.pylori eradication in patients with high level of antibodies before treatment. In 
H.pylori extracts, two protein bands (58 kDa and 68 kDa) were immunostained with T epitope-specific monoclonal 
antibodies. In conclusion, the H.pylori infection is associated with an increased immune response to cancer-associated 
T epitope. This systemic impact appears to be dependent on Lewis phenotype of the host, in part disease type-specific 
and might be explained by T epitope expression in H.pylori. These findings suggest that H.pylori may be indirectly 
involved in gastric carcinogenesis via modulation of natural cancer-related immune mechanisms.
Key Words: Helicobacter pylori, Thomsen -  Friedenreich antigen, host factors, tumor-associated antigens, gastric 
cancer, peptic ulcer.
Естественные антитела к углеводным эпитопам участвуют в защите организма против инфекций и опухолевого роста. 
Мы исследовали, влияет ли инфекция H.pylori на уровень естественных антител к опухолеассоциированному Т-анти- 
гену у людей разного Le wis-фенотипа и .Se/se-статуса. Уровень Т-эпитопспецифичных антител в крови у H.pylori-ин­
фицированных и неинфицированных доноров (191), больных раком (186) и пациентов с неопухолевыми заболевани­
ями (126) желудка определяли с помощью иммуноферментного метода с использованием в качестве антигена Т-ди- 
сахарид-поли акрил амидного конъюгата. Серологический статус H.pylori определяли иммуноферментным методом; 
Lewis(a,b)^eHOTHn — с помощью моноклональных антител; Se/se-статус — по уровню Н-антигена в слюне. Экспрес­
сию Т-эпитопа H.pylori оценивали с помощью метода иммуноблотшнга. Повышенный уровень IgG Т-антител наблю­
дали во всех //.рг//оп‘-инфицированных группах по сравнению с неинфицированными; различия были достоверны для 
больных раком желудка и гастритом. Эго повышение было более выражено у лиц Lewis(b)^eHonma. У больных с 
пептической язвой отмечены самые низкие уровни IgG Т-антител. В экстрактах мембран H.pylori выявлены два белка 
(58 кД и 68 кД), связывающие Т-антигенспецифические моноклональные антитела. Излечение инфекции H.pylori 
приводило к существенному снижению исходно высокого уровня Т-антител. Таким образом, инфекция H.pylori 
ассоциирована с повышением уровня естественных антител к опухолеассоциированному Т-гликотопу. Это системное 
влияние инфекции обнаруживает связь с Le-фенотипом хозяина, что отчасти специфично для определенных заболе­
ваний и, возможно, связано с экспрессией Т-эпитопа на H.pylori. По данным исследования, предполагается участие
Н.pylori в канцерогенезе путем модуляции естественных противоопухолевых механизмов.
Ключевые слова : Helicobacter pylori, антиген Томсена — Фриденрейха, факторы хозяина, опухолеассоцииро­
ванные антигены, рак желудка, пептическая язва.
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Naturell immune response to tumor-related carbohy­
drate epitopes is considered to be one of the natural de­
fence mechanisms against cancer [1-4]. The Thomsen —  
Friedenreich (T) antigen (Galß1,3-GalNAca/ß-0-Ser/ 
Thr) is a blood-group related tumor-associated mole­
cule which is expressed in a majority of carcinomas and 
related to invasion, metastasis and prognosis [5,6]. Natural 
antibodies to T epitope (T antibodies) are present in eve­
ry individual. Their synthesis was considered to be de­
pendent on the antigenic stimuli derived from T antigen- 
positive intestinal flora [5]. A level of T antibodies is fairly 
stable for a given individual but there are appreciable and 
unexplained interindividual variations. A dramatic decrease 
in serum T antibody level has been observed in patients 
with cancer [5-9]. It has been also shown that low level of 
T-spedfic IgM antibodies is associated with an increased 
risk for cancer [5, 7].
We have reported earlier that the individuals suf­
fering from the non-tumor gastric diseases also showed 
very low level of IgM T antibodies [9]. This suggests 
that anti-T  humoral immune response may be altered 
by factors unrelated to cancer but associated with non­
tumor gastric diseases. The H.pylori infection is very 
closely related to gastroduodenal pathology [10,11 ] and 
might be one of the operating factors which alter im­
mune response to T epitope.
The blood-group related carbohydrate antigens such 
as ABH, H -1 , Lewis type 1 and type 2 are expressed in 
H.pylori [12-15]. Their expression was shown to be as­
sociated with host inflammatory response to H.pylori [12- 
16]. We found recently that serum level of natural IgM 
antibody to tumor-related T epitope was dependent on 
H.pylori serologic status [17] and related to the Le phe­
notype of the host [8]. Similar associations were shown 
for anti-Lewis type 2 IgG antibodies [18].
We hypothesized that H.pylori infection may alter 
immune response to tumor-related carbohydrate 
epitopes thus modulating natural resistance against can­
cer and host —  H.pylori relationships. The aim of this 
study was to investigate whether the H.pylori infection 
has any impact on IgM and IgG immune response to 
tumor-associated T glycotope in blood donors, patients 
with gastric cancer and non-tumor gastric diseases. In 
addition, a possible link to Lewis (a, b) phenotype of the 
host, as well as an effect of the H.pylori eradication were 
explored. We report here that the H.pylori infection is 
associated with an increased IgG immune response to 
T epitope.This impact appears to be host-dependent 
and in part disease type-specific. We also present an 
evidence that T epitope is expressed in H.pylori.
Table 1. Characteristics of the subjects and examined parameters
MATERIALS AND METHODS
Subjects and serum samples. Altogether 503 in­
dividuals before any treatment were investigated (Tab­
le 1 ). The patients with histologically verified gastric car­
cinoma were classified according to the histopatho- 
logical TNM classification. All patients with non-tumor 
gastric diseases underwent upper gastrointestinal en­
doscopy. Biopsy specimens were taken from the an­
tral and corpus mucosa and analysed by Sydney sys­
tem. The sera from patients and randomly selected 
blood transfusion donors were separated after blood 
clotting and stored at -20 °C until studied.
Antigen preparation for H.pylori serology. A gly­
cine cell surface antigen extraction of H.pylori strain 
NCTC 11637 was performed according to [19]. The 
strain was grown on Gonococcal agar base/Campylo­
bacter reference agar at 37 °C for 2 days in plastic jars 
filled with a gas mixture of 5% 0 2, 10% C 0 2 and 85% N2. 
A pool of nine different preparations was used as anti­
gen in H.pylori ELISA and immunoblotting.
H.pylori enzyme-linked immunosorbent assay 
(HP-ELISA). Serum samples were examined by EUSA 
as described earlier [20,21]. In brief, 96-well flat bottom 
microtitre plates (Maxi Sorp, Nunc, Roskilde, Denmark) 
were coated with 0.1 ml of antigen (5 ^g/ml) per well 
and incubated at 4 °C overnight. Alkaline phosphatase 
conjugated goat anti-human IgG (Gibco BRL, Life Tech­
nologies, Gaithersburg, MD, USA) and p-nitro-phenyl- 
phosphate (Sigma, St. Louis, MO, USA) as substrate 
were used. A pool of human IgG (Kabi AB, Stockholm, 
Sweden) was placed in each ELISA plate as a positive 
control for 100 units as well as H.pylori seronegative refe­
rence serum was run for negative control. The relative 
antibody activity (RAA) values were calculated accord­
ing to [22]. RAA values < 25 were regarded as negative. 
A specificity of the test has been reported of 97.4% and 
a sensitivity —  89.7% [23]. The subjects with "grey zone" 
RAA values (26-40) were not included in this study.
T-epitope-related proteins in cell surface mem­
brane extract of H.pylori. Immunoblotting was per­
formed as described earlier [24]. The membranes (Im- 
mobilon P, Millipore, Bedford, MA, USA) were treated 
with H.pylori seropositive human serum or with T 
epitope-specific monoclononal antibodies (MAb). Hu­
man MAb TF1, (IgM), was kindly provided by Dr. B. Jans- 
son (Biolnvent Therapeutics AB, Lund, Sweden) and 
murine MAb 3C9 (IgM) from Dr. H. Clausen (Copen­
hagen, Denmark). Unrelated murine monoclonal anti­









Lewis type or 
Se/se status
Blood donors 191 105/86 (1.22) 49.2 (26-65) 145 (75.9) 191 107 191
Patients with gastric carcinoma 186 119/67 (1.78) 59.9 (28-79) 134 (72.0) 186 177 77
Non-tumor gastric diseases: 126 78/48(1.62) 49.8 (31-76) 101 (80.1) 126 122 84***
peptic ulcer disease' 72 47/25 (1.88) 41.3 (27-52) 58 (80.5) 72 72 45
chronic gastritis** 54 31/23 (1.34) 51.7(39-76) 43 (79.6) 54 50 39
Total 503 503 406 352
** Atrophic gastritis —  31 patients, nonatrophic gastritis—  23. The patients with a moderate or severe atrophy in any part of the stomach as evaluated by 
Sydney system were considered as having an atrophic gastritis.
* "  These patients with non-tumor gastric diseases were tested for secretor/nonsecretor status (see Methods). Secretors —  68. nonsecretors — 16.
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a gift from Dr. J. Bara (Villejuif, France)^ The specifiity of 
Mab’s was characterized elsewhere [25-27]. The strips 
were incubated with Mab’s overnight at 4°C in PBS —  
0.5% Tween-20, washed 3 times with PBS —  0.05% 
Tween-20 followed by incubation with alkaline phos­
phatase-labelled rabbit anti-human IgM (1:2000) (Dako 
A/S, Glostrup, Denmark), or rabbit anti-mouse immu- 
noglobulins-alkaline phosphatase (Dako) and developed 
with NBT/BCIP substrate (Sigma, St.Louis, MO, USA).
Lewis (a, b) phenotyping and secretor/nonsecre- 
tor status evaluation. Lewis phenotyping of erythrocytes 
was carried out using anti-Le* and -Leb monoclonal an­
tibody gel system (DiaMed, Switzerland) according to the 
instruction of the manufacturer. In patients with non-tu- 
mor gastric diseases the Se/se status was determined 
by testing of H-antigen in boiled saliva at dilution 1 :1 0  
using H-specific biotin-labelled lectin UEA-1 from Ulex 
europaeus (Sigma) as described by [28]. The method was 
compared with Le erythocyte testing in 25 individuals and 
the results were identical in 96% of cases among the sub­
jects of Le(a+b-) and Le(a-b+) phenotype. All non-secre­
tors showed OD values below 0.25. No overlapping for 
OD values was observed in both groups except 1 donor 
of Le(a-b+) phenotype. He was classified as Le(a-b+)/ 
secretor as detected with MAb but defined as nonsecre- 
tor by UEA-I lectin assay. Apparently he belonged to the 
so-called “weak” secretors [29].
Determination of serum anti-T IgM and IgG anti­
bodies by ELISA. These assays were carried out as 
described earlier [8]. Plates (MaxiSorp, Nunc, Roskilde, 
Denmark) were coated with synthetic T-hapten-potyacry- 
lamide (PAA) conjugate (Synthesom, Munich, Germany; 
10 mol% of carbohydrates) 2 |Ag/ml in carbonate buffer 
50 mM Na2C 03 /NaHC03 and 0.02% NaN3l pH 9.6 or 1% 
BSA in PBS (control wells) at 4 °C overnight. After wash­
ing three times with PBS-Tween (0.13 M NaCI, 8 mM 
NaH2P 0 4/KHzP 04l 3 mM KCI, 0.02% sodium azide, 
pH 7.2, 0.05% Tween 20) the plates were blocked with 
0.15 ml of 1% BSA in PBS for 1 h at room temperature 
(RT) and washed in PBS-Tween. Serum (100 ц1) diluted 
1 : 500 in PBS-Tween was added and incubated over­
night at RT. The plates were then washed and bound IgM 
was detected with 100 (xl of alkaline phosphatase conju­
gated rabbit anti-human IgM (Sigma, St.Louis, MO) di­
luted 1 : 500 in PBS-Tween. Following an incubation for 
90 min at RT and washing, the plates were developed 
with p-nitro-phenyl-phosphate (Sigma), 1 цд/ml in 1 M 
diethanolamine buffer, pH 9.8 for 30 min and absorbance 
values at 405 nm were registered with Labsystem Multi­
scan MCC/340 (Finland). Anti-T IgG antibodies were 
determined by a similar procedure except the plates were 
precoated with T hapten-PAA conjugate at 5 цд/ml, the 
serum diluted 1 : 50 was incubated for 2 h at RT, and 
alkaline phosphatase conjugated goat anti-human IgG 
(Gibco, BRL, Life Technologies, Gaithersburg, MD, USA) 
1 : 1000 was used. An optical density (O.D.) values of 
control wells (PBS-BSA) was subtracted from the values 
of the wells coated with the T conjugate and net O.D. 
values more than 0.4 and 0.3 were considered as strong 
IgM and IgG response, respectively. These cut-off limits
were calculated as described elsewhere [8]. Each serum 
was analysed in duplicate. Two reference serum from 
weak and strong responders were run in every plate as 
internal standards to control the experimental conditions. 
The intraassay variations did not exceed 7%.
H.pylori eradication therapy. Eight patients with 
duodenal ulcer were treated with a standard one week 
triple therapy (amoxycillin 1.0 g, clarithromycin 0.5 g, and 
omeprasol 20 mg twice a day) and seven untreated con­
trol subjects were follow-up’ed for 6-24 month. Serum 
samples taken before and at different intervals (6-
12 months) after therapy were stored at -20 °C and test­
ed in parallel. The decrease of IgG Hpylori antibody level 
(RAA) at 6 month after therapy more than by 50% was 
considered as a sign of successful treatment.
Statistical analysis. Statistical comparisons be­
tween the groups were performed by Fisher’s exact test. 
Odds ratios (ORs) and their 95% confidence intervals 
(95% Cl) were calculated to measure an association 
between the parameters studied. The difference was 
considered to be significant when p < 0.05.
RESULTS
The proportions of H.pyfon'-seropositive and -nega­
tive individuals did not appreciably differ between the 
groups studied (72-80.5%). The changes in IgM and 
IgG T-antibody level in relation to the H.pylori serologic 
status of patients and blood donors are shown in Fig. 1.
IgM antibody: In blood donors, 58.7% and 76.5% 
of individuals were strong IgM responders for H.pylori- 
negative and -positive subjects, respectively: p = 0.02; 
OR —  2.3; 95% Cl —  1.1-4.9). The proportion of strong 
IgM responders was not appreciably influenced by 
Lewis phenotype except the individuals of Le(a-b+)/ 
secretor phenotype who showed a significantly higher 
response for H.pylori-seropositive subjects compared 
to seronegative subgroup (p = 0.004) (Fig. 2A). No sig­
nificant difference was observed between the H.pylori- 
seronegative subgroups of various Lewis phenotype.
As compared with blood donors, a highly significant 
decrease in the proportion of strong IgM responders 
was observed in cancer patients as well as in the pa­
tients with non-tumor gastric diseases irrespective of 
H.pylori serology or disease stage (see Fig. 1 ; Table 2). 
Unlike blood donors, a higher proportion of strong re­
sponders in H.pylori-seropositive group was observed 
among cancer patients of Le(b-) phenotype (p = 0.038) 
compared with the Le(b+) patients (Fig. 2B).
In the group of patients with non-tumor diseases, 
the secretors showed the patterns similar to those in 
cancer patients of Le(a-b+) phenotype, i.e. very low IgM 
response irrespective of H.pylori status. The non-secre­
tors (H.pylori-positive —  10 and -negative— 6) revealed 
no strong responders at all. The patients with stomach 
and duodenal ulcer showed similar proportions.
Thus both the patients with gastric cancer and non­
tumor gastric diseases revealed very low IgM response 
to T epitope compared to blood donors. These differ­
ences were not related to H.pylori status but in part 
influenced by Lewis phenotype of the host.















Fig. 1. The proportion of IgM and IgG strong responders to T epitope in blood donors and patients by H.pylori serology. P values are 
shown for significant differences as calculated by Rsher’s exact test.
* Significantly higher compared with H.pylori-seronegative group of patients with “peptic ulcer” (p = 0.005) and “gastritis” (p = 0.04); 
n —  the number of individuals for H.pylori-seronegative and H.pylori-seropositive groups respectively.
Table 2. The proportion of strong responders to T—epitope in patients with gastric carcinoma by stage of the disease
T antibody isotype H. pylori status Stage of the disease* All stages
I II III IV
IgM — 0(8)** 10.0 (10) 14.3 (21) 30.8 (13) 15.4 (52)
+ 13.6 (22) 21.7(23) 20.5 (39) 14.0 (50) 17.2 (134)
IgG — 42.8 (7) 33.3 (9) 22.2 (18) 33.3 (12) 30.4 (46)
+ 59.1 (22) 56.5 (23) 64.1*** (39) 42.5 (47) 54.2*** (131)
* Based on the international TNM classification.
"  The proportion (%) of strong responders; in brackets -  the number of patients.
*** A significantly higher proportion of strong responders compared with the related H. pylori-seronegative groups.
IgG antibody: The main changes related to the 
H.pylori status were noted for IgG antibody level in the 
patients with gastric cancer and non-tumor gastric 
diseases (see Fig. 1). TheRpyfon-seropositive patients 
with non-tumor gastric disorders (combined group) 
showed a significantly higher proportion of strong IgG 
responders (34%) than related seronegative group (8%, 
p = 0.007). The same was true for the patients with gastric 
cancer: 54.2% and 30.4% for H.pylori-infected and un­
infected patients, respectively; p = 0.004. It is to note 
that the H.pylori-seToposWwe group of cancer patients 
did not differ significantly from the related group of blood 
donors (p = 0.25) whereas the H.pylori seropositive non­
tumor group showed a significantly lower proportion of 
strong responders compared with both blood donors and 
cancer patients (p = 0.0007 and 0.002 respectively). 
Among the H.pylori-seropositive individuals the lowest 
level of IgG T-antibody was found in patients with pep­
tic ulcer disease (25.8% of strong responders). This is 
a significantly lower than in related group of cancer pa­
tients (54.2%, p = 0.002) and blood donors (60.3%; 
p = 0.00009; O R — 4.4; 95%C11.9 — 10.1. The H.pylori 
seropositive patients with chronic gastritis did not reveal 
such difference from donors and cancer patients. In the 
non-tumor group, both the H.pylori-infected secretors 
and nonsecretors showed an insignificantly higher pro­
portion of strong IgG responders than related H.pylori- 
negative subgroups: 37.3% and 30% for H.pylori se­
ropositive secretors and nonsecretors versus 12.5% and 
0% for /-/.pyfo/7-seronegative secretors and nonsecre­
tors, respectively. This difference was mostly related to
H.pylori-infected patients with chronic gastritis: 12 of 25 
secretors (48%) and 2 of 4 (50%) non-secretors were 
strong IgG responders. The seronegative subgroups 
were too small for comparison (peptic ulcer —  7, chro­
nic gastritis —  7).
Unlike IgM response, a significantly higher propor­
tion of strong IgG responders was found in H.pylori- 
seropositive donors of Le(b-) type {see Fig. 2B) com­
pared with the related seronegative group (p = 0.04). 
The H.pylori-infected Le(b+)/secretors showed an in­
crease in IgM T antibody level whereas IgG response 
was increased in Le(b-) group of the infected subjects. 
The patients with cancer showed a similar trend but 
the difference did not reach the statistical significance 
possibly due to a small size of the H.pylori-seronega­
tive and Le(b-) subgroups (see Fig. 2B).
The proportion of strong responders did not differ sig­
nificantly between the patients with atrophic and non-atro- 
phic gastritis or duodenal versus stomach ulcer. Similar­
ly, no significant difference for IgM antibody level was noted 
for the patients at different stages of cancer (see Table 2). 
However, the proportion of IgG strong responders was 
appreciably higher in H.pylori-seropositive cancer patiens 
at all stages of the disease. The difference was signifi­
cant for the patients at stage III and the combined group.
immunodetection of T epitope-related proteins 
of H.pylori by immunoblotting. On blots, both hu­
man (TF1) and murine (3C9) T-specific monoclonal 
antibody but not H type 2 antigen-specific control Mab 
(1-90LE) immunostained two protein bands with mo­
lecular weight -58 kDa and -68  kDa (Fig. 3).
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Fig. 2. The proportions of IgM and IgG strong responders to T epitope in blood donors (A) and patients with gastric cancer (B) in 
relation to H.pylori status and Lewis(a.b) phenotype. P values are shown for significant differences as calculated by Fisher’s exact 
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Fig. 3. T epitope-related protein bands on immunoblots of NCTC 
11637 H.pylori strain
The strips were immunostained with: lane 1 : H.pylori seroposi­
tive serum (IgG antibody profile); lane 2-. human monoclonal an­
tibody TF1 ; lane 3: murine monoclonal antibody 3C9; lane 4: 
murine anti-H type 2 monoclonal antibody 190LE (unrelated IgM 
isotypic control)
Effect o f H.pylori eradication. Only 3 of 8 treated 
patients were strong IgM responders before therapy. 
Two of them were successfully treated and showed an 
appreciable (70% and 500%) decrease of IgM T-anti­
body level (OD values). The only IgG strong responder 
revealed a 170% decrease after successful treatment. 
Three patients with peptic ulcer who were treated un­
successfully and remained strongly H.pylori-seroposi­
tive for 6-12 months after treatment did not reveale ap­
preciable changes in T antibody level and one strong 
IgG responder showed further increase of IgG antibo­
dies. Seven untreated individuals (2— H.pylori serone­
gative and 5 —  seropositive) were tested repeatedly 
(2-4 times) for IgM and IgG T-antibody level in serum 
during 6-24 months. Six of them revealed no appre­
c ia te  changes: the OD values did no vary more than 
by ± 26%. One subject showed a higher IgM response 
with no difference in IgG level. All treated patients were 
the secretors.
The data show that the successful treatment of the 
H.pylori infection may decrease a level of T-antibody 
in some patients. The failed therapy did not alter T an­
tibody level.
DISCUSSION
The changes in T antibody levels were analysed in 
two ways: by comparison (i) between the H.pylori-se­
ronegative and -positive subgroups within each group
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(donors, patients) to look for a relation of the changes 
to the H.pylori infection, and (ii) between the groups for 
both infected and noninfected individuals trying to find 
putative disease type-specific features.
The IgM response was not closely related to H.pylori 
serology. The only difference found was a significantly 
higher IgM response in H.pylori Infected donors of 
Le (a-b+) phenotype compared to uninfected ones. As 
compared with blood donors a highly significant de­
crease in the level of IgM T antibody was found in pa­
tients with gastric cancer and non-tumor gastric di­
seases irrespective of H.pylori status, stage of cancer, 
Le type or secretory status.
In contrast, a common feature for IgG immune re­
sponse was that the H.pylori-seropositive patients 
showed a higher proportion of strong responders com­
pared with the related H.pylori-seronegative subgroups 
(see Fig. 1). This difference was observed in all groups 
of patients and blood donors reaching the statistical sig­
nificance in patients with gastric cancer and gastritis. The 
data suggest that the H.pylori infection stimulates the 
IgG immune response to T-epitope. A more pronounced 
difference between H.pylori-infected and uninfected 
blood donors was observed in those of Le(b-) pheno­
type. Although about 90% of Le(a-b-) type individuals 
are known to be the secretors [29] this subgroup dif­
fered from the secretors of Le{a-b+) type who showed 
no distinction in IgG response to T antigen between 
H.pylori-infected and uninfected blood donors.
Interestingly, some disease type-specific patterns in 
T response may also be seen. The H.pylori-seroposi­
tive patients with gastric cancer and gastritis showed the 
IgG response similar to that of donors. At the same time, 
the H.pyfori-seropositive patients with peptic ulcer di­
sease revealed only slight increase in IgG response: a 
proportion of strong responders was significantly lower 
than in any other H.pylori-seropositive group.
It remains unclear whether a lower level of T -an ti- 
body in Rpyton'-seronegative patients with cancer and 
chronic gastric diseases is due to the disease perse or 
these individuals have been weak responders prior to 
disease development. We did not find any relation of T 
antibody level to the stage of cancer. In fact, IgM and 
IgG T antibody level in uninfected patients was not de­
pendent on the stage of cancer. In contrast, a higher 
proportion of IgG strong responders was mostly found 
in H.pyfon'-infected cancer patients irrespective of the 
stage of cancer. This suggests that the changes ob­
served should not be considered as a secondary tu­
mor-induced event. Since a level of natural antibodies 
is reported to be fairly stable for years [2, 5] we sug­
gest that there is some kind of enrichment of weak T 
responders among the individuals which are predis­
posed to gastric pathology or suffering from chronic 
gastric diseases including cancer. An association of 
T-antibody level with Le(a,b) histo-blood group phe­
notype suggests a possible genetic background.
Our preliminary data about the decrease of immune 
response to T epitope in some patients after H.pylori 
eradication further support the idea that an increase in 
T antibody level is related to H.pylori infection. The ef­
fect seems to be dependent on an initial level of T an­
tibody and was observed in subjects who were obvi­
ously low responders before being infected with H.pylori 
and enhanced their T-specific immune response due 
to the infection.
A similarity in an increase of IgG T-response in dif­
ferent groups of H.pyYon-infected individuals compared 
to uninfected ones suggests an existence of some com­
mon pathway. One of the mechanisms might be an 
expression of T epitope in H.pylori, like it has been 
shown for many carbohydrate epitopes on bacteria. If 
this is the case, an ongoing antigenic stimulation in 
H.pyfo/7-infected subjects may lead to an increased 
antigen-driven antibody response to these structures 
in some individuals. Our findings that cell surface mem­
brane extract of H.pylori contains the protein bands 
which are immunostained with T epitope-specific MAb’s 
but not with unrelated MAb further support this idea. 
We aiso found that proportion of both bands varied 
appreciably in different clinical isolates of H.pylori (un­
published data). Alternatively, H.pylori who lives within 
gastric mucus or on the surface of the mucosal cells 
and displays the glycosidase activity [30] might induce 
an expression of T-epitope, which is normally present 
in a cryptic form in normal gastric glycoconjugates of 
secretors [31, 32], with the similar sequealae. The gly­
cosylation of gastric mucins has been shown to be re- 
versibly altered by H.pylori [33]. An aberrant expres­
sion of Le(x) has been demonstrated in the surface 
gastric epithelium of H.pylori-infected individuals [34]. 
This is in accordance with our findings about the en­
hanced IgG response to Le(x) in infected subjects [18]. 
We suggest that, in addition to locally in situ operating 
mechanisms, the H.pylori infection may be involved in 
gastric pathology via modulation of natural immune re­
sponse to tumor-associated carbohydrate epitopes.
We can conclude that H.pylori infection is associat­
ed with a significantly higher humoral immune response 
to tumor-associated T epitope. This impact was strongly 
pronounced in H.pylori-seropositive patients with any 
stage of cancer and in those with chronic gastritis. Our 
findings is the first evidence that H.pylori infection may 
appreciably modulate humoral immune response to tu­
mor-related T epitope. We also present an evidence that 
T-epitope is expressed in H.pylori. Both humoral and 
cell-mediated immunity to such simple carbohydrate 
epitopes has been shown to correlate with the clinical 
course of cancer and with the efficacy of cancer immu­
notherapy with mucin-type vaccines [3-6]. It remains to 
be elucidated, whether the systemic impact of H.pylori 
infection on immune response to tumor-related T epitope 
may work in concert with or contrary to the other in situ 
operating mechanisms which are known to be involved 
in the pathogenesis of chronic gastric diseases includ­
ing cancer.
ACKNOWLEDGEMENTS
The authors wish to thank Dr. A. Lipping for histo­
logical analysis, T. Djomina and H. Joakimov for tech­
nical assistance. This study was supported by a grant 
#4217 from the Estonian Science Foundation.
44 Экспериментальная онкология 24, 38-44, 2002 (март)
REFERENCES
I. Castronovo V, Colin С, Parent В, Foidart J-M, 
Lambotte R, Mahieu P. Possible role of human natural 
anti-Gal antibodies in the natural antitumor defense sys­
tem. J Natl Cancer Inst 1989; 81: 212-6.
2 Kaveri SV, Lacroix-Desmazes S, Mouthon L, Ka- 
zatchkine MD. Human natural autoantibodies: lessons from 
physiology and prospects for therapy. Immunologist 1998; 
6: 227-33.
3. Maclean GD, Reddish MA, Koganty RR, Longe- 
necker BM. Antibodies against mucin-associated sialyl-Tn 
epitopes correlate with survival of metastatic carcinoma 
patients undergoing active specific immunotherapy with 
synthetic sTn vaccine. J  Immunol 1996; 19: 59-68.
4. Springer GF, Desai PR, Spencer BD, Tegtmeyer H, 
Carlstedt SC, Scanton EF. T/Tn antigen vaccine is effec­
tive and safe in preventing recurrence of advanced breast 
carcinoma. Cancer Detect Prev 1995; 19: 374-80.
5. Springer GF. T and Tn, general carcinoma autoanti­
gens. Science 1984; 224: 1198-206.
6. Springer GF, Desai PR, Tegtmeyer H, Spencer BD, 
Scanlon EF. Pancarcinoma T/Tn antigen detects human car­
cinoma long before biopsy does and its vaccine prevents breast 
carcinoma recurrence. Ann N Y Acad Sei 1993; 690: 355-7.
7. Desai PR, Ujjainwala LH, Carlstedt SC, Sprin­
ger GF. Anti-Thomsen-Friedenreich (T) antibody-based 
ELISA and its application to human breast carcinoma de­
tection. J Immunol Meth 1995; 188: 175-85.
8. Kurtenkov O, Miljukhina L, Smorodin J, Klaa­
mas K, Bovin N, Ellamaa M, Chuzhmarov V. Natural 
IgM and IgG antibodies to Thomsen-Friedenreich (T) 
antigen in serum of patients with gastric cancer and blood 
donors -  relation to Lewis(a,b) histo-blood group pheno­
type. Acta Oncol 1999; 38 (7): 939-43.
9. Smorodin J, Kurtenkov O, Miljukhina L, Ser­
geyev B, Hint E, Bovin N, Upping A, Chuzhmarov V. 
Thomsen-Friedenreich antigen-specific IgM antibodies: dia­
gnostic significance for gastric and breast cancer. Exp Oncol 
1997; 19 (4): 338-42.
10. Kuipers EJ. Review article: exploring the link be­
tween Helicobacter pylori and gastric cancer. Aliment Pharm 
Ther 1999; 13 (Suppl.l): 3-12.
II. Kuipers EJ, Uyterlinde AM, Peria AS, Roosen- 
daal R, Pals G, Nelis GF, Festen HP, Meuwissen SG. 
Long-term sequelae of Helicobacter pylori gastritis. Lancet 
1995; 345: 1525-8.
12. Heneghan MA, Moran AP, Feeley KM, Egan EL, 
Goulding J,-Connolly CE, McCarthy CF. Effect of host 
Lewis and ABH blood group antigen expression on Heli­
cobacter pylori colonisation density and the consequent 
inflammatory response. FEMS Immunol Mèd Microbiol 
1998; 20: 257-66.
13. Heneghan MA, McCarthy CF, Moran AP. Rela­
tionship of blood group determinants on Helicobacter p y ­
lori lipopolysaccharide with host Lewis phenotype and in­
flammatory response. Infect Immun 2000; 68: 937-41.
14. Moran AP. Pathogenic properties of Helicobacter 
pylori. Scand J Gastroenterol 1996; 31 (suppl 215): 22-31.
15. Sherburne R, Taylor DE. Helicobacter pylori ex­
press a complex surface carbohydrate, Lewis X. Infect Im­
mun 1995; 63: 4564-8.
16. Alkout AM, Blackwell CC, Weir DM. Increased 
inflammatory responses of persons of blood group О to 
Helicobacter pylori. J Infect Dis 2000; 181: 1364-9.
17. Kurtenkov O, Klaamas K, Miljukhina L, Engst­
rand L. Increased IgM immune response to tumor-associated 
T antigen in Hpylori infected individuals of Lewis(b+)/secretor 
phenotype. Gut 1999; 45 (Suppl 111): A70, Abstract 09713.
18. Kurtenkov O, Klaamas K, Miljukhina L, Sljapniko- 
va L, Ellamaa M, Bovin N, Wadström T. IgG antibodies to 
Lewis type 2 antigens in serum of H.pylori-miected and nonin­
fected blood donors of different Lewis(a,b) blood-group phe­
notype. FEMS Immunol Med Microbiol 1999; 24: 227-32.
19. Logan SM, Trust TJ. Molecular identification of 
surface protein antigens of Campylobacter jejuni. Infect 
Immun 1983; 42: 675-82.
20. Lelwala-Guruge J, Schalen С, Nilsson I, Ljungh A, 
Tyszkiewicz T, Wikander M, Wadström T. Detection of 
antibodies to Helicobacter pylori cell surface antigens. Scand 
J Infect Dis 1990; 22: 457-65.
21. Klaamas K, Kurtenkov O, Ellamaa M, Wadström T. 
The Helicobacter pylori seroprevalence in blood donors relat­
ed to Lewis(a,b) histo-blood group phenotype. EurJ Gastro­
enterol Hepatol 1997; 9: 367-70.
22. Blomberg J, Nilsson I, Andersson M. Viral anti­
body screening system that uses a standardized single di­
lution immunoglobulin G enzyme immunoassay with mul­
tiple antigens. J Clin Microbiol 1983; 17: 1081-91.
23. Lelwala-Guruge J, Nilsson I, Ljungh A, Wad­
ström T. Cell surface proteins of Helicobacter pylori as an­
tigens in an ELISA and a comparison with three commer- 
tial ELISA. Scand J Infect Dis 1992; 24: 457-65.
24. Klaamas K, Held M, Wadström T, Lipping A, 
Kurtenkov O. IgG immune response to Helicobacter pylori 
antigens in patients with gastric cancer as defined by ELISA 
and immunoblotting. Int J Cancer 1997; 9: 367-70.
25. Dahlenborg K, Hultman I, Carlsson R, Jansson B. 
Human monoclonal antibodies specific for the tumour as­
sociated Thomsen-Friedenreich antigen. Int J Cancer 1997; 
70: 63-71.
26. David L, Nesland JM, Clausen H, Cameiro F, 
Sobrinho-Simoes M. Simple mucin-type carbohydrate 
antigens (Tn, sialosyl-Tn and T) in gastric mucosa, carci­
nomas and métastasés. APMIS 1992; 27: 162-72.
27. Rouge P, Anstee D, Salmon C. First International 
Workshop on monoclonal antibodies against human red blood 
cells and related antigens. Part I: ABH and other glycoconju- 
gates. Blood Transfus Immunohaematol, 1987; 30: 355-720.
28. Rahat A, Stewart J, Blackwell CC, Weir DM. 
Semi-quantitative detrmination of H type 1 and type 2 
antigens on buccal epithelial cells and in saliva of secretors 
and non-secretors. Vox Sang 1990; 59: 101-5.
29. Oriol R, Mollicone R, Coullin P, Dalix A-M, Can- 
delier J-J. Genetic regulation of the expression of ABH 
and Lewis antigens in tissues. APMIS 1992; 27: 28-38.
30. Dwarakanath AD, Tsai HH, Sunderland D, 
Hart CA, Figura N, Crabtree JE, Rhodes JM. The pro­
duction of neuraminidase and fucosidase by Helicobacter 
pylori: their possible relationship to pathogenicity. FEMS 
Immunol Med Microbiol 1995; 12: 213-6.
31. Bara J, Imberty A  Perez S, Imai K, Yachi A  Oriol R. 
A fucose residue can mask the muc-1 epitopes in normal and 
cancerous gastric mucosae. Int J Cancer 1993; 54 607-13.
32. Okada Y, Sotozono M-A, Sakai N, Yonei T, Nakani- 
shi S, Tsuji T. Fucosylated Thomsen-Friedenreich antigen in 
a-anomeric configuration in human gastric surface epithelia: 
an allogeneic carbohydrate antigen possibly controlled by the 
Se gene. J Histochem Cytochem 1994; 42 371-6.
33. Ota H, Nakayama J, Momose M, Hayama M, Aka- 
matsu T, Katsuyama T, Graham DY, Genta RM. Helico­
bacter pylori infection produces reversible glycosylation changes 
to gastric mucins. Virchows Arch 1998; 433: 419-26.
34. Byrd JC, Yan P, Sternberg L, Yunker CK, Schei- 
man JM, Bresalier RS. Aberrant expression of gland-type 
gastric mucin in the surface epithelium of Helicobacter py- 
fori-infected patients. Gastroenterology 1997; 113: 455-64.
36
Klaamas К, Kurtenkov O, Rittenhouse-Olson K, Bijalin V, Miljukhina L, 
Shljapnikova L & Engstrand L. Expression of tumor-associated 
Thomsen-Friedenreich antigen (T Ag) in Helicobacter pylori and modulation 
of T Ag specific immune response in infected individuals.
Immunol Investigations 2002; 31: 191-204.
IMMUNOLOGICAL INVESTIGATIONS 
Vol. 31, Nos. 3 & 4, pp. 191-204, 2002
EXPRESSION OF TUMOR-ASSOCIATED 
THOMSEN-FRIEDENREICH ANTIGEN (T Ag) 
IN HELICOBACTER PYLORI AND MODULATION 
OF T Ag SPECIFIC IMMUNE RESPONSE 
IN INFECTED INDIVIDUALS
Kersti Klaamas,1 Oleg Kurtenkov,1 Kate Rittenhouse-Olson,2 
Vadim Brjalin,1 Ljudmila Miljukhina,1 Ljudmila Shljapnikova,1 
and Lars Engstrand3
institute of Experimental and Clinical Medicine, Hiiu 42, 
Tallinn 11619, Estonia 
departm ents of BCLS and Microbiology,
State University of New York at Buffalo, Buffalo, NY 14214 
3Swedish Institute for Infectious Disease Control, Solna, 
SE-17182 Sweden
ABSTRACT
We tested the hypothesis that the gastric cancer associated bacteria, 
Helicobacter pylori (H . pylori) express the cancer-related Thomsen- 
Friedenreich (T) antigen. We also analysed whether infection with 
H. pylori alters the amount of natural anti-T antibodies in the patients’ 
sera. Cell surface membrane extracts of H. pylori NCTC 11637 strain and 
clinical isolates of H. pylori (n =  13) were analysed by immunoblotting 
and cell-ELISA with five different T antigen-specific monoclonal 
antibodies (MAbs). Two major protein bands of ~68kD a and 58 kDa 
were immunostained on blots of H. pylori extracts with T specific MAbs 
but not immunostained with unrelated MAb. The specificity was shown
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in that immunostaining was blocked with peanut agglutinin (PN A ) and 
rabbit antiserum to T antigen. The binding o f T specific M Ab to the 
58 kD a protein band was also blocked by rabbit antiserum against heat 
shock proteins o f  H. pylori. The relative expression o f T antigen-related 
proteins differed among H. pylori strains, with 68 kD  associated T 
antigen expression higher in patients with more severe pathology. The 
level o f  IgG antibody to T epitope in patients with gastric cancer (n =  66) 
and normal blood donors (n =  62) were compared and the level o f  anti-T  
A b in gastric cancer patients was significantly lower than that in normal 
blood donors. A  significant positive correlation between T specific 
antibody in serum and H. pylori IgG antibody level was found in 
H. pylori-infected normal blood donors (P <  0.001), but this correlation 
was not found in H. pylori-infected cancer patients. In summary, the 
cancer related T epitope is expressed in H. pylori and m odulation o f  T 
antigen-specific immune response in H. /?j>/on-infected individuals 
suggests that H. pylori infection may alter natural immune mechanisms 
against cancer.
INTRODUCTION
The T hom sen-Friedenreich (T) antigen (G a lß l,3 G a lN A c a /ß -0 -  
Ser/Thr) is a tumor-associated antigen expressed in a majority of human 
carcinomas. It has been found to be related to invasion and metastasis 
through interactions with surface lectins. T antigen has also been found to 
relate to prognosis.11,2] N atural anti- T Ag antibodies are present in blood of 
every individual. This Ab level has been shown to be low in serum of patients 
with different malignancies11,31 including gastric cancer*41 and in gastric 
premalignant conditions.[5] It is well established that chronic infection with 
Helicobacter pylori (H . pylori) is strongly associated with peptic ulcer disease, 
chronic gastritis and increased risk for gastric cancer.t6~8] It has been shown 
that both the H. pylori diversity and unique host response to H. pylori may 
contribute to a specific outcome of the infection.^9-153 However, there are 
still no reliable indicators to predict the sequelae of the infection at the 
individual level.
We have found recently that H. pylori infection is associated with an 
increased level o f antibody to tumor-associated T antigen.[16] M oreover,the 
differences between various clinical groups (cancer vs. peptic ulcer disease) 
were dem onstrated suggesting that the T specific immune response may be 
related to clinical outcome of the infection. In this study we present 
immunologic evidence that the cancer-related T-antigen is expressed in 
H. pylori and that the clinical isolates have different amounts of this antigen. 
In addition we found a positive correlation between the level of anti-T 
specific IgG antibody and the level of anti-H. pylori IgG in H. pylori infected 
blood donors.
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MATERIAL AND METHODS 
Subjects and Clinical Samples
Altogether 65 (42 men, 23 women) patients with histologically verified 7 
gastric carcinoma (median age-54.3 y) (47 H. pylori-seropositive) and 62 (29 
men, 33 women) (38 H. pylori-seropositive) random ly selected blood 
transfusion donors (median age-47.8 y) were tested for H. pylori serology 
and T-specific IgG serum antibody. The H. pylori isolates from antral gastric 
mucosa biopsies o f eight patients with benign gastric disorders and five H. 
pylori isolates from patients with gastric cancer (mucosa samples obtained at 
surgery) were further analysed for T antigen expression by im munoblotting 
and cell-ELISA.
All serum samples were stored at -20°С until analyzed.
Antibodies and Antisera
The following T-specific monoclonal antibodies (MAbs) were used 
(Table 1): hum an MAbs 5C7 (IgM) and TF1 (IgM) were a gift from 
B. Jansson (Lund, Sweden); murine M Ab 9H8 (IgM) was from R. Sikut 
(Tartu, Estonia), murine M Ab 3C9 (IgM) from Dr. H. Clausen (Copenha­
gen, Denmark), murine JAA-F11 M Ab (IgG3) from K. Rittenhouse-Olson 
(Buffalo, USA). Anti-H type 2 murine M Ab 190LE (IgM) was a gift from 
Dr. J. Bara (Villejuif, France) and anti-CD43 (leukosialin carrying sialyl-Lea 
MAb 3A1 (IgG l) from R. Sikut (Tartu, Estonia) were used as isotypic 
controls. All M abs except JA A -F11 (purified) were hybridoma supernatants.
Other antibodies: Rabbit antiserum against heat shock protein (hsp60) 
of H. p y l o r i  was kindly provided by I. Nilsson (Lund, Sweden) and rabbit 
antiserum to T hapten-bovine serum albumin conjugate^51 was a gift from 
Dr. K. M atta (Buffalo, USA).
Table 1. Binding Specificity of Monoclonal Antibodies as Reported in the Literature
Designation
Species & 
Isotype Antigen Specificity Authors (Reference)
TF1 Human IgM T Dahlenborg et al., 1997[17]
5C7 Human IgM T Jansson & Borrebaeck, 1992fl8}
9H8 Murine IgM T -|- peptide core Sikut et al., 1996[19]
JAA-F11 Murine IgG3 T Rittenhouse-Diakun et al., 1998[201
3C9 Murine IgM T David et al., 1992[211
19-OLE Murine IgM H type 2 Rouger et al., 19871221
3A1 Murine IgGl CD-43 (leukosialin) Sikut et al., 1999[23]
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H. pylori strain N CTC 11637 was cultured on Gonococcal agar 
base/C am pylobacter (GAB-CAMP) reference agar (Oxoid Ltd, Basingstoke, 
H am pshire, England) supplemented with 10% horse blood, selective 
supplements (Dent) and IsoVitaleX Enrichment (Oxoid) at 37°С for 3 days 
in plastic jars filled with a gas mixture of 5% 0 2, 10% C 0 2 and 85% N 2. 
The clinical H. pylori isolates from antral gastric mucosa were cultured in a 
similar way. A glycine cell surface membrane antigen extraction was 
perform ed according to Logan and Trust.[261
H. pylori ELISA
Serum samples were examined by ELISA as described earlier.[27,28] In 
brief, 96-well flat bottom  microtiter plates (Maxi Sorp, Nunc, Roskilde, 
D enm ark) were coated with 0.1 mL of antigen (5 |ag/mL in carbonate buffer pH 
9.3) per well and incubated at 4°C overnight. Alkaline phosphatase conjugated 
goat anti-hum an IgG  (Gibco BRL, Life Technologies, Gaithersburg, MD, 
USA) and p-nitro-phenyl-phosphate (Sigma, St. Louis, MO) as substrate were 
used. A pool o f hum an IgG (Kabi AB, Stockholm, Sweden) was placed in each 
ELISA plate as a positive control for 100 units and H. pylori seronegative 
reference serum was run for negative control. The relative antibody activity 
(RAA) values were calculated according to Blomberg et al.[29] RAA values <25 
were regarded as negative. The subjects with ‘gray’ zone RAA values (26-40) 
were not included in this study.
Determination of Serum Anti-T IgG Antibodies by ELISA
These assays were carried out as described earlier.[4j Plates (MaxiSorp, 
Nunc, Roskilde, Denmark) were coated with synthetic T-hapten-polyacryl- 
amide (PAA) conjugate (Synthesom, M unich, G erm any; 10m ol%  of 
carbohydrates) 5jag/m L in carbonate buffer 50 mM  N a2C 02/N aH C 03 
and 0.02% N aN 3, pH  9.6 or 1% BSA in PBS (control wells) at 4°C over­
night. After washing three times with PBS-Tween (0.13 M NaCl, 8m M  
N aH 2P 0 4/K H 2P 0 4, 3m M  KC1, 0.02% sodium azide, pH  7.2, 0.05% Tween 
20) the plates were blocked with 0.15m L of 1% BSA in PBS for 1 h at room 
tem perature (RT) and washed in PBS-Tween. Serum (100 x^L diluted 1:50 in 
PBS-Tween was added and incubated for 2h  at RT. The plates were 
then washed and bound IgG  was detected with 100 nL o f alkaline 
phosphatase conjugated goat anti-human IgG (Gibco, BRL, Life Technol­
ogies, Gaithersburg, M D, USA) diluted 1:1000 in PBS-Tween. Following 
an incubation of 90 min at RT and washing, the plates were developed with 
/7-nitro-phenyl-phosphate (Sigma), 1 m g/m L in 1 M diethanolamine buffer,
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pH  9.8 for 30 min and absorbance values at 405 nm were registered with 
Labsystem M ultiscan M CC/340 (Finland). The optical density (O.D.) value 
o f the control well (PBS-BSA) was subtracted from the values of the wells 
coated with the T conjugate. Each serum was analysed in duplicate. The 
intra-assay variations did not exceed 7%.
Sodium-Dodecylsulfate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) and Western Blot Analysis
SDS-PAGE of glycine-extracted cell surface proteins of H. pylori 
NCTC11637 strain or clinical H. pylori isolates was performed in a 5% 
stacking and 12% polyacrylamide separating gel as described elsewhere.t28] 
After separation and blotting, the Immobilon P membrane (Millipore, 
Bedford, MA) was saturated as described by Rucheton et al., 1992[30] and 
incubated with patients sera (1:76) or rabbit antiserum (1:200) diluted in 
washing buffer or with M Ab 1 (ig/mL in PBS-0.5% Tween-20 (0.1% Tween- 
20 for MAbs of IgM isotype), overnight at +  4°C under agitation. The strips 
were washed and incubated for 2 h at RT with alkaline phosphatase-labelled 
rabbit anti-human IgG (1:1000) (Gibco), or anti-hum an IgM (1:2000) (Dako 
A /S, Glostrup, Denmark), or rabbit anti-mouse or sheep anti-rabbit 
immunoglobulins (l:1000)(Dako) and developed with N B T/B C IP substrate 
(Sigma, St.Louis, Mo.). All extracts were tested in parallel under the same 
electrophoretic and blotting conditions, M Ab dilutions etc. For semi- 
quantitative evaluation, the strips were scanned (Sharp image scanner JX- 
330) and the relative proportion of two major T antigen-related bands was 
calculated using ImageM aster TotalLab software (Amersham Pharmacia 
Biotech, Finland).
In blocking experiments, the strips were first treated with rabbit T- 
specific antiserum (1:100 in PBS-0.1% Tween-20),or with rabbit anti-hsp60 
serum (1:200) or PN A  (Sigma) 2m g/m L  in 0.05 M phosphate buffered saline 
pH 7.6-0.05% Tween-20 for 4 h  at RT, washed, incubated with M Ab TF1 or 
JA A -F11 overnight and developed with anti-hum an or anti-mouse Ig alkaline 
phosphatase conjugate and NBT-BCIP as described above.
H. pylori Cell-ELISA
Freshly prepared from 2 days culture H. pylori cells were fixed with
0.5% glutaraldehyde for 20min at RT. After being blocked with 0.15 M 
glycine and 1% bovine serum albumin and washing 3x with PBS, 10 cells per 
tube in 0.1 m L o f PBS were incubated with equal volumes of T antigen- 
specific M Ab dilutions for 2 h at RT. Bacteria were then washed four times in 
PBS-0.05% Tween-20 and incubated with either alkaline phosphatase- 
conjugated rabbit anti-hum an IgM or, for murine M Ab, with biotinylated
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goat anti-mouse immunoglobulins (Dako, Denmark) for 1 h at RT followed 
by streptavidin-alkaline phosphatase conjugate (Dako) for 1 h. A fter
3 additional washes, the bacteria were incubated with p-nitro-phenylphos- 
phate (Sigma,, St.Louis, MO) for 30 min and the A405 of the supernatants was 
determined. Bacteria incubated with PBS instead of MAb were treated in the 
same way and served as the control. The assay was performed in duplicate.
Statistical Methods
The Student’s t-test and Pearson two-tailed correlation were used for 
statistics. P value <0.05 were considered to be significant.
RESULTS
The hum an T antigen-specific MAbs TF1, 5C7, murine MAbs 3C9 and 
JAA-F11 revealed two major protein bands on blots of cell surface 
membrane extract of H. pylori NCTC 11637 strain: a dom inant 58 kDa 
and a more weakly stained 68 kD a protein band (Fig. 1). One M Ab (9H8) as 
well as nonrelated anti-H2 MAb 190LE showed no binding. A different 
pattern o f binding was observed for clinical isolates of H. pylori. All MAbs 
including 9H8 revealed both bands. However, the intensity of immunostain- 
ing as calculated on scans with ImageM aster TotalLab software (see 
M ethods section) varies appreciably among isolates of different origin. The 
relative intensity for 68 kDa band was significantly higher (p< 0 .05) in 
antigenic preparations from H. pylori isolates of patients with either gastric 
cancer (46.7 ± 5 .1 % , n =  4) or duodenal ulcers (40.2 ± 1 8 .2 % , n =  3) 
com pared  to  stra ins derived from  p a tien ts  w ith chronic gastritis 
(25.1% ±  18.3%, n =  5) or NCTC 11637 standard strain (17 .5± 7 .5% , six 
different preparations). These proportions were obtained with TF1 M ab but 
similar data were also observed for 5C7 M Ab (not shown). Six preparations 
from different cultures of the NCTC 11637 H. pylori strain showed invariably 
low im munoreactivity for the 68 kDa glycoprotein. Two additional minor 
bands (~ 5 5  and 62 kDa) which bound TF1, 5C7 and 9H8 MAbs were 
revealed in one extract (chronic gastritis). Anti-H  type 2 murine IgM MAb 
(190LE) did not react with any bands in this area.
In blocking experiments, the PNA and T-specific rabbit antiserum 
almost completely abolished the binding of TF1 and JAA-F11 M Ab (Fig. 2, 
lanes 3 and 7). Similar blocking effect of PNA and anti-T serum was observed 
for M Ab 5C7 and JAA-F11. Anti-hsp60 serum revealed a dom inant ~58 
kD a band (lane 4) and blocked the binding of T-specific TF1 M Ab to 58 kD a 
band but not to 68 kD a band (lane 5). Both T-related bands did not bind the 
anti-H-type-2 mouse IgM MAb (lane 6).
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Figure 1. Western blot analysis of T antigen-specific monoclonal antibodies on cell surface 
membrane extract from H. pylori NCTC 11637 strain. Lane 1, H. pylori seropositive human 
serum (RAA -  94); Lane 2, human MAb 5C7; Lane 3, human MAb TF1; Lane 4, murine 
MAb 3C9; Lane 5, murine MAb 9H8; Lane 6, murine MAb JAA-F11; Lane 7, murine MAb 
180LE (anti-H type 2). Molecular mass markers (kDa) are at left.
In Cell-ELISA, binding of TF1 and 5C7 MAb to H. pylori cells was 
noted as was binding o f JA A -F11 and 9H8 MAb (Fig. 3). All T-specific M abs 
reacted in a dose-dependent manner. T-epitope unrelated anti-leukosialin 
M Ab (3A1) showed very weak nonspecific binding irrespective of the dilution.
The T specific IgG antibody in serum did not differ significantly for 
H. /ту/on-seropositive and negative donors as measured by O.D. values 
(0.642 ±  0.096, n =  38 and 0.54 ±  0.053, n =  24, respectively; t =  0.94, p >  0.5). 
W hen com pared to blood donors, significantly lower Ab was found in 
patients with gastric cancer for both the H. /?;;/ön-seropositive as measured 
by O.D. values (0.359 ±0.030, n —42, t =  3.0, p <  0.002) and H. pylori- 
negative (0.227±0.038; n = 1 8 , t =  4.6, p <0.001) subgroup. The H. pylori- 
seropositive patients with gastric cancer showed a significantly higher anti-T 
Ag response than seronegative cancer patients (t =  2.72, p< 0 .02).
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Figure 2. Immunoblot analysis using clinical isolate of H. pylori (chronic gastritis) as antigen: 
immunostaining with T antigen-specific Mabs, and blocking experiments. Lane 1, H. pylori 
seropositive human serum (RAA 112); Lane 2, human MAb TF1; Lane 3, human MAb TF1, 
blocked with PNA; Lane 4, rabbit antiserum to hsp of H. pylori', Lane 5, human MAb TF1, 
blocked with rabbit antiserum to HSP of H. pylori, Lane 6, murine MAb JAA-F11; Lane 7, 
murine MAb JAA-F11, blocked with rabbit antiserum to T antigen. Molecular mass markers 
(kDa) are at left.
In blood donors, a level of IgG T-specific antibodies (O.D. values) 
positively correlated with anti-Я. pylori IgG antibody level (RAA values) 
(Table 2). In contrast, no correlation between T-specific antibody and H. 
pylori RAA values was observed in the patients with gastric cancer 
irrespective of H. pylori status.
DISCUSSION
The data show that several T antigen-specific hum an and murine 
m onoclonal antibodies of the IgM and IgG isotype reacted with two
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Reciprocal MAb dilution
Figure 3. Binding of T antigen-specific monoclonal antibodies to H. pylori NCTC 11637 
strain cells as assessed by cell-ELISA with 108 bacteria. OD (405 nm), optical density at 
405 nm.
dom inant proteins that are present in cell surface membrane extract o f H. 
pylori. Both immunoblotting and cell-ELISA showed comparable results. 
The specificity was shown by the fact tha t the binding of T antigen-specific 
antibodies was blocked with polyclonal antiserum to T disaccharide-BSA
Table 2. Correlation Between a Level of Serum IgG Antibodies to T Antigen and Anti-Я. 
pylori Antibodies in H. pylori-lnfected and Uninfected Blood Donors and Patients with 
Gastric Cancer
H. pylori Seropositive H. pylori Seronegative
Groups and Compared Parameters n r  P n r P
Donors 38 0.57 <0.001 24 -  0.046 0.80
anti-T IgG vs. anti-H. pylori 
IgG (RAA)
Cancer Patients: 47 —0.13 0.36 18 0.089 0.74
anti-T IgG vs. anti H. pylori 
IgG (RAA)
conjugate and by PNA. One of the H. pylori proteins that contains the T 
epitope is the H. pylori heat shock protein (58 kD a band) as shown by the 
blocking o f the anti-T antigen reaction with antibody to hsp60 of H. pylori. It 
is well established fact that T antigen-specific antibodies of IgG and IgM 
isotype are normally present in the blood of healthy individuals. Their 
synthesis is considered to be induced by T antigen positive resident intestinal 
flora[31,32] like many other natural anti-carbohydrate antibodies.[33]
It is known that some H. pylori antigens in the area of 43-70 kD a are 
responsible for cross-reactivity with other bacterial species.[34,35] It appears 
that, in addition to antigens that are considered to be shared by other 
bacteria (flagellar, HSP etc.), the T antigen may be one of the cross-reacting 
epitopes located in this molecular mass area. The results of the present study 
suggest that H. pylori may provide additional antigenic stimuli for the 
activation of T antigen-specific antibody synthesis.
T epitope is not normally expressed in normal human cells. The only 
exception known so far is an expression of T epitope in surface gastric 
epithelium cells of non-secretors.[36,37] We have reported earlier that natural 
T specific immune response of blood donors and patients with gastric cancer 
was appreciably influenced by Lewis(a,b) phenotype of the host.1-41 We have 
also found recently that blood donors of Le(b—) phenotype revealed a 
significantly higher IgG  response to T antigen in H. pylori-infected blood 
donors compared to uninfected subjects whereas Le(b+) secretors did not 
show such difference J 161
The differences in the binding of 9H8 M Ab between N CTC 11637 H. 
pylori strain and clinical isolates of H. pylori, as well as the variations in 
immunostaining of 58 and 68 kD a proteins with other MAbs, suggest that T 
epitope expression varies appreciably between the strains. This might be 
explained by polymorphism in glycosylation patterns of gastric glycoconju­
gates that are closely related to ABH and Lewis phenotype of the host. 
Interestingly, a standard NCTC 11637 H. pylori strain differed in that 
practically no expression was observed for 68 kD a protein band of H. pylori. 
It has been shown that glycosylation of gastric mucins may be altered by 
H. p y lo r iP s,39] Barresi et al.,[40] found a higher expression of T antigen in
H. pylori-positive mucosa samples: 16% vs. 5% in uninfected patients. The 
glycosidase activity o f H. p y l o r i  may be involved. Possible association 
between the T antigen-related proteins of H. pylori and particular gastric 
disease requires further validation. There is more pronounced expression of 
68 kD a protein in H. pylori strains derived from patients with gastric cancer 
and peptic ulcer disease than in individuals with the more mild gastritis, thus 
T Ag expression on this molecule may be related to more severe pathology.
A difference in a level of T specific antibodies between the infected and 
uninfected subjects was dem onstrated for the patients with gastric cancer. 
However, a positive correlation between anti-T IgG levels (O.D.) and an ti-# . 
pylori specific IgG  antibody was found only in H. pylori-seropositive blood
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donors group. N o correlation was observed in patients with cancer possibly 
due to a significant decrease of T specific antibody levels in a majority of 
p a t i e n t s . N o  difference was observed in anti-H. pylori IgG (RAA) values 
between donors and cancer patients.
It has been shown that higher density of antral gastric mucosa 
colonization with H. pylori was associated with a higher IgG immune 
response to the organismf42,43] and a stronger local inflammatory response to 
H. pylori.ll3,l4] We suggest that the correlation we found between the IgG 
immune response to H. pylori (RAA) and the level of T specific IgG antibody 
may reflect a density of H. pylori colonization or a degree of T epitope 
expression in a given H. pylori strain.
O ur findings are the first evidence that cancer-related autoimmunogenic 
T epitope is expressed in surface membrane glycoconjugates of H. pylori and 
associated with an alteration of natural immune response to T antigen in 
infected subjects. Different H. pylori strains seem to express the T epitope to a 
different degree with some relation to a particular gastric pathology. The 
data suggest that, depending on the ability of the host to elicit an acquired 
immune response to the H. pylori-derived T epitope, the H. pylori infection 
may alter natural immune mechanisms against cancer thus modulating the 
risk associated with this infection.
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ABSTRACT
The survival of patients with histologically verified gastric carcinoma at stage I 
(n = 44) and stage П (n = 43) was analysed by the Kaplan-Meier method depending 
on H.pylori serological status and a level of IgG and IgM antibody to tumor- 
associated Thomson-Friedenreich antigen (T Ag). In cancer patients at stage I, 
significantly better survival for H. pylori seropositive patients was observed compared 
to H.pylori seronegative patients (median±SE survival time: 60.0±3.8 mths and 
37.0 ±7.8 mths, respectively; P < 0.0004, log-rank test). Patients with higher level of 
T Ag-specific IgG antibody (strong responders) showed significantly and dramatically 
better (P < 0.00001) survival rate than weak responders. However, an association of 
better survival with a higher level of anti-T antibody level was limited to the H. pylori 
seropositive patients exclusively (P < 0.00001) with no difference for H.pylori 
seronegative group of patients. The level of IgM anti-T Ag antibody was not 
significantly related to the survival of patients at both stages of the disease, though 
better survival was noted in H.pylori seropositive IgM strong responders at -40-60  
months of observation. Statistically insignificant associations between survival and 
H. pylori status or anti-T antibody levels were also observed in a group of gastric
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cancer patients at stage П. In summary, the survival of patients with early gastric 
cancer (stage I) is significantly better in H.pylori seropositive patients, and this 
phenomenon may be in part explained by up-regulation of T Ag-specific IgG immune 
response in H. pylori infected individuals.
Key Words: Helicobacter pylori', Thomsen-Friedenreich antigen; T antigen-specific 
immune response; Gastric cancer; Survival.
INTRODUCTION
Helicobacter pylori (H.pylori) infection is closely related to the pathogenesis of 
various gastroduodenal diseases including gastric cancer. Several factors have been 
considered to influence the specific clinical outcome of the infection including H. pylori 
diversity, unique host response, evironmental exposures or the combination of several 
factors in genetically susceptible host (Blaser and Berg, 2001; Ernst et al., 2001; Solnic 
and Schauer, 2001). H.pylori elicits a strong systemic and mucosal immune response 
both humoral and cell-mediated. The proinflammatory cytokine cascade induced by 
H.pylori is an important factor leading to mucosal damage, atrophy and genetic 
instability of the gastric epitthelial cells (Bamford et al., 1998; Nardone et al., 1999; 
Ren et al., 2000). However, few strong associations have been demonstrated regarding 
the disease type-specific changes in immune response to H. pylori (Bontkes et al., 1992, 
Pineros et al., 2001). One of the reasons is that immune response to H.pylori is highly 
polymorphic in terms of its strength, profile and degree of inflammation which are all 
dependent on host polymorphism.
Evidence is accumulating that an ongoing immune stimulation by H.pylori 
antigens may lead to the autoimmune reactions of various specificities (Faller et al., 
2000; Negrini et al., 1996; Vorobjova et al., 2000). Blood group related antigens such 
as Lewis type 1 and type 2, have been shown to be targets (Appelmelk et al., 1996; 
Kurtenkov et al., 1999b). We have reported previously that, in different groups of 
patients with gastroduodenal pathology including gastric cancer, H. pylori infection was 
associated with an enhanced humoral immune response to tumor-associated blood 
group related Thomsen-Friedenreich antigen (T Ag) (Galßl,3GalNAca/ß-0-Ser/Thr 
(Klaamas et al., 2002a). This impact was influenced by Lewis phenotype of the host 
and in part disease-type specific. Recently we have presented an immunological 
evidence that H. pylori itself expresses T Ag with an appreciable variation in expression 
of T Ag-related glycoproteins in H. pylori isolates derived from patients with different 
gastroduodenal diseases (Klaamas et al., 2002b).
The expression of T antigen in cancer cells is related to biological behaviour of 
tumor and the prognosis of cancer patients (Baldus and Hanish, 2000; Springer, 1984; 
Takanami, 1999). T antigen may be related to metastasis through interaction of this 
saccharide on the tumor cell with receptors on metastatic sites (Glinsky et al., 2001). 
An increase of antibodies against T and Tn epitopes after active immunotherapy of 
cancer with mucin-type vaccines containing these epitopes was associated with a more 
favourable prognosis of patients with cancer (Livingston and Ragupathi, 1997; 
Livingston et al., 1997; Maclean et al., 1992). In addition, low level of T-specific 
antibodies is associated with an increased risk for cancer (Springer, 1984).
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To evaluate the possible clinical relevance of H. pylori infection-induced 
modulation of humoral immune response to T antigen, we analyzed the survival time 
of patients with early gastric cancer depending on their H. pylori serologic status and 
the level of T Ag-specific antibodies in their blood before surgery. We found that the 
H.pylori seropositive patients at stage I had significantly better survival compared to 
H.pylori seronegative patients and this effect was related to a higher level of T Ag- 
specific IgG antibodies in H.pylori infected patients.
MATERIAL AND METHODS
Patients with histologically verified gastric carcinoma at stage I (n = 44, median 
age 62yrs, male/female ratio-1.58) and stage П (n = 43, median age 64yrs, male/ 
female ratio-1.39) were included in the study. Tumor stage was evaluated according to 
the international classification of malignant tumors (Sobin and Wittekind, 1997). The 
patients were tested for H.pylori serologic status and the level of anti-T Ag-specific 
IgG and IgM antibody. Venous blood was taken before surgery and serum was stored 
at -20 °C untill tested.
H.pylori Serology
H.pylori serologic status was determined by ELISA as described elsewhere 
(Klaamas et al., 1997). The relative antibody activity (RAA) value less than or equal to 
25 was considered as seronegativity.
Determination of T Ag Specific Antibodies
The level of T Ag specific IgG and IgM antibodies in serum was tested by ELISA 
using synthetic T disaccharide-polyacrylamide conjugate (Synthesom, Germany) as 
antigen (Kurtenkov et al., 1999a). Serum dilution was 1:50 and 1:500 for IgG and IgM 
antibody determination, respectively. Depending on the optical density (O.D.) values 
for IgG and IgM antibodies, the patients were divided into ‘strong’ and ‘weak’ 
responders. The O.D. value more than 0.26 and 0.3 for IgM and IgG antibody level 
respectively, were considered as strong response. Patients with O.D. values less than or 
equal to these cut-off limits were considered as weak responders. These cut-off limits 
were calculated on the basis of the O.D. values distribution for the whole group of 
cancer patients tested, and allowed the best discrimination between the patients with 
low and high O.D. values.
Statistics
The cumulative survival of cancer patients was estimated by the Kaplan-Meier 
method, and the resulting curves were compared by use of the log-rank test (SPSS 
software, version 10.0.5). Mean and median survival time with the standard error and 
95% confidence interval was calculated for every group of patients divided by H.pylori 




Figure 1. Cumulative survival plots (Kaplan-Meier) of H. pylori seropositive and Я. pylori 
seronegative gastric cancer patients. The survival rate of gastric cancer patients in relation to 
H. pylori serologic status. A -  stage I (n = 44), В -  stage П (n = 43). Dark line-Я. pylori 
seropositive patients; Dotted line-Я. pylori seronegative patients.
difference in survival between the groups was considered significant if P < 0.05. The 
proportions of strong responders were compared by the Fisher’s exact test.
RESULTS
The cumulative survival of patients in relation to H. pylori serologic status and/or a 
level of T Ag-specific IgG and IgM antibodies (O.D. values) is presented in 
Figures 1-4. A significantly better survival was observed in H.pylori seropositive 
patients at stage I of the disease compared to H.pylori seronegative ones (Figure 1A). 
The survival time (median±SE) was 60.0±3.8 and 37.0±7.8 months for H.pylori 
positive and H. pylori negative patients, respectively (P = 0.0004). A similar trend was 
noted for the patients at stage П (Figure IB): 56±2.7 and 46±11.3, P = 0.06).
Table 1. The proportions of gastric cancer patients with higher level of IgG and IgM antibody to 
T antigen (strong responders) in Я. pylori seropositive and Я  pylori seronegative patients.
Anti-T IgM antibody Anti-T IgG antibody
Stage Я  pylori ( + ) Я  pylori ( -  ) Я  pylori ( + ) Я  pylori ( -  )
Stage I 13/30a (43.3%) 7/14 (50.0%) 18/26 (69.2 %)b 3/11 (27.3%)
Stage II 15/28 (53.6%) 4/13 (30.8%) 12/22 (54.5%) 3/11 (27.3%)
Я  pylori ( + ) and Я  pylori ( —) : Я  pylori seropositive and Я  pylori seronegative patients, 
respectively.
*The number of patients with high level of antibody/the number of tested subjects. In brackets -  the 
percentage of strong responders.
bSignificantly higher proportion of strong IgG responders compared to Я  pylori seronegative 
patients of stage I (P = 0.023, Fisher’s exact test).
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Figure 2. Cumulative survival plots (Kaplan-Meier) of gastric cancer patients in relation to anti-T 
Ag IgG (A,B) and IgM (C,D) antibody level calculated irrespective of H. pylori status. A -  stage I, 
IgG antibody (n = 37); В -  stage П, IgG antibody (n = 34); С -  stage I, IgM antibody (n = 44); 
D -  stage П -  IgM antibody (n = 43). Dark line -  strong responders (O.D.values above cut-off 
limit); Dotted line -  weak responders (O.D. values below or equal to the cut off limit).
A significant over-representation of strong IgG responders was observed among 
H.pylori seropositive stage I patients compared to H.pylori seronegative ones (Table 
1). Similar trend was found in patients at stage П, but the differences did not reach the 
statistical significance (P = 0.13). The same was true for IgM T antibody level 
(P = 0.12).
A comparison of patient’s survival in relation to anti-T Ag antibody levels, 
calculated irrespective of H. pylori status, showed that stage I patients with higher level 
of T Ag specific IgG antibody had significantly better survival compared to those with 
low level of antibody (weak responders): median survival time 62.0 ±2.1 and 35 ±1.4 
months, respectively; P = 0.00001 (Figure 2A). However, only H.pylori seropositive 
strong IgG responders were better survivors (P = 0.00001), (Figure 3, A) whereas 
strong IgG responders in H. pylori seronegative group were not (P = 0.96)(Figure 4A). 
Similar trends were observed in a group of patients at stage П (Figures 3B, 4B).
A slight tendency for better survival survival was also shown for H.pylori 
seropositive IgM strong responders compared to IgM weak responders in this group 
(Figure 3C,D). The difference concerned a period of -40-60 months of observation 
and disappeared later. Interestingly, in contrast to H.pylori seropositive patients, a
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Figure 3. Cumulative survival plots (Kaplan-Meier) of H. pylori seropositive gastric cancer 
patients depending on a level of T Ag-specific IgG (A,B) and IgM (C,D) antibodies. A -  stage I, 
IgG antibody (n = 26); В -  stage П, IgG antibody (n = 22); С -  stage I, IgM antibody (n = 30); 
D -  stage П, IgM antibody (n = 30). Dark line -  strong responders; Dotted line -  weak 
responders.
slightly better survival was found for H.pylori seronegative IgM weak responders at 
both stages of the disease (P = 0.12-0.18), (Figure 4C,D). Nevertheless, the H.pylori 
seropositive strong IgM responders (Figure 3C,D) showed significantly better median 
survival time compared to H. pylori seronegative IgM weak responders (Figure 4C,D): 
60.0±4.02 vs. 33.0± 1.15 mths, P < 0.001, and 57.0±1.4 vs. 32.0± 3.50 mths,P <0.001) 
for stage I and stage П, respectively.
DISCUSSION
The data suggest that H.pylori positive serologic status is associated with a better 
long-term survival of patients with early gastric cancer. Comparing the survival 
irrespective of H. pylori status (Figure 2), a high level of T Ag specific IgG antibodies 
was also related to a significantly better survival of cancer patients at stage I. However, 
the difference in survival between the patients with high and low level of T Ag IgG 
antibody was found only for H.pylori seropositive individuals (Figure 3). Some
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Figure 4. Cumulative survival plots (Kaplan-Meier) of H. pylori seronegative gastric cancer pa­
tients depending on a level of T Ag-specific IgG (A,B) and IgM (C,D) antibodies. A -  stage I, IgG 
antibody (n = 11); В -  stage П, IgG antibody (n = 13); С -  stage I, IgM antibody (n = 14); D -  
stage П, IgM antibody (n = 13). Dark line -  strong responders; Dotted line -  weak responders.
additive effect on the survival observed in H. pylori seropositive IgG strong responders 
compared to H.pylori seropositive status alone (Figure 1A) suggest that both high level 
of T-antibody and H.pylori seropositive status are involved. The absence of beneficial 
effect on the survival in H.pylori seronegative strong responders indicates that the 
presence of H.pylori infection seems to be an important independent prognostic fac­
tor. Since H.pylori seropositive patients had a higher proportion of strong responders, 
it appears that higher level of T Ag-specific IgG antibody associated with H.pylori 
infection may be in part responsible for a better survival observed in H.pylori 
seropositive patients. In contrast, the H. pylori seronegative patients did not reveal any 
appreciable differences in the survival.
Thus, in general for H.pylori seropositive patients individuals with higher 
level of T Ag antibody had better survival. In H.pylori seronegative group, a level 
of IgG T antibody was not significantly associated with the survival. Moreover, 
median survival time values in H.pylori seronegative group (37±7.9mths, calcu­
lated irrespective of T antibody level, Figure 1) were similar to those of weak 
IgG responders in H.pylori seropositive group (34.0±l,2mths; Figure ЗА). This 
suggests that both H.pylori status and high level of T antibody was beneficial for 
the patient’s survival.
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Interestingy, a significant association was found only for IgG T Ag-specific 
antibody. One may speculate that acquired IgG immune response to T Ag induced by 
H.pylori is a more potent mechanism to eliminate tumor cells in the circulation by 
antibody-dependent effector mechanisms, and to interfere with metastasis. Very low 
levels of natural IgM T antibody, already at early stages of the disease, is a characteristic 
of the patients with various cancers (Springer, 1984, Kurtenkov et al., 1999a). Our 
preliminary data (unpublished) showed no significant difference in survival for patients 
with advanced gastric cancer irrespective of both H.pylori status and/or anti-T Ag 
antibody level suggesting that this mechanism may be effective for elimination of only 
small number of tumor cells or micrometastasis which are present or appear in the 
circulation after surgery, thus preventing metastasis and improving the survival.
In addition to antibody-dependent reactions, other immunological mechanisms 
might be considered to explain an association between H.pylori infection and better 
survival rate of patients with early gastric cancer. H. pylori upregulates the 
proinflammatory cytokines IL-6, EL-8, TNFa, IFNy that have anti-tumor or growth 
inhibiting potential (Kang et al., 1999), inhibitory effect on angiogenesis (Jenkinson et 
al., 2002) or stimulate differentiation (Arany et al., 1999). Contact of lymphocytes with 
H.pylori was reported to stimulate the production of IFN-y and natural killer cell 
activity (Tarkkanen et al., 1993). Theoretically, the H. pylori glycosidases and/or 
glycosyltransferases may create the tumor-related epitopes on host gastric glycoconju­
gates or tumor cells, with the following induction of autoimmune response. A similar 
production of saccharide tumor-associated antigens has been shown, for instance, for 
tumor-associated alphaGal-epitope expression induced by Klebsiella pneumonia 
enzymes on erythrocytes (Hamadeh et al., 1996).
A growing body of evidence suggests that H.pylori infection may actually have 
some beneficial effects. The carriage of the more virulent CagA-positive strain was 
shown to be associated with a reduced risk of esophageal and gastric cardial ade­
nocarcinoma and of the gastroesophageal reflux disease (Chow et al., 1998; Kuipers, 
1999; Loffeld et al., 2000). H.pylori infection may protect against diarrheagenic 
gastrointestinal infections in children (Rothenbacher et al., 2000). Our data shows better 
survival of H.pylori infected patients with gastric cancer and indicates that, in some 
situations, this infection may be beneficial for the host. Therefore, eradication of 
H.pylori becomes more controversial, especially in individuals of older age.
Our findings are important and are the first evidence that H.pylori seropositive 
patients with early gastric cancer have better survival than H.pylori seronegative 
patients, and that this impact is related to the up-regulation of T Ag specific immune 
response by H.pylori infection. This further supports the idea that stimulation of 
immune response to T Ag may be beneficial for the host in a situation when primary 
tumor is removed. Since infection with H.pylori is relatively common, it may be 
considered as a good model to study the impact of infections on anti-tumor im­
munological mechanisms.
ACKNOWLEDGMENTS
The authors thank Kate Rittenhouse-Olson (PhD) for critical remarks and fruitful 
discussion of the manuscript. This study was supported by a grant #4217 from the 
Estonian Science Foundation.
H. pylori Infection and Survival of Cancer Patients 91
REFERENCES
Appelmelk, B. J., Simmons Smith, I., Negrini, R., Moran, A., Aspinall, G. O., Forte, J.
G., De Vries, T., Quan, H., Verboom, T., Maaskant, J. J., Ghiara, P., Kuipers, E. J., 
Bloemena, E., Tadema, Т. M., Townsend, R. R., Tyagaijan, K., Crothers, J. M., 
Monteiro, M. A., Savio, A., De Graf, J. (1996). Potential role of molecular mimicry 
between Helicobacter pylori lipopolysaccharide and host Lewis blood group 
antigens in autoimmunity. Infect. Immun. 64:2031-2040.
Arany, I., Adler-Storthz, K., Chen, Z., Tyring, S. K., Brysk, H., Lei, G., Brysk, M. M. 
(1999). Local inflammation may influence oral tumor cell differentiation. 
Anticancer Res. 19 (2A): 1065-1067.
Baldus, S. E., Hanish, F. -G. (2000). Biochemistry and pathological importance of 
mucin-associated antigens in gastrointestinal neoplasia. Adv. Cancer Res. 79:201- 
248.
Bamford, K. B., Fan, X. J., Crowe, S. E., Leary, J. F., Gourley, W. K., Luthra, G. K., 
Brooks, E. G., Graham, D. Y., Reyes, V. E., Ernst, P. B. (1998). Lymphocytes in 
the human gaStric mucosa during Helicobacter pylori have a helper cell 1 
phenotype. Gastroenterology 114:482-492.
Blaser, M. J., Berg, D. E. (2001). Helicobacter pylori genetic diversity and risk of human 
disease. J. Clin. Invest. 107:767-773.
Bontkes, H. J., Veenendaal, R. A., Pena, A. S., Goedhard, J. G., van Duijn, W., Kuiper, I. 
(1992). Meijer JI & Lamers CBHW. IgG subclass response to Helicobacter pylori 
in patients with chronic active gastritis and duodenal ulcer. Scand. J. Gastroenterol. 
27:129-133.
Chow, W. H., Blaser, M. J., Blot, W. J., Gammon, M. D., Vaughan, T. L., Risch, H. A., 
Perez-Perez, G. I., Schoenberg, J. B., Stanford, J. V., Rotterdam, H., West, A. B., 
Fraumeni, J. F. (1998). An inverse relation between cagA+ strains of Helicobacter 
pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer 
Res. 58:588-590.
Ernst, P. B., Takaishi, H., Crowe, S. E. (2001). Helicobacter pylori infection as a model 
for gastrointestinal immunity and chronic inflammatory diseases. Dig Dis. 19:104- 
111.
Faller, G., Ruff, N., Hochberger, J., Hahn, E. C., Kirchner, T. (2000). Mucosal production 
of antigastric autoantibodies in Helicobacter pylori gastritis. Helicobacter 5:129- 
134.
Glinsky, V. V., Glinsky, G. V., Rittenhouse-Olson, K., Huflejt, M. E., Glinsky, О. V., 
Deutscher, S. L., Quinn, T. P. (2001). The role of Thomsen-Friedenreich antigen in 
adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res. 
61:4851-4857.
Hamadeh, R. M., Jarvis, G. A., Zhou, P., Cotleur, A. C., Griffiss, J. M. (1996). Bacterial 
enzymes can add galactose alphal,3 to human erythrocytes and create a senecence- 
associated epitope. Infect. Immun. 64:528—534.
Jenkinson, L., Bardhan, K. D., Atherton, J., Kalia, N. (2002). Helicobacter pylori prevents 
proliferative stage of angiogenesis in vitro: role of cytokines. Dig. Dis. Sei. 
47:1857-1862.
Kang, H. S., Cho, D. H., Kim, S. S., Pyun, K. H., Choi, I. (1999). Anti-tumor effects of 
IL-6 on murine liver tumor cells in vivo. J. Biomed. Sei. 6:142-144.
Klaamas, K., Held, M., Wadstrom, T., Lipping, A., Kurtenkov, О. (1997). IgG immune
92 Kurtenkov et al.
response to Helicobacter pylori antigens in patients with gastric cancer as defined 
by ELISA and immunoblotting. Int. J. Cancer 9:367-370.
Klaamas, K., Kurtenkov, O., Bijalin, V., Miljukhina, L., Shljapnikova, L., Engstrand, L. 
(2002a). Enhanced humoral immune response to tumor-associated T glycotope 
(Galßl,3GalNAc) in Helicobacter pylori-infected patients with gastric cancer and 
non-tumor gastric diseases. Exp. Oncol. 24:38-44.
Klaamas, K., Kurtenkov, O., Rittenhouse-Olson, K., Brjalin, V., Miljukhina, L., 
Shljapnikova, L., Engstrand, L. (2002b). Expression of tumor-associated 
Thomsen-Friedenreich antigen (T Ag) in Helicobacter pylori and modulation of 
T Ag specific immune response in infected individuals. Immunol. Invest. 31:191 — 
204.
Kuipers, E. J. (1999). Review article: exploring the link between Helicobacter pylori and 
gastric cancer. Aliment. Pharmacol. Ther. 13 (Suppl. 1):3-1L
Kurtenkov, O., Miljukhina, L., Smorodin, J., Klaamas, K., Bovin, N., Ellamaa, M., 
Chuzmarov, V. (1999a). Natural IgM and IgG antibodies to thomsen-Friedenreich 
(T) antigen in serum of patients with gastric cancer and blood donors. Acta Oncol. 
38:939-943.
Kurtenkov, O., Klaamas, K., Miljukhina, L., Shljapnikova, L., Ellamaa, M., Bovin, N., 
Wadström, T. (1999b). IgG antibodies to Lewis type 2 antigens in serum of 
H. pylori-infected and noninfected blood donors of different Lewis(a,b) blood- 
group phenotype. FEMS Immunol Med. Microbiol. 24:227-232.
Livingston, P. О., Ragupathi, G. (1997). Carbohydrate vaccines that induce antibodies 
against cancer. 2. Previous experience and future plans. Cancer Immunol. 
Immunother. 45:10-19.
Livingston, P. O., Zhang, S., Lloyd, К. O. (1997). Carbohydrate vaccines that induce 
antibodies against cancer. 1. Rationale. Cancer Immunol. Immunother. 45:1-9.
Loffeld, R. J., Werdmuller, B. F., Küster, J. G., Perez-Perez, G. I., Blaser, M. J., Kuipers, 
E. J. (2000). Colonization with cagA-positive Helicobacter pylori strains inversly 
associated with reflux esophagitis and Barret’s esophagus. Digestion 62:95-99.
MacLean, G. D., Bowen-Yacyshyn, M. B., Samuel, J., Meikle, A., Stuart, G., Nation, J., 
Poppema, S., Jerry, M., Koganty, R., Wong, T., Longenecker, В. М. (1992). Active 
immunization of human ovarian cancer patients against a common carcinoma 
(Thomsen-Friedenreich) determinant using syntyhetic carbohydrate antigen, J. 
Immunother. 11:292-301.
Nardone, G., Staibano, S., Rocco, A., Mezza, E., D’Armiento, F. P., Insabato, L., 
Coppola, A., Salvatore, G., Lucariello, A., Figura, N., De Rosa, G., Budillon, G. 
(1999). Effect of Helicobacter pylori infection and its eradication on cell 
proliferation; DNA status, and oncogene expression in patients with chronic 
gastritis. Gut 44:789-799.
Negrini, R., Saviuo, A., Poiesi, C., Appelmelk, B. J., Buffoli, F., Paterlini, A., Cesari, P., 
Graffeo, M., Vaira, D., Franzin, G. (1996). Antigenic mimicry between 
Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic 
gastritis. Gastroenterology 111:655-665.
Pineros, D. M. C., Riveros, S. C. H., Marin, J. D. M., Ricardo, O,, Diaz, O. O. (2001). 
Helicobacter pylori in gastric cancer and peptic ulcer disease in a Colombian 
population. Strain heterogeneity and antibody profiles. Helicobacter 6:199-206.
Ren, Z., Pang, G., Lee, R., Batey, R., Dunkley, M., Borody, T., Clancy, R. (2000).
H. pylori Infection and Survival of Cancer Patients 93
Circulating T-cell response to Helicobacter pylori infection in chronic gastritis. 
Helicobacter 5:135-141.
Rothenbacher, D., Blaser, M. J., Bode, G., Brenner, H. (2000). Inverse relationship 
between gastric colonization of Helicobacter pylori and diarrheal illnesses in 
children: results of a population-based cross-sectional study. J. Infect. Dis. 
182:1446-1449.
Sobin, L. H., Wittekind, C. H. (1997). TNM Classification of Malignant Tumors. UICC. 
N.Y. Wiley & Sons.
Solnic, J. V., Schauer, D. B. (2001). Emergence of diverse Helicobacter species in the 
pathogenesis of gastric and enteroheaptic diseasees. Clin. Microbiol. Rev. 14:59- 
97.
Springer, G. F. (1984). T and Tn, general carcinoma autoantigens. Science 224:1198- 
1206.
Takanami, I. (1999). Expression of Thomsen-Friedenreich antgen as a marker of poor 
prognosis in pulmonary adenocarcinoma. Oncol. Rep. 6:341-344.
Tarkkanen, J., Kosunen, T. U., Saksela, E. (1993). Contact of lymphocytes with He­
licobacter pylori augments natural killer cell activity and induces production of 
gamma interferon. Infect. Immun. 61:3012-3016.
Vorobjova, T., Faller, G., Maaroos, H.-I., Sipponen, P., Villako, K., Uibo, R., Kirchner, 
T. (2000). Significant increase in antigastric autoantibodies in a long-term follow- 





Bom June 27, 1963 in Tallinn, Estonia
Personal status: single
Children: Katarina Klaamas, bom October 3, 1998
Address: National Institute for Health Development
Hiiu 42, 11619 Tallinn
Tel: (0) 6 706 815, fax: (0) 6 706 814
E-mail: kersti@ekmi.ee
Education
1970-1978 Tallinn Secondary School No. 20 
1978-1981 Tallinn Secondary School No. 22
1983-1990 The Second Moscow State Medical Institute, medico-biological 
faculty
1994 Master of Science in Biology, The Second Moscow State Medical
Institute
Special courses
International Summer School, Palanga, Lithuania, 1993.
Immunochemical methods, Lund University, Lund, Sweden, 1994.
Course in immunotechnology, Biotechnology Research Foundation, Lund, 
Sweden, 1995.
H.pylori infection: clinical significance, diagnosis and treatment. Tartu Uni­
versity, Tartu, 1996 
Modem epidemiology. Department of Public Health, Tartu University, 2003
Knowledge of languages: Estonian, Russian, English.
171
Professional employment
1990-1992 Estonian Institute of Experimental and Clinical Medicine (IECM) 
Department of Experimental Oncology, senior technician 
1992-1995 IECM, Department of Experimental Oncology, junior research 
scientist
1995-2003 IECM, Department of Oncology, research scientist 
since 2003 National Institute for Health Development Department of Onco­
logy, research scientist
Scientific work
Major areas of research: (1) H.pylori and gastric cancer: the immune response 
to H.pylori infection in gastric cancer patients; H.pylori infection and the 
mechanisms of anti-tumor natural immune response. (2) Tumor 
immunology: tumor associated antigens.
Member of the Estonian Society of Immunology (since 1992) and the Baltic 
Immunological Society (since 1993).
Grant funding: (1) H.pylori infection in patients with gastric cancer: immuno­
logical study of microbial and host related factors (1997-1999, Estonian 
Science Foundation, grant no 2697). (2) Systemic impact of the Helicobacter 
pylori infection on natural immune response to tumor associated carbo­
hydrate antigens in patients with gastric cancer and chronic gastric diseases. 




Sünd. 27. juunil 1963 Tallinnas 
Kodakondsus: Eesti 
Perekonnaseis: vallaline 
Lapsed: Katarina Klaamas, sünd. 3.10.1998 
Aadress: Tervise Arengu Instituut 
Hiiu 42, 11619 Tallinn 
Tel: (0) 6 706 815, fax: (0) 6 706 814 
E-post: kersti@ekmi.ee
Haridus
1970-1978 Tallinna 20. Keskkool 
1978-1981 Tallinna 22. Keskkool
1983-1990 Moskva П Meditsiini Instituudi biomeditsiini teaduskond, bio­
keemia eriala
1994 Bioloogiateaduste magister, Moskva П Meditsiini Instituut
Erialane täiendus
Rahvusvaheline Immunoloogide Suvekool, Palanga, Leedu,. 1993
H.pylori antigeenspektri uurimine immunokeemilste meetoditega, Lundi Üli­
kooli meditsiinilise mikrobioloogia instituut, Lund, Rootsi 1994 
Immunotehnoloogia kursus, Biotechnology Research Foundation, Lund, Rootsi,
1995.
H.pylori infektsiooni kliiniline tähendus, diagnoosimine ja ravi. TÜ arstide ja 
proviisorite täienduskeskus, Tartu 1996 
Moodsa epidemioloogia kursus, TÜ tervishoiu instituut, 2003
Keelteoskus: eesti, vene, inglise
44 173
Teenistuskäik
1990-1992 Eksperimentaalse ja  Kliinilise Meditsiini Instituut (EKMI), 
eksperimentaalse onkoloogia osakond, kõrghar. vanemlaborant 
1992-1995 EKMI, eksperimentaalse onkoloogia osakond, nooremteadur 
1995-2003 EKMI, onkoloogia osakond, teadur 
alates 2003 Tervise Arengu Instituut, onkoloogia osakond, teadur
Teadustegevus
Põhilised uurimissuunad: (1) H.pylori ja  maovähk: anti-H.pylori immuunvastus 
maovähihaigetel; H.pylori infektsioon ja  loomuliku kas vaja vastase resis­
tentsuse mehhanismid. (2) Kasvaja immunoloogia: kasvajaseoselised anti­
geenid.
Eesti Immunoloogide (alates 1992) ja  Balti Immunoloogide Seltsi (alates 1993) 
liige.
Saadud kaks granti: (1) Helicobacter pylori infektsioon maovähihaigetel: 
mikroobist ja  peremehest sõltuvate tegurite immunoloogiline uuring. ETF 
grant nr. 2697, 1997-1999; (2) Helicobacter pylori infektsiooni süsteemne 
mõju kasvajaseoselistele süsivesikantigeenidele suunatud loomulikule 
immuunvastusele maovähi ja  mao krooniliste haigustega patsientidel. ETF 




1. Heidi-Ingrid Maaroos. The natural course of gastric ulcer in connection 
with chronic gastritis and Helicobacter pylori. Tartu, 1991.
2. Mihkel Zilmer. Na-pump in normal and tumorous brain tissues: Structural 
functional a. tumorigenesis aspects. Tartu, 1991.
3. Eero Vasar. Role of cholecystokinin receptors in the regulation of 
behaviour and in the action of haloperidol and diazepam. Tartu, 1992.
4. Tiina Talvik. Hypoxic-ischaemic brain damage in neonates (clinical, 
biochemical and brain computed tomographical investigation). Tartu, 
1992.
5. Ants Peetsalu. Vagotomy in duodenal ulcer disease: A study of gastric 
acidity, serum pepsinogen I, gastric mucosal histology and Helicobacter 
pylori. Tartu, 1992.
6. Marika Mikelsaar. Evaluation of the gastrointestinal microbial ecosystem 
in health and disease. Tartu, 1992.
7. Hele Everaus. Immuno-hormonal interactions in chronic lymphocytic 
leukaemia and multiple myeloma. Tartu, 1993.
8. Ruth Mikelsaar. Etiological factors of diseases in genetically consulted 
children and newborn screening: dissertation for the commencement of the 
degree of doctor of medical sciences. Tartu, 1993.
9. Agu Tamm. On metabolic action of intestinal microflora: clinical aspects. 
Tartu, 1993.
10. Katrin Gross. Multiple sclerosis in South-Estonia (epidemiological and 
computed tomographical investigations). Tartu, 1993.
11. Oivi Uibo. Childhood coeliac disease in Estonia: occurrence, screening, 
diagnosis and clinical characterization. Tartu, 1994.
12. Viiu Tuulik. The functional disorders of central nervous system of 
chemistry workers. Tartu, 1994.
13. Margus Viigimaa. Primary haemostasis, antiaggregative and antico­
agulant treatment of acute myocardial infarction. Tartu, 1994.
14. Rein Kolk. Atrial versus ventricular pacing in patients with sick sinus 
syndrome. Tartu, 1994.
15. Toomas Podar. Incidence of childhood onset type 1 diabetes mellitus in 
Estonia. Tartu, 1994.
16. Kiira Subi. The laboratory surveillance of the acute respiratory viral 
infections in Estonia. Tartu, 1995.
17. Irja Lutsar. Infections of the central nervous system in children (epidemi­
ologic, diagnostic and therapeutic aspects, long term outcome). Tartu, 1995.
18. Aavo Lang. The role of dopamine, 5-hydroxytryptamine, sigma and 
NMD A receptors in the action of antipsychotic drugs. Tartu, 1995.
175
19. Andrus Arak. Factors influencing the survival of patients after radical 
surgery for gastric cancer. Tartu, 1996.
20. Tõnis Karki. Quantitative composition of the human lactoflora and 
method for its examination. Tartu, 1996.
21. Reet Mändar. Vaginal microflora during pregnancy and its transmission 
to newborn. Tartu, 1996.
22. Triin Remmel. Primary biliary cirrhosis in Estonia: epidemiology, clinical 
characterization and prognostication of the course of the disease. Tartu,
1996.
23. Toomas Kivastik. Mechanisms of drug addiction: focus on positive rein­
forcing properties of morphine. Tartu, 1996.
24. Paavo Pokk. Stress due to sleep deprivation: focus on GABAa receptor- 
chloride ionophore complex. Tartu, 1996.
25. Kristina Allikmets. Renin system activity in essential hypertension. 
Associations with atherothrombogenic cardiovascular risk factors and with 
the efficacy of calcium antagonist treatment. Tartu, 1996.
26. Triin Parik. Oxidative stress in essential hypertension: Associations with 
metabolic disturbances and the effects of calcium antagonist treatment. 
Tartu, 1996.
27. Svetlana Päi. Factors promoting heterogeneity of the course of 
rheumatoid arthritis. Tartu, 1997.
28. Maarike Sallo. Studies on habitual physical activity and aerobic fitness in
4 to 10 years old children. Tartu, 1997.
29. Paul Naaber. Clostridium difficile infection and intestinal microbial 
ecology. Tartu, 1997.
30. Rein Pähkla. Studies in pinoline pharmacology. Tartu, 1997.
31. Andrus Juhan Voitk. Outpatient laparoscopic cholecystectomy. Tartu, 1997.
32. Joel Starkopf. Oxidative stress and ischaemia-reperfusion of the heart. 
Tartu, 1997.
33. Janika Kõrv. Incidence, case-fatality and outcome of stroke. Tartu, 1998.
34. Ülla Linnamägi. Changes in local cerebral blood flow and lipid peroxida­
tion following lead exposure in experiment. Tartu, 1998.
35. Ave Minajeva. Sarcoplasmic reticulum function: comparison of atrial and 
ventricular myocardium. Tartu, 1998.
36. Oleg Milenin. Reconstruction of cervical part of esophagus by revascular- 
ised ileal autografts in dogs. A new complex multistage method. Tartu,
1998.
37. Sergei Pakriev. Prevalence of depression, harmful use of alcohol and 
alcohol dependence among rural population in Udmurtia. Tartu, 1998.
38. Allen Kaasik. Thyroid hormone control over ß-adrenergic signalling 
system in rat atria. Tartu, 1998.
39. Vallo Matto. Pharmacological studies on anxiogenic and antiaggressive 
properties of antidepressants. Tartu, 1998.
176
40. Maire Vasar. Allergic diseases and bronchial hyperreactivity in Estonian 
children in relation to environmental influences. Tartu, 1998.
41. Kaja Julge. Humoral immune responses to allergens in early childhood. 
Tartu, 1998.
42. Heli Grünberg. The cardiovascular risk of Estonian schoolchildren. 
A cross-sectional study of 9-, 12- and 15-year-old children. Tartu, 1998.
43. Epp Sepp. Formation of intestinal microbial ecosystem in children. Tartu,
1998.
44. Mai Ots. Characteristics of the progression of human and experimental 
glomerulopathies. Tartu, 1998.
45. Tiina Ristimäe. Heart rate variability in patients with coronary artery 
disease. Tartu, 1998.
46. Leho Kõiv. Reaction of the sympatho-adrenal and hypothalamo-pituitary- 
adrenocortical system in the acute stage of head injury. Tartu, 1998.
47. Bela Adojaan. Immune and genetic factors of childhood onset IDDM in 
Estonia. An epidemiological study. Tartu, 1999.
48. Jakov Shlik. Psychophysiological effects of cholecystokinin in humans. 
Tartu, 1999.
49. Kai Kisand. Autoantibodies against dehydrogenases of a-ketoacids. Tartu,
1999.
50. Toomas Marandi. Drug treatment of depression in Estonia. Tartu, 1999.
51. Ants Kask. Behavioural studies on neuropeptide Y. Tartu, 1999.
52. Ello-Rahel Karelson. Modulation of adenylate cyclase activity in the rat 
hippocampus by neuropeptide galanin and its chimeric analogs. Tartu, 1999.
53. Tanel Laisaar. Treatment of pleural empyema — special reference to 
intrapleural therapy with streptokinase and surgical treatment modalities. 
Tartu, 1999.
54. Eve Pihl. Cardiovascular risk factors in middle-aged former athletes. 
Tartu, 1999.
55. Katrin Ounap. Phenylketonuria in Estonia: incidence, newborn screening, 
diagnosis, clinical characterization and genotype/phenotype correlation. 
Tartu, 1999.
56. Siiri Kõljalg. Acinetobacter — an important nosocomial pathogen. Tartu,
1999.
57. Helle Karro. Reproductive health and pregnancy outcome in Estonia: 
association with different factors. Tartu, 1999.
58. Heili Varendi. Behavioral effects observed in human newborns during 
exposure to naturally occurring odors. Tartu, 1999.
59. Anneli Beilmann. Epidemiology of epilepsy in children and adolescents 
in Estonia. Prevalence, incidence, and clinical characteristics. Tartu, 1999.
60. Vallo Volke. Pharmacological and biochemical studies on nitric oxide in 
the regulation of behaviour. Tartu, 1999.
45 177
61. Pilvi Ilves. Hypoxic-ischaemic encephalopathy in asphyxiated term in­
fants. A prospective clinical, biochemical, ultrasonographical study. Tartu,
1999.
62. Anti Kalda. Oxygen-glucose deprivation-induced neuronal death and its 
pharmacological prevention in cerebellar granule cells. Tartu, 1999.
63. Eve-Irene Lepist. Oral peptide prodrugs — studies on stability and 
absorption. Tartu, 2000.
64. Jana Kivastik. Lung function in Estonian schoolchildren: relationship 
with anthropometric indices and respiratory symptomas, reference values 
for dynamic spirometry. Tartu, 2000.
65. Karin Kull. Inflammatory bowel disease: an immunogenetic study. Tartu,
2000.
66. Kaire Innos. Epidemiological resources in Estonia: data sources, their 
quality and feasibility of cohort studies. Tartu, 2000.
67. Tamara Vorobjova. Immune response to Helicobacter pylori and its 
association with dynamics of chronic gastritis and epithelial cell turnover 
in antrum and corpus. Tartu, 2001.
68. Ruth Kalda. Structure and outcome of family practice quality in the 
changing health care system of Estonia. Tartu, 2001.
69. Annika Krüüner. Mycobacterium tuberculosis — spread and drug 
resistance in Estonia. Tartu, 2001.
70. Marlit Veldi. Obstructive Sleep Apnoea: Computerized Endopharyngeal 
Myotonometry of the Soft Palate and Lingual Musculature. Tartu, 2001.
71. Anneli Uusküla. Epidemiology of sexually transmitted diseases in Estonia 
in 1990-2000. Tartu, 2001.
72. Ade Kallas. Characterization of antibodies to coagulation factor УШ. 
Tartu, 2002.
73. Heidi Annuk. Selection of medicinal plants and intestinal lactobacilli as 
antimicrobil components for functional foods. Tartu, 2002.
74. Aet Lukmann. Early rehabilitation of patients with ischaemic heart 
disease after surgical revascularization of the myocardium: assessment of 
health-related quality of life, cardiopulmonary reserve and oxidative stress. 
A clinical study. Tartu, 2002.
75. Maigi Eisen. Pathogenesis of Contact Dermatitis: participation of Oxida­
tive Stress. A clinical — biochemical study. Tartu, 2002.
76. Piret Hussar. Histology of the post-traumatic bone repair in rats. Elabora­
tion and use of a new standardized experimental model — bicortical per­
foration of tibia compared to internal fracture and resection osteotomy. 
Tartu, 2002.
77. Tõnu Rätsep. Aneurysmal subarachnoid haemorrhage: Noninvasive moni­
toring of cerebral haemodynamics. Tartu, 2002.
78. Marju Herodes. Quality of life of people with epilepsy in Estonia. Tartu, 
2003.
178
79. Katre Maasalu. Changes in bone quality due to age and genetic disorders 
and their clinical expressions in Estonia. Tartu, 2003.
80. Toomas Sillakivi. Perforated peptic ulcer in Estonia: epidemiology, risk 
factors and relations with Helicobacter pylori. Tartu, 2003.
81. Leena Puksa. Late responses in motor nerve conduction studies. F and A 
waves in normal subjects and patients with neuropathies. Tartu, 2003.
82. Krista Lõivukene. Helicobacter pylori in gastric microbial ecology and 
its antimicrobial susceptibility pattern. Tartu, 2003.
83. Helgi Kolk. Dyspepsia and Helicobacter pylori infection: the diagnostic 
value of symptoms, treatment and follow-up of patients referred for upper 
gastrointestinal endoscopy by family physicians. Tartu, 2003.
84. Helena Soomer. Validation of identification and age estimation methods 
in forensic odontology. Tartu, 2003.
85. Kersti Oselin. Studies on the human MDR1, MRP1, and MRP2 ABC 
transporters: functional relevance of the genetic polymorphisms in the 
MDR1 and MRP1 gene. Tartu, 2003.
86. Jaan Soplepmann. Peptic ulcer haemorrhage in Estonia: epidemiology, 
prognostic factors, treatment and outcome. Tartu, 2003.
87. Margot Peetsalu. Long-term follow-up after vagotomy in duodenal ulcer 
disease: recurrent ulcer, changes in the function, morphology and 
Helicobacter pylori colonisation of the gastric mucosa. Tartu, 2003.
ISSN 1024-395X 
ISBN 9985-56-793-5
